10 – 13 JUNE 2015
BRUSSELS, BELGIUM

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

FINAL PROGRAMME

WWW.ECFS.EU/BRUSSELS2015

HIGHLIGHTS OF THE CONFERENCE

INTERACTIVE CASE STUDIES FRIDAY 08:30 – 10:00

Each interactive case presents an evolving patient history and a serie of questions designed to test your diagnostic and/or therapeutic skills. You will receive immediate feedback on your answers and treatments choices, along with the opportunity to compare your final score with those of your peers.

INTERACTIVE DEBATES - PROS/CONS SATURDAY 09:00 – 10:30

Come discuss the pros and cons, and perhaps even change your viewpoint!



MEET THE EXPERTS SESSIONS

THURSDAY & FRIDAY: 07:15 – 08:15
ePOSTER CORNERS

In these small interactive breakfast sessions you will have the opportunity to ask questions and discuss a specific topic with experts from the field. The format encourages a more personal approach to learning.
Registration for these sessions is additional to the conference.

ECFS TOMORROW LOUNGE

The ECFS Tomorrow initiative is specially geared towards assembling those who are interested in building their future career in the Cystic Fibrosis community and the ECFS of tomorrow.
The ECFS Tomorrow Lounge will feature:

- An exciting series of mini-workshops aimed at career development
- A relaxed space for conversation and networking

More information page 71

JOIN US ON LINKEDIN * VISIT US ON FACEBOOK

TABLE OF CONTENTS

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

WELCOME / COMMITTEES / ECFS

CONFERENCE OVERVIEW

SCIENTIFIC PROGRAMME

POSTERS

MEETINGS & COURSES

EXHIBITION & SATELLITE SYMPOSIA

GENERAL INFORMATION & INDICES

PATRON & COMMITTEES

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

38TH EUROPEAN CYSTIC FIBROSIS CONFERENCE

UNDER THE PATRONAGE OF

Her Majesty the Queen Mathilde

COMMITTEES

STEERING COMMITTEE

Kris De Boeck, BE
Stuart Elborn, UK
Georges Casimir, BE
Mario Vaneechoutte, BE
Ulrike Pypops, BE
Miguel Cámara, UK
Eitan Kerem, IL
Su Madge, UK
David Sheppard, UK

SCIENTIFIC COMMITTEE

Jürg Barben, CH
Thomas Bjarnsholt, DK
Mark Butler, UK
Marc Chanson, CH
Raphael Chiron, FR
Gary Connett, UK
Jane Davies, UK
Isabelle de Monestrol, SE
Elke De Wachter, BE
Nico Derichs, DE
Lieven Dupont, BE
Carlos Farinha, PT
Marita Gilljam, SE
Gunnar C. Hansson, SE
Dominic Hartl, DE
Trudy Havermans, BE
Helge Hebestreit, DE
Andreas Jung, CH
Ferenc Karpati, SE
Batsheva Kerem, IL
Maya Kirszenbaum, FR
Karsten Kötz, SE
Uros Krivec, SI
Philipp Latzin, CH
Fred Lessire, BE
Irene Maguire, IE
Eshwar Mahenthiralingam, UK
Luigi Maiuri, IT
Marcus Mall, DE
Anne Munck, FR
Lutz Nährlich, DE
Helen Parrott, UK
Nicolas Regamey, CH
Kirsten Schaffer, IE
Bob Scholte, NL
Carsten Schwarz, DE
Nick Simmonds, UK
Kevin Southern, UK
Giovanni Taccetti, IT
Doris Thomsen, DK
Harm Tiddens, NL
Helen White, UK

LOCAL LIAISON COMMITTEE

Belgian Cystic Fibrosis Association
J. Borlélaan 12
1160 Brussels, Belgium
Tel: +32 2 675 57 69
Fax: +32 2 675 58 99
E-mail: info@muco.be
www.muco.be

CONFERENCE ORGANISER

European Cystic Fibrosis Society
Kastanieparken 7
DK-7470 Karup J.
Denmark
Tel: +45 8667 6260
Fax: +45 8667 6290
E-mail: info@ecfs.eu

CONFERENCE SECRETARIAT

ECFS 2015
Conference Secretariat
c/o K.I.T. Group GmbH
Kurfürstendamm 71
D-10709 Berlin

Registration
Tel: +49 30 24603 338
E-mail: ecfs2015@kit-group.org

Hotel Accommodation
Tel: +49 30 24603 336
E-mail: ecfs2015-hotel@kit-group.org

Exhibition/Satellite Symposia/Sponsorship
Tel: +49 30 24603 242

Exhibition Services/ESOS
Tel: +49 30 24603 337
E-mail: ecfs2015-sponsorship@kit-group.org

WELCOME TO THE 38TH ECFS CONFERENCE

Dear Friends and Colleagues,

It is a great pleasure to welcome you to the 38th European Cystic Fibrosis Conference.

At the ECFS Conference, we provide a forum for the discussion of the best and most recent basic and applied science to facilitate translation of the latest knowledge into daily clinical practice. The programme reflects these priorities and brings together scientific and clinical teams from around the world. A high quality programme is planned with international leaders in the field delivering plenary and symposia lectures.

The 38th ECFS Conference takes place at Square Brussels conveniently located at the very heart of the city, in the cultural and historic district of Brussels, overlooking the city from the hillside of the Mont des Arts.
The conference center has a contemporary design conceived by a team of European designers and is also home to original murals by Belgian painters amongst whom the famous surrealist painter René Magritte.

Graced with a majestic historic heart, a unique atmosphere and a host of activities for all ages, Brussels has surprises around every corner. The capital is known for its authentic architectural heritage considered one of the finest in the world, as well as its many churches and historic houses.
As headquarters of many European institutions, Brussels might also be considered something of a capital for the European Union. Being at the crossroads of cultures and playing an important role in Europe, Brussels fits the definition of the archetypal "melting pot", but still retains its own unique character.

The conference is an excellent opportunity to discuss the important new developments in CF research and clinical care. We are confident the conference will invigorate all in the CF community to continue their efforts to improve quality of life and survival for people with CF.

We are delighted that you have joined us for this exciting and challenging event and we extend a very warm welcome to Brussels.

WELCOME TO BRUSSELS

It is a great pleasure to welcome you to Brussels for the 38th European Cystic Fibrosis Conference.

It's been 20 years since the conference came to Belgium. Since then a lot has changed, for the better. People with CF live longer and better, in many countries 50% or more are adults, the care is organized by multidisciplinary teams in CF centers following European standards of care and the first treatments tackling the cause of the disease are developed.

But people with CF and their families still face many challenges. CF is still an incurable and life threatening disease. Many children are still diagnosed too late; treatments are time consuming and not effective enough. Although Belgian patients have access to top care in our CF, rehab and transplant centers, we do not have a national newborn screening programme yet. Specialized care for adults is lacking resources all over Europe. Patients spend on average 3, 4 hours a day on their treatment and face many obstacles with an impact on school, work, social and family life. Each day missed at school or work, each infection, each day in hospital and each youngster or adult who loses the fight is one too many. We have made some big steps forward, but a lot of work is still to be done.

Next year, our association will celebrate its 50 years. The CF families asked us to spread this clear message: "together for more breath, life and hope". We know this is what everyone attending this conference is working for, each day.
A mother of a baby with CF expresses the hope of many parents worldwide: *"Who says 'research' says 'hope' for my little daughter. We are positive that research for better treatment is ongoing, we keep our faith and hope and we know that with the support of all of you, we'll get there."*

We hope that this conference will enable us all to set further steps forward in realising the dream of all patients and families: a long and healthy life for all!

Have a great conference!

Karleen De Rijcke, for the Local Liaison Committee

Kris De Boeck
ECFS President

Georges Casimir
Conference President

Mario Vaneechoutte
Conference Vice President

Ulrike Pypops
Conference Vice President

Karleen De Rijcke
Member Local Liaison Committee

EUROPEAN CYSTIC FIBROSIS SOCIETY

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

The European Cystic Fibrosis Society is an international community of scientific and clinical professionals committed to improving survival and quality of life for people with CF by promoting high quality research, education and care.

ECFS PROJECTS

CLINICAL TRIALS NETWORK

CTN Director: Tim Lee, Leeds, UK

The aim of the European Cystic Fibrosis Clinical Trial Network (ECFS CTN) is to intensify clinical research and to bring new medicines to the patients as quickly as possible. This is done by:

- Sharing expertise among dedicated CF researchers
- Involving and cooperating with the patient organizations
- Centralizing review of clinical trial protocols in cooperation with the pharmaceutical industry
- Supporting the study conduct in the 30 network sites
- Standardizing research procedures and outcome parameters
- Providing training to the site's staff

Apart from study design, motivating patients to take part in research and promoting safety of participants in clinical trials are of great importance. The CTN is also in close contact with the CFF Therapeutics Development Network in the US to work together on the review and conduct of global studies.

Number of sites: 30 in 11 countries – Expansion in 2016
Number of patients represented: 14,000
www.ecfs.eu/ctn

PATIENT REGISTRY

ECFSPR Director: Ed McKone, Dublin, IE

The ECFS Patient Registry collects demographic and clinical data from consenting CF patients in Europe. The outcomes of data-analyses and comparisons are used to better understand CF, encourage new standards of dealing with the disease, provide data for research and facilitate public health-planning.

Currently 28 countries participate in the Patient Registry and the database contains data of over 30,000 CF patients. These data are anonymised and collected according to agreed inclusion criteria, definitions and coding, and used for annual reports with key demographic and clinical data on a country level.

See more about the Patient Registry on www.ecfs.eu/projects/ecfs-patient-registry/intro

CONFERENCES

Annual ECFS Conference

The ECFS annual conference provides a forum for all with a common interest in CF to meet and discuss their latest findings.

Basic Science Conference

The "New Frontiers in Basic Science of Cystic Fibrosis" Conference is characterised by active discussion of data and ideas at the forefront of research on CF and CFTR, in an informal, co-operative environment.

PUBLICATIONS:

JOURNAL OF CYSTIC FIBROSIS

The journal is devoted to promoting the research and treatment of Cystic Fibrosis. The journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to CF. There are currently 6 issues a year with supplements. The Journal of Cystic Fibrosis is published by Elsevier and the Editor in Chief is Dr. Scott Bell, Brisbane, AU.

ECFS GUIDELINES

ECFS Guidelines on issues associated with Cystic Fibrosis: www.ecfs.eu/ecfs_guidelines

CF CONSENSUS REPORTS

www.ecfs.eu/publications/consensus_reports

To learn more about the ECFS, visit us at our booth located in the CF Community Area!

CONTACT US
European Cystic Fibrosis Society
Kastanieparken 7
DK – 7470 Karup J.
Tel: +45 86 67 6260
Fax: +45 86 67 6290
Email: info@ecfs.eu
Website: www.ecfs.eu

DIAGNOSTIC NETWORK WORKING GROUP

www.ecfs.eu/ecfs_dnwg
Coordinator: Nico Derichs, Berlin, DE

AIMS:
- To evaluate new diagnostic techniques
- To standardize procedures throughout Europe
- To achieve pan-European cooperation on the definitions of disease, standardization of electrophysiological and genetic technique and the exchange of information, difficult cases and the development of new diagnostic technologies
- Application of the diagnostic techniques for drug development and clinical trials in CF, in cooperation with the ECFS Clinical Trials Network

NEONATAL SCREENING WORKING GROUP

www.ecfs.eu/www.ecfs.eu/ecfs-neonatal-screening-wg
Coordinator: Kevin Southern, Liverpool, UK

AIMS:
- To support the implementation of newborn screening (NBS) for CF
- To monitor performance and compare protocols to optimise effectiveness, whilst reducing negative impact
- To encourage enrolment of all infants identified through NBS in clinical trials
- To determine the optimal management of infants with an equivocal diagnosis following newborn screening

EXERCISE WORKING GROUP

www.ecfs.eu/ecfs_exercise_wg
Coordinator: Helge Hebestreit, Würzburg, DE

AIMS:
To advance patient care in Europe by improving exercise/physical activity assessments and exercise counselling. Specifically, the group addresses the following objectives:
- Evaluate existing knowledge on exercise testing, physical activity assessment and exercise counselling/conditioning programmes in Cystic Fibrosis and standardise procedures by generating consensus statements in collaboration with experts from North America and Australia
- Stimulate projects to obtain missing information
- Foster collaboration between European centres and beyond

ECFS CYSTIC FIBROSIS MOLECULAR & CELL BIOLOGY AND PHYSIOLOGY BASIC SCIENCE WORKING GROUP

www.ecfs.eu/Mol_CellBiol_Physiol_wg
Coordinator: Margarida Amaral, Lisbon, PT / **Vice-Coordinator:** Marcus Mall, Heidelberg, DE

AIMS:
To establish solid grounds for Molecular & Cell Biology and Physiology of Cystic Fibrosis through:
- Widening the number of European scientists doing fundamental research on those areas of CF as ECFS members, in particular to attract, train and maintain younger investigators in the CF field
- Disseminating recommendations for best reagents on the ECFS website and promoting best practice procedures
- Developing a network (jointly with ECFS-CTN and Registry) for the creation of biobanks of CF patients' materials across Europe for the generation and distribution of resources for CF research
- Producing consensus guidelines for standardization of research-derived laboratory techniques that can be applied to the clinic
- Prioritizing topics related to emergent needs in the field so as to create "task forces"
- Promoting excellence in CF research by fostering European-scale research to avoid effort duplication at national level and fragmentation and to achieve competitiveness for EU consortia
- Liaising with basic scientists in other societies and patient associations to maximize and optimize efforts

ECFS YOUNG INVESTIGATORS AWARDS

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

Following the recommendations of the Scientific Committee during the abstracts review process, the ECFS wishes to commend the quality of the work presented in the abstracts of some young investigators under the age of 35 having applied for the award. The Young Investigator Award includes a monetary grant of € 750, a free registration to the Conference, and a 2015 ECFS membership subscription. We wish to extend our congratulations to the following Young Investigators:

SUSANNE DITTRICH

Susanne Dittrich is a clinician scientist at the Translational Lung Research Center Heidelberg (TLRC), member of the German Center for Lung Research (DZL) and the Molecular Medicine Partnership Unit (MMPU), University of Heidelberg. In 2013, she graduated from medical school at the Dresden University of Technology, where she conducted her experimental M.D. thesis on pulmonary inflammation in acute respiratory distress syndrome. This was associated with a research stay at the Massachusetts General Hospital, Boston (USA). In 2015, Susanne Dittrich was awarded with the HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship.

About the research presented at the 38th European CF Conference, abstract number ePS06.3:

Neutrophilic airway inflammation is a hallmark of Cystic Fibrosis (CF). Previous studies identified free neutrophil elastase (NE) in bronchoalveolar lavage fluid and sputum as a key risk factor for early bronchiectasis and decline in lung function in CF. Until now, studies have focused on soluble NE activity in supernatants of airway secretions, while little is known about the relevance of membrane-associated NE activity on the surface of inflammatory cells. In the presented work, NE activity was quantified on sputum neutrophils of 37 patients with CF, using a novel approach based on Foerster resonance energy transfer. Correlations with pulmonary function indices (FEV_1% predicted, residual volume) revealed that membrane-associated NE activity might be a valuable biomarker in CF lung disease.

REBECCA KEYTE

Rebecca completed her undergraduate Psychology degree with First Class Honours at Birmingham City University in 2014. Alongside her undergraduate degree, Rebecca worked in a variety of positions within the field of psychology: As a research assistant investigating interpersonal partner coercion and manipulation amongst young people; as a volunteer at “Addactions” drug and alcohol rehabilitation centre; as a volunteer at “Resources for Autism”; and as an “AimHigher” secondary school mentor. Rebecca was awarded school scholarship and started studying for her PhD at Birmingham City University in 2014. Rebecca‘s doctoral research is investigating the role of health beliefs in predicting and explaining risky health behaviours within Cystic Fibrosis patients. Alongside studying for her PhD, Rebecca is a Visiting Lecturer in Psychology.

About the research presented at the 38th European CF Conference, abstract number ePS03.1:

The increasing life expectancy within the Cystic Fibrosis population is creating manifold challenges for patients in independently maintaining their complex and time consuming treatment regimen. To improve adherence, factors associated with compliance need to be identified. We therefore investigated the relationships between the beliefs of Cystic Fibrosis adults about their treatment and reported adherence. Participants completed the Hospital Anxiety and Depression Scale and the Beliefs about Medicine Questionnaire. Adherence to pancreatic enzymes, vitamins, physiotherapy and exercise was recorded over two days using daily telephone diaries. It was concluded that in this research, beliefs about treatment did not predict adherence well, demonstrating the need to further investigate the experiences of people with Cystic Fibrosis in relation to health behaviours. Research utilising qualitative interviews is under way to better understand the health related practices and their potential interrelationships with identity and values, and how these relate to adherence. This research will help to develop tools for health professionals to use with young people to discuss risky health behaviours in a way which reflects their experiences and acknowledges the particular issues for this population.

EMMA REECE

Emma Reece graduated from University College Dublin with an Honours Degree in Biochemistry and Molecular Biology in 2010. Currently she is a PhD student in the department of Clinical Microbiology in Trinity College Dublin. Her research focuses on *Pseudomonas aeruginosa* and *Aspergillus fumigatus* co-infections in patients with Cystic Fibrosis and understanding how these pathogens interact with each other, the host and how they impact on disease progression. This research is funded by the National Children’s Hospital Tallaght.

About the research presented at the 38th European CF Conference, abstract number ePS02.3:

Pseudomonas aeruginosa and *Aspergillus fumigatus* are the most common bacterial and fungal pathogens isolated from Cystic Fibrosis (CF) airways. This research aims to investigate how these two pathogens interact at the CF bronchial epithelial (CFBE) cell surface, contributing to CF lung disease.

P. aeruginosa (mucoid and non-mucoid) and *A. fumigatus* isolates from colonised CF patients were studied. The effect of *P. aeruginosa* and *A. fumigatus* co-infection on the host immune response was examined by ELISAs for pro-inflammatory cytokines, IL-6 and IL-8. The signalling pathways involved in activating this inflammatory response were investigated employing MAP kinase inhibitors and ELISA. *P. aeruginosa* isolates inhibited or reduced the growth of *A. fumigatus* isolates in a strain-dependent manner. A greater pro-inflammatory response was observed when CFBEs were infected with the non-mucoid *P. aeruginosa* isolates compared to the mucoid isolates. CFBE pro-inflammatory response to co-infections was significantly lower than the cumulative inflammatory response predicted. The co-infection induced IL-6 and IL-8 response occurs via the ERK and p38 MAPK pathways.

This study demonstrates *P. aeruginosa* is capable of inhibiting the growth of *A. fumigatus*. The competition between these microbes may result in a reduced airway inflammatory response which could allow these microbes to chronically co-colonise the CF airways.

TRAVEL GRANTS 2015

This year 21 Travel Grants were awarded to outstanding young European investigators who are under the age of 35 registered for a PhD or post-graduate degree or who have graduated within the last 12 months.

The Travel Grant includes a monetary grant of € 300, a free registration to the Conference, and a 2015 ECFS membership subscription.

We wish to extend our congratulations to the following Travel Award Winners.

TRAVEL GRANTS AWARDEES	ABSTRACT NUMBER
Yasmeen Abu-Fraiha, Jerusalem, IL	WS04.5
Christin Arnold, Jena, DE	ePS06.4
Reka Bodnar, Budapest, HU	ePS03.6
Natália Caçador, Ribeirão Preto, BR	WS19.2
Helen Chadwick, Leeds, UK	295
Silvia D'Arcangelo, Trento, IT	316
Davide De Rocco, Rome, IT	142
Raje Dhillon, Glasgow, UK	53
Nagehan Emiralioglu, Ankara, TR	21
Fiona Fouhy, Cork, IE	48
Gonçalo Freire, Lisbon, PT	ePS02.2
Sarah Kennedy, Toronto, CA	114
Sophie Le Trionnaire, Rennes, FR	40
Manon Pritchard, Cardiff, UK	WS02.8
Mohammad Razai, Barnstaple, UK	16
Rocio Rivas, Brest, FR	317
Nicola Ronan, Cork, IE	WS20.4
Karen Semple, Stirling, UK	WS05.5
Benjamin Silberberg, Newcastle upon Tyne, UK	52
Ranjani Somayaji, Calgary, CA	65
Emilie Vallières, Belfast, UK	102

ECFS AWARD

Dr Carlo Castellani trained in the Pediatric Department of the University of Verona. He is registered Pediatrician and registered Medical Geneticist. In 1992 he joined the Verona Cystic Fibrosis Centre, where he is now in charge of the Clinical Genetics and Neonatal Screening Services and of the adult section.

In Italy he has served on a number of committees including the Board of the Italian Cystic Fibrosis Working Group and the Commission on Patterns of Genetic Analysis for Cystic Fibrosis. He has been professor (teaching in Clinical Genetics) at the Medical Genetics School of the Verona University and is presently President of the Italian Cystic Fibrosis Society.

His international functions include membership of the CF Diagnostic Network and participation in scientific committees of the European Cystic Fibrosis Conference and North American Cystic Fibrosis Conference. He has been advisor in the Subcommittee on Newborn Screening for Cystic Fibrosis of the Clinical and Laboratory Standard Institute. Dr Castellani has started and chaired the ECFS Working Group on Neonatal Screening and has been Board member, Secretary and Vice President of the European Cystic Fibrosis Society. He has led several ECFS consensus initiatives which produced guidelines on CFTR mutation analysis in clinical practice, CF neonatal screening, CF carrier screening and CF standards of care. Dr Castellani is a member of the CFTR2 core team.

His main clinical and research interests lie in CF epidemiology, genotype/phenotype correlation, CF diagnosis, CFTR-related disorders, neonatal screening and CF adult care. He has published in several peer reviewed journals, including JAMA, Nature Genet, the Lancet, Am J Respir Crit Care Med, Am J Hum Genet, Am J Med Genet, J of Pediatr, J Med Genet, Pancreatology, Acta Paediatr, Thorax, Pediatric Pulmonol, J Mol Med, Am J Gastroenterol, Am J Epidemiol, Eur Resp J, Hum Mutation, Hum Genet, Arch Dis Childhood, J Cyst Fibros and Eur J Hum Genet.

His present international research projects include the North American Cystic Fibrosis Foundation “CFTR2” project (European coordinator).

In addition to his comprehensive scientific activities, Professor Döring was an outstanding leader of the European Cystic Fibrosis community. He became President of the European Cystic Fibrosis Society in 1998 following its successful move from the European Working Group for Cystic Fibrosis. During his Presidency, the society became internationally very successful with membership numbers doubled by the end of his term in 2006. During this time he also initiated a highly successful annual conference on basic science and consensus conferences on the treatment of lung infection, early intervention and prevention of lung disease, drug inhalation and related devices, nutrition, along with recommendations for several clinical trials in Cystic Fibrosis, which have had a significant impact on treatment. At the completion of his Presidency of ECFS, Prof. Döring became the Editor-in-Chief of the Journal of Cystic Fibrosis and worked tirelessly including the days before his passing on making JCF the pre-eminent journal in the field of Cystic Fibrosis. The support of young investigators was a high priority for Professor Döring.

To honour the enormous contribution of Professor Döring, the ECFS has initiated a Gerd Döring Award that will be given annually to honour an exceptional early career young European scientist.
The award is primarily judged on a paper published in the previous 3 calendar years, which has made a significant impact on the understanding or treatment of Cystic Fibrosis. This year, the Gerd Döring Award has been granted to Ms Florijn Dekkers, in acknowledgement of her recent remarkable contribution to Cystic Fibrosis. The Award, which includes a monetary grant of € 5 000 to support research, will be presented by Mrs. Döring during the Opening Plenary of the 38th European Cystic Fibrosis Conference.

FLORIJN DEKKERS

Florijn started her PhD project in 2010 in Jeffrey Beekman's lab in Utrecht, The Netherlands. She rapidly learned to culture intestinal organoids, a stem cell-based culture technology that allows rapid and limitless expansion of subject-specific tissue. Within 18 months of the observation, Nature Medicine accepted her first paper describing forskolin induced swelling of intestinal organoids as disease model for CF. This was the first disease model described in adult stem cultures with great impact on CF diagnosis, drug discovery and personalized medicine.

This paper described a novel functional CFTR assay in organoids generated from rectal tissue biopsies that were leftovers from diagnostics. This simple and robust assay relies on CFTR-dependent phenotypic organoid swelling induced by forskolin, and can be used to quantitate the residual subject-specific CFTR function and response to CFTR-modulating drugs. Importantly, organoids from individuals with either different or identical CFTR mutations responded differently to medication.

CF organoids are also important for the discovery of novel CFTR-modulating compounds by the pharmaceutical industry. Florijn is co-inventor on a patent application that is licensed to HUB, a foundation that already has performed drug screens with lead compounds for 8 out of 9 companies that are currently developing CFTR-restoring drugs. Together with HUB, Florijn has helped to establish the currently largest CF stem cell biobank worldwide that will have open access for the full research CF community in the near future.

Florijn's work furthermore resulted in multiple collaborations, helping to establish mechanism of action of CFTR-restoration approaches (Okiyoneda et al, Nat Chem Biol, 2013; Eckford et al, Chem Biol, 2014; Roth et al, Plos Biol 2014), and functional repair of adult stem cells by Crispr-Cas9 (Schwank et al., Cell Stem Cell, 2013).

The impact of her discovery will reach beyond CF. personalized therapy using individual living disease models in the lab is currently being explored by many labs worldwide for many types of diseases. Understanding the relations between the CFTR genotype, protein function and response to therapy for this monogenetic disease will be important to develop personalized treatments for complex genetic diseases such as cancer using adult stem cell cultures that are currently being set up. Moreover, collaborators found agonist-induced swelling of organoids derived from many tissues, indicating this simple swell readout can form the basis for other ion channel assays and drug discovery efforts.

Florijn will present her research in the Late Breaking Science Session, Friday, June 12, 17:00 – 18:30 in Hall 100.

PROGRAMME CONTENT DESCRIPTION

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

PLENARY
The Plenary sessions, lasting 90 minutes, comprise keynote lectures of experts in the field.

SYMPOSIA
The sessions, lasting 90 minutes, comprise 3 to 4 lectures by experts in the field covered by the symposium and specifically in the topic presented. Each presentation is followed by a discussion time when all attendees are invited to ask questions about/discuss the presentation.

WORKSHOPS
The sessions, lasting 90 minutes, comprise oral presentations of scientific work as outlined in the abstracts. The moderators of the workshops, experts in the field covered by the workshop, will introduce the different presentations and facilitate the discussion time when all attendees are invited to ask questions about/discuss the presentation.

CASE PRESENTATIONS
Informative cases related to diagnosis or management of CF will be presented and discussed. A panel of experts in the field facilitate the discussion and foster exchange of information or discuss treatment possibilities based on their expertise and knowledge of the latest scientific publications.

INTERACTIVE CASE STUDIES
Each interactive case presents an evolving patient history and a series of questions designed to test your diagnostic and/or therapeutic skills. You will receive immediate feedback on your answers and treatments choices, along with the opportunity to compare your final score with those of your peers.

MEET THE EXPERTS
The Meet the Experts sessions are small interactive sessions led by experts to stimulate discussion, answer questions and offer advice. The format encourages a more personal approach to learning.

GUIDED POSTER TOURS
These one-hour tours are led by an expert in the field commenting on the posters displayed at the Conference.

ePOSTER SESSIONS
These are moderated thematic sessions, during which ePosters will be presented on a 50-inch flat screen. These are scheduled in the ePoster Corners A and B, located within the Exhibition and ePoster Corner C, located on Level 3 of the conference venue.

POSTER EXHIBITION
Only abstracts accepted as posters will be presented in their respective categories.

ePOSTERS
An ePoster is an electronic version of the traditional paper poster displayed on computers. You will be able to consult the ePosters by using one of the computers in the ePosters Area located within the Exhibition. Abstracts selected for an oral presentation do not have a corresponding paper poster but an ePoster only.

SATELLITE SYMPOSIA
The most recent developments in the CF field will be presented during Satellite Symposia supported by industrial partners.

INDUSTRY EXHIBITION
The exhibition includes companies involved in Cystic Fibrosis and features the latest products and services offered by the industry.

MEETINGS
Each year several special interest CF groups hold their meetings in conjunction with the conference.

OPENING HOURS

INDUSTRY EXHIBITION	
Wednesday, June 10	18:00 – 21:30
Thursday, June 11	09:00 – 18:00
Friday, June 12	09:00 – 18:00
Saturday, June 13	09:00 – 12:30

SPEAKER PREVIEW ROOM	
Wednesday, June 10	10:00 – 19:00
Thursday, June 11	06:45 – 18:00
Friday, June 12	06:45 – 18:00
Saturday, June 13	08:00 – 11:00

REGISTRATION	
Tuesday, June 9	07:45 – 17:00
Wednesday, June 10	08:00 – 20:00
Thursday, June 11	07:00 – 19:30
Friday, June 12	07:00 – 19:00
Saturday, June 13	08:30 – 13:30

CLOAKROOM & BAGGAGE CLAIM	
Wednesday, June 10	08:00 – 21:30
Thursday, June 11	07:00 – 21:00
Friday, June 12	07:00 – 19:00
Saturday, June 13	08:30 – 13:30

POSTER AREA	
Wednesday, June 10	18:00 – 21:30
Thursday, June 11	08:00 – 18:00
Friday, June 12	08:00 – 18:00
Saturday, June 13	08:30 – 12:30

POSTERS PRESENTERS ACCESS	
Wednesday, June 10	14:00 – 18:00
Thursday, June 11	08:00 – 18:00
Friday, June 12	08:00 – 18:00
Saturday, June 13	08:30 – 14:00

SCHEDULE AT A GLANCE

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

TUESDAY, JUNE 9

08:15 – 16:45	Course	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	Room 211+212
08:30 – 17:30	Meeting	ECFS Board Meeting*	Room 202
08:30 – 17:00	Course	Quality Management / Quality Improvement Training Course**	Room 204

WEDNESDAY, JUNE 10

08:00 – 16:30	Meeting	International Nurse Specialist Group/CF Meeting**	Room 201 A/B
08:15 – 12:30	Course	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	Room 211+212
08:30 – 15:30	Meeting	ECFS CTN Training and Development*	Room 202
09:00 – 18:15	Course	CF Course**	Room 204
09:00 – 12:30	Meeting	CFE/ECFS Joint Symposium: Access to new therapies: How can patient organizations, researchers, health professionals, authorities and industry contribute?	Hall 400
09:00 – 13:45	Meeting	ECFS Exercise Working Group*	Room 311
09:00 – 16:30	Meeting	European Cystic Fibrosis Nutrition Group Meeting	Room 213+215
09:30 – 15:00	Meeting	ECFS Neonatal Screening Working Group Meeting	Arc Room
09:30 – 16:00	Meeting	European Psychosocial Special Interest Group (EPSIG) Meeting**	Room 206
12:30 – 14:00	Meeting	International Physiotherapy Group for Cystic Fibrosis (IPG/CF) Annual General Meeting*	Room 211+212
13:00 – 16:00	Meeting	Journal of Cystic Fibrosis Editorial Board Meeting*	Room 203
13:15 – 17:00	Meeting	ECFS CTN Steering Group Meeting*	Room 202
14:00 – 16:00	Meeting	ECFS Patient Registry Executive Committee Meeting*	Room 311
14:30 – 17:00	Meeting	Physiotherapy Case Presentations	Room 211+212
15:15 – 17:00	Meeting	ACTIVATE-CF Meeting*	Arc Room
16:00 – 18:00	Meeting	CF Pharmacists Meeting	Room 214-216
16:00 – 17:00	Meeting	ECFS Patient Registry Harmonisation Group Meeting*	Room 311
17:00 – 18:00	Meeting	ECFS Annual General Meeting*	Hall 400
18:30 – 20:00	Opening Plenary	Opening Plenary	Gold Hall
20:00 – 21:30		Welcome Reception	Exhibition

THURSDAY, JUNE 11

07:15 – 08:15	Meet the Experts	Understanding the basic CF defect to design novel therapies	ePoster Corner A
07:15 – 08:15	Meet the Experts	Clinical practice guideline on exercise counselling	ePoster Corner B
07:15 – 08:15	Meet the Experts	Distal Intestinal Obstruction Syndrome (DIOS)	ePoster Corner C
08:30 – 10:00	Symposium 1	CFTR modulation in real life	Gold Hall
08:30 – 10:00	Symposium 2	Best and future practices in CF infection diagnostics	Copper Hall
08:30 – 10:00	Symposium 3	How to monitor CF lung disease in infancy and early childhood?	Silver Hall
08:30 – 10:00	Symposium 4	Building a bridge between international guidelines in CF care and the CF clinical practice	Hall 100
08:30 – 10:00	Symposium 5	Cystic Fibrosis Related Diabetes	Hall 400
08:30 – 10:00	Symposium 6	Registry - Deploying the present - Shaping the future	Arc Room
10:00 – 10:30	COFFEE BREAK		Exhibition
10:30 – 12:00	Symposium 7	Understanding CF pathogen evolution and transmission using genomics	Gold Hall

* closed meeting ** extra registration required

SCHEDULE AT A GLANCE

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

10:30 – 12:00	Symposium 8	Systemic inflammation outside of the lung	Copper Hall
10:30 – 12:00	Symposium 9	Personalized monitoring and treatment of CF lung disease: Are we there?	Silver Hall
10:30 – 12:00	Symposium 10	CF 2015 - Next generation phenotyping	Hall 100
10:30 – 12:00	Symposium 11	Bacterial clearance by CF macrophages	Hall 400
10:30 – 12:00	Symposium 12	Assessing and achieving the best possible nutritional outcomes	Arc Room
12:00 – 14:00	LUNCH BREAK		
12:00 – 15:00	Posters	Poster Viewing	Poster Area
12:30 – 14:00	Satellite Symposium	The effect of CFTR modulation on the disease progression of Cystic Fibrosis in the era of precision medicine	Copper Hall
12:30 – 14:30	Meeting	ECFS CTN Standardisation Committee Meeting	Hall 400
12:30 – 13:30	Meeting	ECFS Patient Registry Data Quality Project Group Meeting	Hall 100
13:00 – 14:00	Meeting	UK Newborn Screening Special Interest Group*	Silver Hall
13:30 – 14:30	Meeting	ECFS Patient Registry - Meeting for Interested Parties	Hall 100
14:00 – 16:00	Meeting	UK Cystic Fibrosis Trust Meeting*	Room 202
14:00 – 15:00	Posters	ePoster Sessions	ePoster Corners
14:00 – 15:00	Posters	Guided Poster Tour	Poster Area
15:00 – 16:30	Workshop 1	Strategies to correct CFTR defects	Gold Hall
15:00 – 16:30	Workshop 2	Antimicrobial therapy, eradication and biofilm disruption	Copper Hall
15:00 – 16:30	Workshop 3	Through the cycle of life	Silver Hall
15:00 – 16:30	Workshop 4	Hormone and vitamin D metabolism	Hall 100
15:00 – 16:30	Workshop 5	e-Health	Hall 400
15:00 – 16:30	Workshop 6	Fixing ion transport	Arc Room
16:30 – 17:00	COFFEE BREAK		Exhibition
17:00 – 18:30	Workshop 7	Monitoring CF lung disease	Gold Hall
17:00 – 18:30	Workshop 8	Inhalation therapy: Wet & dry	Copper Hall
17:00 – 18:30	Workshop 9	Diversity in CF care	Silver Hall
17:00 – 18:30	Workshop 10	Emerging topics on bacterial-host interactions	Hall 100
17:00 – 18:30	Workshop 11	Newborn Screening - Still some work to do!	Hall 400
17:00 – 18:30	Special Sympoisum	Research Opportunities in EU	Arc Room
18:30 – 20:30	Meeting	ECFS CTN Blood Inflammatory Markers Standardisation Group	Gold Hall
18:30 – 19:30	Meeting	ECFS Patient Registry Software Training Reports & Encounters*	Arc Room
19:00 – 20:00	Meeting	European CF Registry Forum*	Copper Hall
19:00 – 20:30	Satellite Symposium	Anti-pseudomonal treatments – Enhancing the potency of regimen	Silver Hall

FRIDAY, JUNE 12

07:15 – 08:15	Meet the Experts	CFTR gene sequencing pitfalls	ePoster Corner A
07:15 – 08:15	Meet the Experts	Microbiome	ePoster Corner B
07:15 – 08:15	Meet the Experts	Transplant	ePoster Corner C
08:30 – 10:00	Symposium 13	Interactive case studies	Gold Hall
08:30 – 10:00	Symposium 14	Electronic patient record: Access for the patient!	Copper Hall
08:30 – 10:00	Symposium 15	Education and teamwork	Silver Hall
08:30 – 10:00	Symposium 16	Interventions in gastroenterology and nutrition	Hall 100

* closed meeting ** extra registration required

SCHEDULE AT A GLANCE

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

08:30 – 10:00	Symposium 17	Surviving CF - Challenges for the physiotherapist	Hall 400
08:30 – 10:00	Symposium 18	CFTR structure, trafficking and interactors in the chase for new correctors	Arc Room
10:00 – 10:30	COFFEE BREAK		Exhibition
10:30 – 12:00	Symposium 19	Growing old with CF	Gold Hall
10:30 – 12:00	Symposium 20	New approaches targeting the basic defect	Copper Hall
10:30 – 12:00	Symposium 21	Living with CF: Day-to-day adjustment	Silver Hall
10:30 – 12:00	Symposium 22	Managing difficult pathogens: Case studies	Hall 100
10:30 – 12:00	Symposium 23	Newborn Screening for CF – The next stage of the journey	Hall 400
10:30 – 12:00	Symposium 24	Mechanisms of early respiratory mucus malfunction	Arc Room
12:00 – 14:00	LUNCH BREAK		
12:00 – 15:00	Posters	Poster Viewing	Poster Area
12:30 – 14:00	Satellite Symposium	Focus on *Pseudomonas aeruginosa* in Cystic Fibrosis: Past, present and future	Copper Hall
12:30 – 14:00	Satellite Symposium	Personalising care to meet lifelong challenges in Cystic Fibrosis	Gold Hall
12:30 – 14:30	Meeting	ECFS Diagnostic Network Working Group Meeting	Hall 100
12:30 – 14:30	Meeting	ECFS Patient Registry Steering Group Meeting	Silver Hall
14:00 – 15:00	Posters	ePoster Sessions	ePoster Corners
14:00 – 15:00	Posters	Guided Poster Tour	Poster Area
15:00 – 16:30	Workshop 13	Bugs and drugs	Gold Hall
15:00 – 16:30	Workshop 14	Why exercise?	Copper Hall
15:00 – 16:30	Workshop 15	Psychosocial and nursing case presentations	Silver Hall
15:00 – 16:30	Workshop 16	GI and liver abnormalities	Hall 100
15:00 – 16:30	Workshop 17	Genotype matters	Hall 400
15:00 – 16:30	Workshop 18	Modeling the future	Arc Room
16:30 – 17:00	COFFEE BREAK		Exhibition
17:00 – 18:30	Workshop 19	Influence of host environment on bacterial diversity	Gold Hall
17:00 – 18:30	Workshop 20	How to measure and modulate CFTR dysfunction	Copper Hall
17:00 – 18:30	Workshop 21	Cleaning the lungs	Silver Hall
17:00 – 18:30	Workshop 22	Late breaking science	Hall 100
17:00 – 18:30	Special Symposium	Mental health screening programmes in Europe: Results and panel discussion of implementation practices	Hall 400
SATURDAY, JUNE 13			
09:00 – 10:30	Symposium 25	Bad bugs new drugs	Gold Hall
09:00 – 10:30	Symposium 26	Managing exacerbations – Interactive debates	Copper Hall
09:00 – 10:30	Symposium 27	Inflammation and lung remodeling, towards alternative therapeutic strategies	Silver Hall
09:00 – 10:30	Symposium 28	Gut inflammation and gastro-oesophageal reflux disease (GERD)	Hall 100
09:00 – 10:30	Symposium 29	Registry: Which data to enter for optimizing surveillance?	Hall 400
10:30 – 11:00	COFFEE BREAK		Exhibition
11:00 – 12:30	Closing Plenary	Closing Plenary	Gold Hall
12:00 – 17:00	Meeting	CF Europe/CF Belgium Family Conference: "Research, hope for today and tomorrow!"	Silver Hall
12:30 – 13:00	Closing Ceremony	Closing Ceremony	Gold Hall
13:30 – 18:00	Meeting	ECFS Scientific Committee Meeting - Basel 2016*	Room 213+215

* closed meeting ** extra registration required

WEDNESDAY, JUNE 10

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

	Gold Hall	Exhibition & Poster Area	Hall 400	Other
07:30				
08:00				
08:30				
09:00				MEETINGS & COURSES 08:30 – 18:30
09:30				
10:00			CFE/ECFS JOINT SYMPOSIUM 09:30 – 12:30	
10:30			Access to new therapies: How can patient organizations, researchers, health professionals, authorities and industry contribute?	
11:00				
11:30				
12:00				
12:30				
13:00				
13:30				
14:00				
14:30		POSTER HANGING		
15:00				
15:30				
16:00				
16:30				
17:00				
17:30			ECFS ANNUAL GENERAL MEETING 17:00 – 18:00	
18:00				
18:30		EXHIBITION & POSTER AREA OPEN		
19:00	OPENING PLENARY 18:30 – 20:00			
19:30				
20:00				
20:30		WELCOME RECEPTION 20:00 – 21:30		
21:00				
21:30				

17:00 – 18:00 ECFS Annual General Meeting* — Hall 400

*closed meeting (ECFS Members only)

18:30 – 20:00 Opening Plenary — Gold Hall

In the presence of:

Kris De Boeck, ECFS President
Georges Casimir, Conference President
Mario Vaneechoutte, Conference Vice President
Ulrike Pypops, Conference Vice President
Herman Van Rompuy, First President of the European Council
Annika Nowak, Directorate General for Health and Consumers, European Commission

The Opening will include:

- Welcome Address
- A year in review - Lieven Dupont, Leuven, BE
- Presentation of the ECFS Award
- ECFS Award Lecture - Carlo Castellani, Verona, IT
- Presentation of the Gerd Döring Award

The ECFS Award is awarded to honour a person or persons who have made a significant contribution to our understanding of Cystic Fibrosis or to the treatment or care of patients with Cystic Fibrosis. The award, previously named the Rossi Medal, is now called the European Cystic Fibrosis Society Award at the request of Prof. Rossi's family. This year the award goes to Carlo Castellani, Verona, Italy. In previous years the award has been presented to the following:

2002 Prof. Margaret Hodson (UK)
2003 Prof. Gianni Mastella (IT)
2004 Dr. James Littlewood (UK)
2005 Prof. John Govan (UK)
2006 Dr. Christian Koch (DK)
2007 Dr. Edith Puchelle (FR)
2008 Prof. Véra Vávrová (CZ)
2009 Prof. Francis Collins (US), Prof. Batsheva Kerem (IL), Prof. John Riordan (US), Prof. Lap-Chee Tsui (HK)
2010 Prof. Margarida D. Amaral (PT), Dr. David N. Sheppard (UK)
2011 Prof. Gerd Döring (DE)
2012 Prof. Niels Høiby (DK)
2013 Prof. Kevin Webb (UK)
2014 Prof. Eitan Kerem (IL)

20:00 – 21:30 Welcome Reception — Exhibition Area

The Welcome Reception is free of charge to all registered participants.

THURSDAY, JUNE 11

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

	Gold Hall	Copper Hall	Silver Hall
07:00			
07:30			
08:00			
08:30			
09:00	SYMPOSIUM 1 08:30 – 10:00	SYMPOSIUM 2 08:30 – 10:00	SYMPOSIUM 3 08:30 – 10:00
09:30	CFTR modulation in real life	Best and future practices in CF infection diagnostics	How to monitor CF lung disease in infancy and early childhood?
10:00			
10:30	COFFEE BREAK IN EXHIBITION		
11:00	SYMPOSIUM 7 10:30 – 12:00	SYMPOSIUM 8 10:30 – 12:00	SYMPOSIUM 9 10:30 – 12:00
11:30	Understanding CF pathogen evolution and transmission using genomics	Systemic inflammation outside of the lung	Personalized monitoring and treatment of CF lung disease: Are we there?
12:00			
12:30	LUNCH BREAK		LUNCH BREAK
13:00		SATELLITE SYMPOSIUM 12:30 – 14:00	
13:30		The effect of CFTR modulation on the disease progression of Cystic Fibrosis in the era of precision medicine	
14:00			
14:30			
15:00			
15:30	WORKSHOP 1 15:00 – 16:30	WORKSHOP 2 15:00 – 16:30	WORKSHOP 3 15:00 – 16:30
16:00	Strategies to correct CFTR defects	Antimicrobial therapy, eradication and biofilm disruption	Through the cycle of life
16:30			
17:00	COFFEE BREAK IN EXHIBITION		
17:30	WORKSHOP 7 17:00 – 18:30	WORKSHOP 8 17:00 – 18:30	WORKSHOP 9 17:00 – 18:30
18:00	Monitoring CF lung disease	Inhalation therapy: Wet & dry	Diversity in CF care
18:30			
19:00			
19:30			SATELLITE SYMPOSIUM 19:00 – 20:30
20:00			Anti-pseudomonal treatments - Enhancing the potency of regimen
20:30			
21:00			

THURSDAY, JUNE 11

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

	Hall 100	Hall 400	Arc Room	Exhibition & Poster Area
07:00				
07:30				MEET THE EXPERTS 07:15 – 08:15
08:00				
08:30				
09:00	SYMPOSIUM 4 08:30 – 10:00	SYMPOSIUM 5 08:30 – 10:00	SYMPOSIUM 6 08:30 – 10:00	
09:30	Building a bridge between international guidelines in CF care and the CF clinical practice	Cystic Fibrosis Related Diabetes	Registry - Deploying the present - Shaping the future	EXHIBITION & POSTERS
10:00				
10:30	COFFEE BREAK IN EXHIBITION			
11:00	SYMPOSIUM 10 10:30 – 12:00	SYMPOSIUM 11 10:30 – 12:00	SYMPOSIUM 12 10:30 – 12:00	
11:30	CF 2015 - Next generation phenotyping	Bacterial clearance by CF macrophages	Assessing and achieving the best possible nutritional outcomes	
12:00				
12:30	LUNCH BREAK			
13:00				
13:30				
14:00				
14:30				GUIDED POSTER TOUR & ePOSTER SESSIONS
15:00				
15:30	WORKSHOP 4 15:00 – 16:30	WORKSHOP 5 15:00 – 16:30	WORKSHOP 6 15:00 – 16:30	EXHIBITION & POSTERS
16:00	Hormone and vitamin D metabolism	e-Health	Fixing ion transport	
16:30				
17:00	COFFEE BREAK IN EXHIBITION			
17:30	WORKSHOP 10 17:00 – 18:30	WORKSHOP 11 17:00 – 18:30	SPECIAL SYMPOSIUM 17:00 – 18:30	
18:00	Emerging topics on bacterial-host interactions	Newborn Screening - Still some work to do!	Research opportunities in EU	
18:30				
19:00				
19:30				
20:00				
20:30				
21:00				

THURSDAY, JUNE 11

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

07:15 – 08:15	Meet the Experts - Understanding the basic CF defect to design novel therapies	
	Experts: Marcus Mall, Heidelberg, DE / William Balch, La Jolla, US	ePoster Corner A

07:15 – 08:15	Meet the Experts - Clinical practice guideline on exercise counseling	
	Experts: Helge Hebestreit, Würzburg, DE / Nancy Alarie, Montreal, CA	ePoster Corner B

07:15 – 08:15	Meet the Experts - Distal Intestinal Obstruction Syndrome (DIOS)	
	Experts: Anne Munck, Paris, FR / Roderick Houwen, Utrecht, NL	ePoster Corner C

08:30 – 10:00	Symposium 1 - CFTR modulation in real life	
	Moderators: Tim Lee, Leeds, UK / Isabelle Durieu, Lyon, FR	Gold Hall
08:30 – 08:52	Combination therapy – Tim Lee, Leeds, UK	
08:52 – 09:14	Efficacy: Who benefits most? – Barry Plant, Cork, IE	
09:14 – 09:36	Safety and pharmacokinetics – Martin Hug, Freiburg, DE	
09:36 – 10:00	Dealing with rare mutations – Kris De Boeck, Leuven, BE	

08:30 – 10:00	Symposium 2 - Best and future practices in CF infection diagnostics	
	Moderators: Kirsten Schaffer, Dublin, IE / Miles Denton, Leeds, UK	Copper Hall
08:30 – 08:52	Best practice in routine CF bacteriology – Jerina Boelens, Ghent, BE	
08:52 – 09:14	Diagnosis of CF fungal infection – Laurence Delhaes, Lille, FR	
09:14 – 09:36	Identification of non-tuberculous mycobacteria in CF – Michael Hogardt, Frankfurt, DE	
09:36 – 10:00	MALDI-TOF in CF infection diagnostics – Ingrid Wybo, Brussels, BE	

08:30 – 10:00	Symposium 3 - How to monitor CF lung disease in infancy and early childhood?	
	Moderators: Dominik Hartl, Tübingen, DE / Philipp Latzin, Basel, CH	Silver Hall
08:30 – 08:52	BAL surveillance to predict the course of CF lung disease – Peter Sly, Brisbane, AU	
08:52 – 09:14	Advanced lung function: LCI and beyond – Florian Singer, Zurich, CH	
09:14 – 09:36	Immune signatures of early CF lung disease – Scott Sagel, Denver, US	
09:36 – 10:00	Imaging approaches for early CF lung disease – Pierluigi Ciet, Rotterdam, NL	

08:30 – 10:00	Symposium 4 - Building a bridge between international guidelines in CF care and the CF clinical practice	
	Moderators: Trudy Havermans, Leuven, BE / Mark Butler, London, UK	Hall 100
08:30 – 08:52	Infection control guidelines: Challenges and barriers in the clinic – Samantha Henman, Cambridge, UK	
08:52 – 09:14	European best practice guidelines for CF neonatal screening – Jet van der Hulst, Groningen, NL	
09:14 – 09:36	Standards of care: Building the bridge to the clinic – Mandy Bryon, London, UK	
09:36 – 10:00	Guidelines in end of life/transplantation: Is the advanced care plan the future? – Lieven Dupont, Leuven, BE	

08:30 – 10:00	**Symposium 5 - Cystic Fibrosis Related Diabetes**	
	Moderators: Harry Heijerman, The Hague, NL / Tacjana Pressler, Copenhagen, DK	Hall 400
08:30 – 08:52	What did we learn from animal models on the CF pancreas – Andrew Norris, Iowa City, US	
08:52 – 09:14	Clinical characteristics of CFRD: Lessons from the ECFSPR – Hanne Olesen, Aarhus, DK	
09:14 – 09:36	Can CFRD be reversed by CFTR modifiers? – Antoinette M. Moran, Minneapolis, US	
09:36 – 10:00	Nutritional interventions in the different stages of CFRD – Hila Elyashar-Earon, Jerusalem, IL	

08:30 – 10:00	**Symposium 6 - Registry - Deploying the present - Shaping the future**	
	Moderators: Edward McKone, Dublin, IE / Bruce Marshall, Bethesda, US	Arc Room
08:30 – 08:40	Registry in Brazil – Luiz Vicente Ribeiro Ferreira da Silva Filho, Sao Paulo, BR	
08:40 – 08:50	Experiences from international CF registries: Europe and beyond – Vincent Gulmans, Baarn, NL	
08:50 – 09:13	Future directions of the European CF Registry – Edward McKone, Dublin, IE	
09:13 – 09:36	Scientific projects within ECFSPR – Andreas Jung, Zurich, CH	
09:36 – 10:00	Making longitudinal data sets from annual cross-sectional data – Anil Mehta, Dundee, UK	

10:00 – 10:30	COFFEE BREAK

10:30 – 12:00	**Symposium 7 - Understanding CF pathogen evolution and transmission using genomics**	
	Moderators: Jean-Marc Rolain, Marseille, FR / Eshwar Mahenthiralingam, Cardiff, UK	Gold Hall
10:30 – 10:52	Long term tracking of *Pseudomonas* by whole genome sequencing – Lars Jelsbak, Lyngby, DK	
10:52 – 11:14	Evolution of *Burkholderia* in the CF lung – Vaughn Cooper, Durham, US	
11:14 – 11:36	Nontuberculous mycobacteria – Josephine Bryant, Hinxton, UK	
11:36 – 12:00	Understanding viral community in the CF lung – Yanwei Lim, San Diego, US	

10:30 – 12:00	**Symposium 8 - Systemic inflammation outside of the lung**	
	Moderators: Raphael Chiron, Montpellier, FR / Marita Gilljam, Gothenburg, SE	Copper Hall
10:30 – 10:52	Inflammation as part of the CF defect – Luigi Maiuri, Milan, IT	
10:52 – 11:14	Arthropathy and vasculitis – Ali Jawad, London, UK	
11:14 – 11:36	Hypersensitivity and drug allergy – Davide Caimmi, Montpellier, FR	
11:36 – 12:00	Is there systemic inflammation with CF? – Hartmut Grasemann, Toronto, CA	

10:30 – 12:00	**Symposium 9 - Personalized monitoring and treatment of CF lung disease: Are we there?**	
	Moderators: Harm Tiddens, Rotterdam, NL / Barry Plant, Cork, IE	Silver Hall
10:30 – 10:52	Preschool age: Can we differentiate high from low risk? – Stephen Stick, Perth, AU	
10:52 – 11:14	School age: How to recognize a stepwise change in risk? – Harm Tiddens, Rotterdam, NL	
11:14 – 11:36	Adults: Can patients monitor themselves? – Alexandra Quittner, Miami, US	
11:36 – 12:00	Advanced lung disease: How to personalize treatment – Isabelle Durieu, Lyon, FR	

THURSDAY, JUNE 11

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

10:30 – 12:00	**Symposium 10 - CF 2015 - Next generation phenotyping**	
	Moderators: Nico Derichs, Berlin, DE / Elke De Wachter, Brussels, BE	Hall 100
10:30 – 10:52	Does sequencing have the answer? – Harry Cuppens, Leuven, BE	
10:52 – 11:14	What can the sweat gland tell us about the patient? – Tanja Gonska, Toronto, CA	
11:14 – 11:36	The clinical impact of respiratory and intestinal CFTR & ENaC function – Isabelle Sermet, Paris, FR	
11:36 – 12:00	CF and its new relatives: Perspectives for CF diagnostic guidelines – Sheila Scheinert, Berlin, DE	

10:30 – 12:00	**Symposium 11 - Bacterial clearance by CF macrophages**	
	Moderators: Marc Chanson, Geneva, CH / Jean-Louis Herrmann, Paris, FR	Hall 400
10:30 – 10:52	*Mycobacterium abscessus* – Jean-Louis Herrmann, Paris, FR	
10:52 – 11:14	Autophagy-mediated Clearance of *Burkholderia cenocepacia* – Benjamin T. Kopp, Colombus, US	
11:14 – 11:36	Reactive-oxygen-species-mediated *P. aeruginosa* killing – Paola del Porto, Rome, IT	
11:36 – 12:00	Impact of impaired macrophage function in infection – Corinne Martin-Chouly, Rennes, FR	

10:30 – 12:00	**Symposium 12 - Assessing and achieving the best possible nutritional outcomes**	
	Moderators: Chris Smith, Brighton, UK / Helen McCabe, Newcastle, UK	Arc Room
10:30 – 10:52	A novel approach to correcting sub-optimal fat absorption – Steve D. Freedman, Boston, US	
10:52 – 11:14	What are the best nutritional outcome measures? – Helen White, Leeds, UK	
11:14 – 11:36	Is there a role for probiotics? – Bruno Hauser, Brussels, BE	
11:36 – 12:00	What should our patients eat? – Willie Woestenenk, Utrecht, NL	

12:00 – 14:00	LUNCH BREAK

12:30 – 14:00	**Satellite Symposium - The effect of CFTR modulation on the disease progression of Cystic Fibrosis in the era of precision medicine**	
		Copper Hall

See detailed programme page 72

14:00 – 15:00	**Posters**	
14:00 – 15:00	ePoster Sessions:	
	ePS1: Genetics across the continents	ePoster Corner A
	ePS2: Challenges of fungal infections	ePoster Corner B
	ePS3: Adherence	ePoster Corner C

See detailed programme page 44

14:00 – 15:00	Guided Poster Tour in the following category Microbiology: Epidemiology and sources of infection

14:00 – 15:00 Poster Viewing:
Poster presenters in the following categories are asked to be available at their posters for discussion:

- Immunology/Inflammation/Cell Biology
- Microbiology
- Upper and Lower Airways
- Bone/Vitamin D/Liver Disease
- Gastroenterology/Nutrition

See detailed programme page 43

15:00 – 16:30 Workshop 1 - Strategies to correct CFTR defects

Moderators: Jane Davies, London, UK / Silke van Koningsbruggen-Rietschel, Cologne, DE — Gold Hall

15:00 – 15:15	WS01.1	rAAV2/5 encoding a truncated CFTR rescues the CF phenotype in intestinal organoids and a CF mouse model – Marianne Carlon, Leuven, BE
15:15 – 15:30	WS01.2	QR-010, an RNA therapy, restores CFTR function using *in vitro* and *in vivo* models of ΔF508 CFTR – Wouter Beumer, Leiden, NL
15:30 – 15:45	WS01.3	Lumacaftor in combination with ivacaftor in patients with Cystic Fibrosis who are homozygous for the F508del-CFTR mutation – Stuart Elborn, Belfast, UK
15:45 – 16:00	WS01.4	VX-661 in combination with ivacaftor in patients with Cystic Fibrosis and the F508del-CFTR mutation – Joseph Pilewski, Pittsburgh, US
16:00 – 16:15	WS01.5	An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with Cystic Fibrosis and a CFTR gating mutation: The KIWI study – Margaret Rosenfeld, Seattle, US
16:15 – 16:30	WS01.6	The rational design of nanomedicines for chronic pulmonary infection treatment: Does size really matter? – Katrien Forier, Ghent, BE

15:00 – 16:30 Workshop 2 - Antimicrobial therapy, eradication and biofilm disruption

Moderators: Pavel Drevinek, Prague, CZ / Niels Høiby, Copenhagen, DK — Copper Hall

15:00 – 15:11	WS02.1	Efficacy of a protocol for eradication of newly acquired MRSA: Results of the STAR-too trial – Christopher Goss, Seattle, US
15:11 – 15:22	WS02.2	Aztreonam for inhalation solution (AZLI) for eradication of new onset *Pseudomonas aeruginosa* (PA) infection in children with Cystic Fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use – Harm Tiddens, Rotterdam, NL
15:22 – 15:33	WS02.3	Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD) – Patrick Flume, Charleston, US
15:33 – 15:44	WS02.4	Short-term and long-term effects of ivacaftor treatment on sputum microbiota in people with the G551D CFTR mutation – Lucas Hoffman, Seattle, US
15:44 – 15:55	WS02.5	Pharmacodynamics of ceftazidime combined with β-lactamase inhibitors in biofilm *P. aeruginosa in vitro* – Christian Jørgensen, Copenhagen, DK
15:55 – 16:06	WS02.6	Increased bactericidal activity of colistin on *Pseudomonas aeruginosa* biofilms in anaerobic conditions – Mette Kolpen, Copenhagen, DK
16:06 – 16:18	WS02.7	Initial and chronic MRSA infection in Cystic Fibrosis – Deirdre Gilpin, Belfast, UK
16:18 – 16:30	WS02.8	Altered therapeutic susceptibility of mucoid *Pseudomonas aeruginosa* in artificial sputum medium – Manon Pritchard, Cardiff, UK

THURSDAY, JUNE 11

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

15:00 – 16:30 Workshop 3 - Through the cycle of life

Moderators: Susan Madge, London, UK / Anne Munck, Paris, FR — Silver Hall

15:00 – 15:15	WS03.1	Positive effects of a coaching program for parents after the diagnosis of CF following newborn screening – Jacquelien Noordhoek, Baarn, NL
15:15 – 15:30	WS03.2	Coping with stress of mothers of children and adolescents with Cystic Fibrosis – Renata Zubrzycka, Lublin, PL
15:30 – 15:45	WS03.3	Preparing first school entry for a child with Cystic Fibrosis: Contribution of a group education session – Suzy Gonsseaume, Paris, FR
15:45 – 16:00	WS03.4	Trust, transition and choosing your battles: An exploration of partnership between young expert patients with CF and the healthcare team – Kath MacDonald, Musselburgh, UK
16:00 – 16:15	WS03.5	Employment and work disability in adults with Cystic Fibrosis: A cohort study – Maxime Digonnet, Paris, FR
16:15 – 16:30	WS03.6	Pregnancies after lung transplantation: A retrospective multicenter French study about 39 pregnancies – Dominique Hubert, Paris, FR

15:00 – 16:30 Workshop 4 - Hormone and vitamin D metabolism

Moderators: Gary Connett, Southampton, UK / Michael Wilschanski, Jerusalem, IL — Hall 100

15:00 – 15:15	WS04.1	Hypersecretion of glucagon-like peptide 1 (GLP1) in Cystic Fibrosis – Gareth Jones, Liverpool, UK
15:15 – 15:30	WS04.2	Growth hormone deficiency (GHD) in adult patients (pts) with Cystic Fibrosis (CF) – Chiara Pascucci, Rome, IT
15:30 – 15:45	WS04.3	Deficiency of dehydroepiandrosterone sulfate in pediatric and adult patients with Cystic Fibrosis – Nataliya Kashirskaya, Moscow, RU
15:45 – 16:00	WS04.4	Prevalence of vitamin D deficiency and effectiveness of two different high dose (stoss) oral vitamin D supplementation protocols in a paediatric Cystic Fibrosis clinic in Australia – Natalie VanderHaak, Adelaide, AU
16:00 – 16:15	WS04.5	Vitamin D influence on respiratory exacerbations and hospitalizations in Cystic Fibrosis patients – Yasmeen Abu-Fraiha, Jerusalem, IL
16:15 – 16:30	WS04.6	Children with Cystic Fibrosis: How compromised is bone? – Philippe Reix, Lyon, FR

15:00 – 16:30 Workshop 5 - e-Health

Moderators: Ulrike Pypops, Brussels, BE / Steve Cunningham, Edinburgh, UK — Hall 400

15:00 – 15:24		e-Health: Big Brother or effective support? – Ulrike Pypops, Brussels, BE
15:24 – 15:35	WS05.1	The development of a website to facilitate transition from paediatric to adult CF services – Samantha Henman, Cambridge, UK
15:35 – 15:46	WS05.2	30 day challenge - Using social media to support adult CF patients to exercise in the adult CF service Dundee – Alison Smith, Dundee, UK
15:46 – 15:57	WS05.3	Sleep architecture in CF patients as assessed by the Body Media's SenseWear® Armband (SWA) – Christian Opdekamp, Brussels, BE
15:57 – 16:08	WS05.4	Video games for positive expiratory pressure (PEP) therapy in children with Cystic Fibrosis: A pilot study – Annie Brochu, Montreal, CA
16:08 – 16:19	WS05.5	Developing an audio-visual intervention to support children's adherence to home chest physiotherapy for Cystic Fibrosis – Karen Semple, Stirling, UK
16:19 – 16:30	WS05.6	A pilot study of enhanced community support via internet videoconferencing and physiotherapist home visits – Andy Clayton, Nottingham, UK

15:00 – 16:30	Workshop 6 - Fixing ion transport	
	Moderators: Olivier Tabary, Paris, FR / Gunnar C. Hansson, Gothenburg, SE	Arc Room
15:00 – 15:15	WS06.1	Stabilization of CFTR at the membrane by EPAC1 activation occurs through interaction with NHERF-1 – Carlos Farinha, Lisbon, PT
15:15 – 15:30	WS06.2	R117H-CFTR has a defect in channel gating activity that can be potentiated by ivacaftor – Fredrick Van Goor, San Diego, US
15:30 – 15:45	WS06.3	Evaluation of novel corrector-potentiator combinations for treating Cystic Fibrosis in various assays – Corina Balut, Chicago, US
15:45 – 16:00	WS06.4	miR-9 and ANO1: Therapeutic targets in Cystic Fibrosis? – Florence Sonneville, Paris, FR
16:00 – 16:15	WS06.5	SLC26A9 chloride channels: Generation and functional characterization of stably-overexpressing FRT epithelial cells – Johanna Salomon, Heidelberg, DE
16:15 – 16:30	WS06.6	Mucociliary transport is impaired in Cystic Fibrosis pig airways – Anna Ermund, Gothenburg, SE
16:30 – 17:00	COFFEE BREAK	
17:00 – 18:30	Workshop 7 - Monitoring CF lung disease	
	Moderators: Philipp Latzin, Basel, CH / Dominik Hartl, Tübingen, DE	Gold Hall
17:00 – 17:15	WS07.1	Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations – Natalile West, Baltimore, US
17:15 – 17:30	WS07.2	Bronchoalveolar lavage in children with Cystic Fibrosis and increasing Lung Clearance Index – Marcus Svedberg, Gothenburg, SE
17:30 – 17:45	WS07.3	FEF_{25-75} does not contribute to the interpretation of spirometry in patients with Cystic Fibrosis – François Vermeulen, Leuven, BE
17:45 – 18:00	WS07.4	MBW and MRI as sensitive markers of stable CF lung disease and at exacerbation in children and adolescents – Mirjam Stahl, Heidelberg, DE
18:00 – 18:15	WS07.5	Rhinovirus associated pulmonary exacerbations show a lack of FEV_1 improvement in children with Cystic Fibrosis – Mathias Cousin, Montpellier, FR
18:15 – 18:30		Wrap-up and close
17:00 – 18:30	Workshop 8 - Inhalation therapy: Wet & dry	
	Moderators: Harm Tiddens, Rotterdam, NL / Helen Parrott, London, UK	Copper Hall
17:00 – 17:07		Introduction – Helen Parrott, London, UK
17:07 – 17:22	WS08.1	Aerosol delivery practice in Italian Cystic Fibrosis centres - A national survey – Federica Carta, Milan, IT
17:22 – 17:41	WS08.2	Use of the AKITA JET® for inhalation treatment in Cystic Fibrosis patients (WS08.2/1 and WS08.2/2) – Hanneke Eyns, Brussels, BE
17:41 – 17:56	WS08.3	"Real world" experience of introduction of Colobreathe®(Colo) in adults with Cystic Fibrosis – Hannah Langman, Manchester, UK
17:56 – 18:15	WS08.4	1 year tolerability and patient experience of dry powder mannitol (WS08.4/1 and WS08.4/2) – Fiona Shaw, London, UK
18:15 – 18:30	WS08.5	Cayston® in clinical practice - One year follow-up – Mark Jackson, Liverpool, UK

17:00 – 18:30	Workshop 9 - Diversity in CF care	
	Moderators: Jacquelien Noordhoek, Baarn, NL / Doris Thomsen, Copenhagen, DK	Silver Hall
17:00 – 17:09	WS09.1	Should we advocate a structured venous access policy in adults with CF? – Kristine Colpaert, Leuven, BE
17:09 – 17:18	WS09.2	Radiation exposure in adults with CF attending Bristol Adult CF Centre – Charlotte Addy, Bristol, UK
17:18 – 17:27	WS09.3	Professional quality of life among CF healthcare providers – Lutz Goldbeck, Ulm, DE
17:27 – 17:36	WS09.4	The role of resilience in quality of life of adult patients with Cystic Fibrosis (CF) – Bianca Rabanser, Innsbruck, AT
17:36 – 17:45	WS09.5	Effect of ivacaftor on wellness, quality of life and cognitive function in adults with Cystic Fibrosis and G551D mutation – Brenda Button, Melbourne, AU
17:45 – 17:54	WS09.6	The effect of a 12-month adherence intervention, "CF My Way", on medication possession, clinical outcomes and quality of life in CF adolescents and young adults – Edwina Landau, Tel Aviv, IL
17:54 – 18:03	WS09.7	The CF CARE programme for adherence training in the CF multidisciplinary team – Damian Downey, Belfast, UK
18:03 – 18:12	WS09.8	End-of-life care in CF patients: France, 2007-2010 – Pierre-Régis Burgel, Paris, FR
18:12 – 18:21	WS09.9	Learning from patient deaths in CF: An audit of team debrief sessions at a UK adult centre – Helen Oxley, Manchester, UK
18:21 – 18:30	WS09.10	"Writing for the future", addressing the challenges of family communication at the end of life in Cystic Fibrosis – Anne Calvert, Belfast, UK

17:00 – 18:30	Workshop 10 - Emerging topics on bacterial-host interactions	
	Moderators: Joanne Fothergill, Liverpool, UK / Burkhard Tümmler, Hannover, DE	Hall 100
17:00 – 17:13	WS10.1	Investigating exogenous CFTR dysfunction in healthy human neutrophils – Denver Mooney, Belfast, UK
17:13 – 17:26	WS10.2	Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in Cystic Fibrosis-like lung disease – Zhe Zhou-Suckow, Heidelberg, DE
17:26 – 17:39	WS10.3	Monitoring the pro-inflammatory effect of *Pseudomonas aeruginosa* culture supernatants and the inhibitory effect of azithromycin by *in vivo* imaging in IL-8 transiently transgenized mice – Paola Melotti, Verona, IT
17:39 – 17:52	WS10.4	Transcriptomic analysis of normal and Cystic Fibrosis human bronchial epithelial cells infected with *Pseudomonas aeruginosa* reveals distinct gene activation – Viviane Balloy, Paris, FR
17:52 – 18:05	WS10.5	*Pseudomonas aeruginosa* adaptation as a potential risk factor to the progression of Cystic Fibrosis airway disease in mice and humans – Alessandra Bragonzi, Milan, IT
18:05 – 18:18	WS10.6	How does airway infection with chronic Gram negative and nontuberculous mycobacteria affect lung function? A longitudinal study – David Taylor-Robinson, Liverpool, UK
18:18 – 18:30	WS10.7	The role of C-Type lectins in the recognition of *Pseudomonas aeruginosa* – Tamanna Rahman, Nottingham, UK

17:00 – 18:30	**Workshop 11 - Newborn Screening - Still some work to do!**		
	Moderators: Anne Munck, Paris, FR / Margaret Rosenfeld, Seattle, US		Hall 400
17:00 – 17:09	WS11.1	Highlighting the importance of carrier testing in CF families – Virginie Scotet, Brest, FR	
17:09 – 17:18	WS11.2	The benefits of newborn screening for Cystic Fibrosis: The Canadian experience – Larry Lands, Montreal, CA	
17:18 – 17:27	WS11.3	Newborn screening for Cystic Fibrosis in Switzerland - Performance after 4 years – Maja Jurca, Bern, CH	
17:27 – 17:36	WS11.4	The significance of a neonatal screening program in the early diagnosis of Cystic Fibrosis – Nataliya Kashirskaya, Moscow, RU	
17:36 – 17:45	WS11.5	The consequences of no newborn Cystic Fibrosis screening in a well-developed country – Maya Graham-Pedersen, Aarhus , DK	
17:45 – 17:54	WS11.6	Newborn screening for Cystic Fibrosis: Rationale for P.Arg117His (R117H) removal from the CFTR mutation panel in France – Anne Munck, Paris, FR	
17:54 – 18:03	WS11.7	Feeding, growth and nutritional status of infants with CF diagnosed through newborn screening (NBS): Findings from a new multi-center study in the USA – HuiChuan Lai, Madison, US	
18:03 – 18:12	WS11.8	Early diagnosis through newborn screening (NBS) improved long-term growth and adult height at age 18 years in CF patients with pancreatic insufficiency – HuiChuan Lai, Madison, US	
18:12 – 18:21	WS11.9	Parental perspectives of the experience of receiving a positive newborn screening result for Cystic Fibrosis – Jane Chudleigh, London, UK	
18:21 – 18:30	WS11.10	What words do we use when telephoning a parent to inform we suspect their baby has Cystic Fibrosis? The development of a phone-call script as a result of a quality improvement project – Mandy Bryon, London, UK	

17:00 – 18:30	**Special Symposium - Research opportunities in EU**	
	Moderators: Margarida Amaral, Lisbon, PT / Michel Goldman, Brussels, BE	Arc Room
17:00 – 17:20	Goals, achievements and ambition of the ECFS – Kris De Boeck, Leuven, BE	
17:20 – 17:40	Interdisciplinary innovation: Preparing the future of European research for Cystic Fibrosis – Michel Goldman, Brussels, BE	
	DG Research and Horizon 2020: Presentations of case stories	
17:40 – 17:50	iABC consortium – Stuart Elborn, Belfast, UK	
17:50 – 18:00	CFMATTERS – Barry Plant, Cork, IE	
18:00 – 18:10	MyCyFAPP – Joaquim Calvo Lerma, Valencia, ES	
18:10 – 18:20	RescueCFTRpreclinic – Luigi Maiuri, Milan, IT	
18:20 – 18:30	CF-EVE – Kevin Southern, Liverpool, UK	

19:00 – 20:30	**Satellite Symposium - Anti-pseudomonal treatments – Enhancing the potency of regimen**	
		Silver Hall

See detailed programme page 72

FRIDAY, JUNE 12

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

	Gold Hall	Copper Hall	Silver Hall
07:00			
07:30			
08:00			
08:30			
09:00	SYMPOSIUM 13 08:30 – 10:00	SYMPOSIUM 14 08:30 – 10:00	SYMPOSIUM 15 08:30 – 10:00
09:30	Interactive case studies 	Electronic patient record: Access for the patient!	Education and teamwork
10:00			
10:30	COFFEE BREAK IN EXHIBITION		
11:00	SYMPOSIUM 19 10:30 – 12:00	SYMPOSIUM 20 10:30 – 12:00	SYMPOSIUM 21 10:30 – 12:00
11:30	Growing old with CF	New approaches targeting the basic defect	Living with CF: Day-to-day adjustment
12:00			
12:30			LUNCH BREAK
13:00	SATELLITE SYMPOSIUM 12:30 – 14:00	SATELLITE SYMPOSIUM 12:30 – 14:00	
13:30	Personalising care to meet lifelong challenges in Cystic Fibrosis	Focus on *Pseudomonas aeruginosa* in Cystic Fibrosis: Past, present and future	
14:00			
14:30			
15:00			
15:30	WORKSHOP 13 15:00 – 16:30	WORKSHOP 14 15:00 – 16:30	WORKSHOP 15 15:00 – 16:30
16:00	Bugs and drugs	Why exercise?	Psychosocial/Nursing case presentations
16:30			
17:00	COFFEE BREAK IN EXHIBITION		
17:30	WORKSHOP 19 17:00 – 18:30	WORKSHOP 20 17:00 – 18:30	WORKSHOP 21 17:00 – 18:30
18:00	Influence of host environment on bacterial diversity	How to measure and modulate CFTR dysfunction	Cleaning the lungs
18:30			
19:00			
19:30			
20:00			
20:30			
21:00			

FRIDAY, JUNE 12

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

	Hall 100	Hall 400	Arc Room	Exhibition & Poster Area
07:00				
07:30				MEET THE EXPERTS 07:15 – 08:15
08:00				
08:30				
09:00	SYMPOSIUM 16 08:30 – 10:00	SYMPOSIUM 17 08:30 – 10:00	SYMPOSIUM 18 08:30 – 10:00	
09:30	Interventions in gastroenterology and nutrition	Surviving CF - Challenges for the physiotherapist	CFTR structure, trafficking and interactors in the chase for new correctors	EXHIBITION & POSTERS
10:00				
10:30	COFFEE BREAK IN EXHIBITION			
11:00	SYMPOSIUM 22 10:30 – 12:00	SYMPOSIUM 23 10:30 – 12:00	SYMPOSIUM 24 10:30 – 12:00	
11:30	Managing difficult pathogens: Case studies	Newborn Screening for CF - The next stage of the journey	Mechanisms of early respiratory mucus malfunction	
12:00				
12:30	LUNCH BREAK			
13:00				
13:30				
14:00				
14:30				GUIDED POSTER TOUR & ePOSTER SESSIONS
15:00				
15:30	WORKSHOP 16 15:00 – 16:30	WORKSHOP 17 15:00 – 16:30	WORKSHOP 18 15:00 – 16:30	EXHIBITION & POSTERS
16:00	GI and liver abnormalities	Genotype matters	Modeling the future	
16:30				
17:00	COFFEE BREAK IN EXHIBITION			
17:30	WORKSHOP 22 17:00 – 18:30	SPECIAL SYMPOSIUM 17:00 – 18:30		
18:00	Late breaking science	Mental health screening programmes in Europe: Results and panel discussion of implementation practices		
18:30				
19:00				
19:30				
20:00				
20:30				
21:00				

FRIDAY, JUNE 12

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

07:15 – 08:15	Meet the Experts - CFTR gene sequencing pitfalls	
	Experts: Harry Cuppens, Leuven, BE / Patrick Sosnay, Baltimore, US	ePoster Corner A

07:15 – 08:15	Meet the Experts - Microbiome	
	Experts: Peter Vandamme, Ghent, BE / Kenneth Bruce, London, UK	ePoster Corner B

07:15 – 08:15	Meet the Experts - Transplant	
	Experts: Christiane Knoop, Brussels, BE / Lieven Dupont, Leuven, BE	ePoster Corner C

08:30 – 10:00	Symposium 13 - Interactive case studies	
	Moderators: Eitan Kerem, Jerusalem, IL / Barbara Bosch, Leuven, BE	Gold Hall

08:30 – 08:52	Growth retardation and Cystic Fibrosis – Alexandra Masson, Paris, FR
08:52 – 09:14	The geneticist disguised as Sherlock Holmes – Mieke Boon, Leuven, BE
09:14 – 09:36	Rectal blood loss in Cystic Fibrosis – Yordi van Dooren, Rotterdam, NL
09:36 – 10:00	Ethical dilemmas in patients with advanced lung disease – Shoshana Palmor, Jerusalem, IL

08:30 – 10:00	Symposium 14 - Electronic patient record: Access for the patient!	
	Moderators: Kris De Boeck, Leuven, BE / Alexandra Quittner, Miami, US	Copper Hall
08:30 – 08:52	One side of the coin: The physician's view – Daniel Peckham, Leeds, UK	
08:52 – 09:14	The other side of the coin: The patient's view – Martijn Oudeman, Rotterdam, NL	
09:14 – 09:36	Ethical considerations – Suzanne van de Vathorst, Rotterdam, NL	
09:36 – 10:00	Legal considerations – Ségolène Aymé, Paris, FR	

08:30 – 10:00	Symposium 15 - Education and teamwork	
	Moderators: Doris Thomsen, Copenhagen, DK / Mark Butler, London, UK	Silver Hall
08:30 – 08:52	What education do nurses require and what is available? – Susan Madge, London, UK	
08:52 – 09:14	Educating parents and relatives – Eileen Savage, Cork, IE	
09:14 – 09:36	Patient education – Karin Bæk Knudsen, Copenhagen, DK	
09:36 – 10:00	Educating the multidisciplinary team – Marlène Clairicia, Paris, FR	

08:30 – 10:00	Symposium 16 - Interventions in gastroenterology and nutrition	
	Moderators: Anne Munck, Paris, FR / Frank Bodewes, Groningen, NL	Hall 100
08:30 – 08:52	Lessons from the gut microbiota and liver disease in animal models – Dominique Debray, Paris, FR	
08:52 – 09:14	Lessons from gut motility studies – Daniel Gelfond, Batavia, US	
09:14 – 09:36	The management of meconium ileus – Paul J. Farrelly, Manchester, UK	
09:36 – 10:00	New EU guidelines for nutrition – Michael Wilschanski, Jerusalem, IL	

08:30 – 10:00	**Symposium 17 - Surviving CF - Challenges for the physiotherapist**	
	Moderators: Helen Parrott, London, UK / Fred Lessire, De Haan, BE	Hall 400
08:30 – 08:52	The changing spectrum of CF disease – What is the future? – Dominique Hubert, Paris, FR	
08:52 – 09:14	The asymptomatic adult - Is routine airway clearance necessary? - PRO – Ruth Dentice, Sydney, AU	
09:14 – 09:36	The asymptomatic adult - Is routine airway clearance necessary? - CON – Mark Elkins, Sydney, AU	
09:36 – 10:00	Why now, why me? Coping with disease progression – Gary Latchford, Leeds, UK	

08:30 – 10:00	**Symposium 18 - CFTR structure, trafficking and interactors in the chase for new correctors**	
	Moderators: Carlos Farinha, Lisbon, PT / Karl Kunzelmann, Regensburg, DE	Arc Room
08:30 – 08:52	Advances in the understanding of CFTR structure – Isabelle Callebaut, Paris, FR	
08:52 – 09:14	CFTR trafficking: Connections with TGFβ signalling – Agnieska Swiatecka-Urban, Pittsburgh, US	
09:14 – 09:36	CFTR and anoctamins – Karl Kunzelmann, Regensburg, DE	
09:36 – 10:00	Proteostasis regulators as novel CFTR correctors – William Balch, La Jolla, US	

10:00 – 10:30	COFFEE BREAK

10:30 – 12:00	**Symposium 19 - Growing old with CF**	
	Moderators: Nicholas Simmonds, London, UK / Marita Gilljam, Gothenburg, SE	Gold Hall
10:30 – 10:52	Ageing and long-term survival with CF: The changing landscape – Nicholas Simmonds, London, UK	
10:52 – 11:14	Emerging CF-related clinical challenges as patients grow older – Harry Heijerman, The Hague, NL	
11:14 – 11:36	Improving quality not just quantity of life in CF – Carsten Schwarz, Berlin, DE	
11:36 – 12:00	Diseases of ageing in the general population and CFTR – Scott Bell, Brisbane, AU	

10:30 – 12:00	**Symposium 20 - New approaches targeting the basic defect**	
	Moderators: Jane Davies, London, UK / Isabelle Fajac, Paris, FR	Copper Hall
10:30 – 10:52	Mutation-specific therapies for CF: Modulators – Batsheva Kerem, Jerusalem, IL	
10:52 – 11:14	Modulators in organoids – Florijn Dekkers, Utrecht, NL	
11:14 – 11:36	Alternative approaches to restore epithelial ion transport in CF – Marcus Mall, Heidelberg, DE	
11:36 – 12:00	Gene therapy: Moving to the clinic – Eric Alton, London, UK	

10:30 – 12:00	**Symposium 21 - Living with CF: Day-to-day adjustment**	
	Moderators: Maya Kirszenbaum, Paris, FR / Ulrike Pypops, Brussels, BE	Silver Hall
10:30 – 10:52	The challenges of families in living with CF – Alice Morgan, Melbourne, AU	
10:52 – 11:14	Helping children to live with CF – Diana Kadosh, Petah Tikva, IL	
11:14 – 11:36	Goals and achievements of adolescents – Liesbet Goubert, Ghent, BE	
11:36 – 12:00	Preparation for transplantation – Raphaelle Pauthe, Paris, FR	

FRIDAY, JUNE 12

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

10:30 – 12:00	**Symposium 22 - Managing difficult pathogens: Case studies**	
	Moderators: Dervla Kenna, London, UK / William Flight, Oxford, UK	Hall 100
10:30 – 10:52	*Pseudomonas:* Persistence and failed eradication – Helle Krogh Johansen, Copenhagen, DK	
10:52 – 11:14	Emerging Gram-negative bacteria in CF – Heather Green, Manchester, UK	
11:14 – 11:36	Managing an outbreak of NTM and long term follow of infected patients – Charles Haworth, Cambridge, UK	
11:36 – 12:00	Treatment of difficult fungal infections in CF – Eitan Kerem, Jerusalem, IL	

10:30 – 12:00	**Symposium 23 - Newborn Screening for CF – The next stage of the journey**	
	Moderators: Marijke Proesmans, Leuven, BE / Jürg Barben, St. Gallen, CH	Hall 400
10:30 – 10:52	Exploring barriers to implementation of screening for CF – Carlo Castellani, Verona, IT	
10:52 – 11:14	Strategies to improve performance of newborn screening for CF – Anne Munck, Paris, FR	
11:14 – 11:36	CF Screen Positive, Inconclusive Diagnosis (CF-SPID) – Kevin Southern, Liverpool, UK	
11:36 – 12:00	Overview of newborn screening for CF in Latin America – Alejandro Teper, Buenos Aires, AR	

10:30 – 12:00	**Symposium 24 - Mechanisms of early respiratory mucus malfunction**	
	Moderators: Gunnar C. Hansson, Gothenburg, SE / Jeffrey J. Wine, Stanford, US	Arc Room
10:30 – 10:52	A functional anatomical defect in CF airways – Kengyeh K. Chu, Boston, US	
10:52 – 11:14	Abnormal mucus and detachment in the CF lungs – Gunnar C. Hansson, Gothenburg, SE	
11:14 – 11:36	The function of normal and CF glands in relation to mucus release – Jeffrey J. Wine, Stanford, US	
11:36 – 12:00	The MUC5B mucin is necessary for normal mucus clearance of the lungs – Dave Thornton, Manchester, UK	

12:00 – 14:00	LUNCH BREAK

12:30 – 14:00	**Satellite Symposium - Personalising care to meet lifelong challenges in Cystic Fibrosis**	
		Gold Hall

See detailed programme page 73

12:30 – 14:00	**Satellite Symposium - Focus on *Pseudomonas aeruginosa* in Cystic Fibrosis: Past, present and future**	
		Copper Hall

See detailed programme page 73

14:00 – 15:00	**Posters**	
14:00 – 15:00	ePoster Sessions:	
	ePS4: Lung function, imaging and intervention	ePoster Corner A
	ePS5: Highlights in nutrition	ePoster Corner B
	ePS6: Triggers of decline?	ePoster Corner C

See detailed programme page 45

14:00 – 15:00	Guided Poster Tour in the following category Education

14:00 – 15:00 Poster Viewing:
Poster presenters in the following categories are asked to be available at their posters for discussion:

- Genetics
- Screening/Diagnosis
- New Therapies
- Physiotherapy
- Complications of CF
- Nursing/Psychosocial/Quality Improvement
- Epidemiology/Registry

See detailed programme page 43

15:00 – 16:30 Workshop 13 - Bugs and drugs
Moderators: Edward McKone, Dublin, IE / Tacjana Pressler, Copenhagen, DK — Gold Hall

15:00 – 15:15		Do infection rates differ between countries? – Edward McKone, Dublin, IE
15:15 – 15:30	WS13.1	Microevolution of *Pseudomonas aeruginosa* in Cystic Fibrosis lungs – Nina Cramer, Hannover, DE
15:30 – 15:45	WS13.2	The role of PGE_2 in Cystic Fibrosis (CF) lung inflammation and the potential association with ivacaftor therapy and treatment response – Grace O'Callaghan, Cork, IE
15:45 – 16:00	WS13.3	Impact of implementation of enhanced infection control and early eradication regimen for *Mycobacterium abscessus* infection in children with Cystic Fibrosis – Shefali Parikh, Leeds, UK
16:00 – 16:15	WS13.4	Prolongation of antibiotic treatment for Cystic Fibrosis pulmonary exacerbations – Valerie Waters, Toronto, CA
16:15 – 16:30	WS13.5	Pharmacokinetics and safety of once daily double dose inhaled tobramycin administered with the controlled-inhalation AKITA® and conventional PARI-LC® Plus nebulizer in Cystic Fibrosis – Annelies van Velzen, The Hague, NL

15:00 – 16:30 Workshop 14 - Why exercise?
Moderators: Helge Hebestreit, Würzburg, DE / Sarah Rand, London, UK — Copper Hall

15:00 – 15:15	WS14.1	Ivacaftor improves exercise capacity in patients with G551D CF gene mutations – Deirdre Edgeworth, Melbourne, AU
15:15 – 15:30	WS14.2	Short-term effect of different physical exercise-physiotherapy combinations on sputum production, oxygen saturation and lung function in young patients with Cystic Fibrosis – Thomas Radtke, Zurich, CH
15:30 – 15:45	WS14.3	Exercise testing as diagnostic marker for the outcome after intravenous antibiotic therapy for patients with Cystic Fibrosis – Laura Hatzler, Berlin, DE
15:45 – 16:00	WS14.4	Does exercise participation affect FEV_1 and the number of IV antibiotic days over 5 years in adults with CF? – Katie McAuley, Southampton, UK
16:00 – 16:15	WS14.5	Exercise testing as a supplementary measure to assess the benefit of intravenous antibiotic courses – Fiona Haynes, Nottingham, UK
16:15 – 16:30	WS14.6	Gender differences and exercise performance in adults with Cystic Fibrosis – Daniela Savi, Rome, IT

15:00 – 16:30 Workshop 15 - Psychosocial and Nursing case presentations

Moderators: Kath MacDonald, Musselburgh, UK / Alice Morgan, Melbourne, AU — Silver Hall

15:00 – 15:16	Double adjustment - Supporting a patient diagnosed with CF in adulthood – Rachel Massey-Chase, London, UK
15:16 – 15:32	The role of positive psychology in working with a young person diagnosed with Cystic Fibrosis in adolescence – Anna McCulloch, Penarth, UK
15:32 – 15:48	Involving children in decision-making for lung transplant: When does "no" mean no? – Andrea Ralph, London, UK
15:48 – 16:04	A strategy to prevent chaotic admissions – Clare Sumner, Liverpool, UK
16:04 – 16:20	Emotional reaction to ivacaftor, social work input, and QoL changes - A case study – Joan Fitzjohn, Manchester, UK
16:20 – 16:30	Jury and presentation of the award

15:00 – 16:30 Workshop 16 - GI and liver abnormalities

Moderators: Helen White, Leeds, UK / Birgitta Strandvik, Gothenburg, SE — Hall 100

15:00 – 15:13	WS16.1	Clinical Outcomes of Real-World Kalydeco (CORK) study - Investigating the impact of CFTR potentiation on the intestinal microbiota, exocrine pancreatic function and intestinal inflammation prospectively over 12 months – Jennifer Deane, Cork, IE
15:13 – 15:26	WS16.2	The prevalence of gastroesophageal reflux disease in infants with Cystic Fibrosis diagnosed by newborn screening and the relationship with lung infection – Rebecca Thursfield, Liverpool, UK
15:26 – 15:39	WS16.3	Consecutive transient elastography measurements to detect Cystic Fibrosis liver disease – Stephanie Van Biervliet, Ghent, BE
15:39 – 15:52	WS16.4	Non invasive liver elastography (LSM) and computed tomography (CT) for evaluation of liver disease in 57 Cystic Fibrosis adult patients – Sophie Hillaire, Suresnes, FR
15:52 – 16:05	WS16.5	Pathological analysis of native liver in Cystic Fibrosis (CF) with severe portal hypertension reveals a vascular liver disease without cirrhosis – Sophie Hillaire, Suresnes, FR
16:05 – 16:18	WS16.6	Is primary sclerosing cholangitis (PSC) a Cystic Fibrosis-related disorder? - Electrophysiological testing and full sequencing of the CFTR gene – Michael Wilschanski, Jerusalem, IL
16:18 – 16:30	WS16.7	A cross-sectional and longitudinal metaproteomics approach reveals intestinal dysbiosis and the presence of markers of chronic inflammation and mucus-related proteins in faecal samples of patients with Cystic Fibrosis – Griet Debyser, Ghent, BE

15:00 – 16:30 Workshop 17 - Genotype matters

Moderators: Milan Macek, Prague, CZ / Alexander Horsley, Manchester, UK — Hall 400

15:00 – 15:15	WS17.1	The ancient origin of F508del-CF: When and where the mutation arose – Claude Férec, Brest, FR
15:15 – 15:30	WS17.2	Identification of CF mutations in deep intronic regions: Design of antisense oligonucleotides for a targeted therapeutic approach – Caroline Raynal, Montpellier, FR
15:30 – 15:45	WS17.3	Errors in documentation of genotype results in a large adult CF centre – Claire Hartley, Manchester, UK
15:45 – 16:00	WS17.4	Unexpected findings in the broadly used Elucigene CF-EU2 CFTR genotyping assay – Milan Macek, Prague, CZ
16:00 – 16:15	WS17.5	Patients with Cystic Fibrosis and the R117H mutation: The European experience – Lutz Nährlich, Gießen, DE
16:15 – 16:30	WS17.6	FEV_1% predicted in patients with at least one nonsense mutation and patients homozygous for F508del – Anna Zolin, Milan, IT

15:00 – 16:30	Workshop 18 - Modeling the future	
	Moderators: Pierre-Régis Burgel, Paris, FR / Siobhan Carr, London, UK	Arc Room
15:00 – 15:15		Introduction – Siobhan Carr, London, UK
15:15 – 15:30	WS18.1	Towards a better understanding of survival data in CF – Virginie Scotet, Brest, FR
15:30 – 15:45	WS18.2	Using funnel plots to make meaningful centre comparisons – Livia Pierotti, London, UK
15:45 – 16:00	WS18.3	Accuracy of modelling future trends in Cystic Fibrosis demography using the French Cystic Fibrosis Registry – Pierre-Régis Burgel, Paris, FR
16:00 – 16:15	WS18.4	Five-year survivorship in Cystic Fibrosis: Outcomes improve but the disease remains the same – Theodore Liou, Salt Lake City, US
16:15 – 16:30	WS18.5	Direct medical cost of CF care in the Irish public healthcare system – Abi Jackson, Dublin, IE

16:30 – 17:00	COFFEE BREAK

17:00 – 18:30	Workshop 19 - Influence of host environment on bacterial diversity	
	Moderators: Lucas Hoffman, Seattle, US / Michael Tunney, Belfast, UK	Gold Hall
17:00 – 17:11	WS19.1	Disease-causing CFTR mutation and carriage of airway infections – Taylor Block, Salt Lake City, US
17:11 – 17:22	WS19.2	*Staphylococcus aureus* population from Cystic Fibrosis patients in Spain: Results from a point-prevalence multicentre study – Juan De Dios Caballero, Madrid, ES
17:22 – 17:33	WS19.3	Prevalence of small colony variants of *Staphylococcus aureus* from lower respiratory tract specimens – Louise King, Parkville, AU
17:33 – 17:44	WS19.4	Molecular epidemiology of hot-spots of mutation in antimicrobial resistance loci of *Pseudomonas aeruginosa* isolates from Cystic Fibrosis airways – Leonie Greipel, Hannover, DE
17:44 – 17:55	WS19.5	Alginate phenotypes of *P. aeruginosa* from a Brazilian CF center compared to Scandinavian CF centers – Natália Caçador, Ribeirão Preto, BR
17:55 – 18:06	WS19.6	Diversity of *Pseudomonas aeruginosa* in Cystic Fibrosis airways – Lea Sommer, Hørsholm, DK
18:06 – 18:18	WS19.7	*Pseudomonas aeruginosa* genotyping: Predicting transition to chronic colonization in Cystic Fibrosis patients – Leander Jonckheere, Ghent, BE
18:18 – 18:30	WS19.8	Comparative proteomic profiling of two Swedish CF *Pseudomonas aeruginosa* isolates reveals possible factors associated with the transmissible Cystic Fibrosis strain J-2 – Ewa Anneli Johansson, Gothenburg, SE

17:00 – 18:30	Workshop 20 - How to measure and modulate CFTR dysfunction	
	Moderators: Marcus Mall, Heidelberg, DE / Giovanni Taccetti, Florence, IT	Copper Hall
17:00 – 17:15		Introduction – Marcus Mall, Heidelberg, DE
17:15 – 17:30	WS20.1	Structure-activity relationship for OligoG-induced normalization of the CF mucus phenotype – Anna Ermund, Gothenburg, SE
17:30 – 17:45	WS20.2	Intra-patient variability of sweat chloride concentrations in patients with Cystic Fibrosis (CF) – François Vermeulen, Leuven, BE
17:45 – 18:00	WS20.3	Acquired CFTR dysfunction in patients with Primary Ciliary Dyskinesia (PCD)? – Malena Cohen-Cymberknoh, Jerusalem, IL

18:00 – 18:15	WS20.4	Clinical outcomes of Real-World Kalydeco (CORK) study - A prospective 12 month analysis addressing the impact of CFTR modulation on the Cystic Fibrosis lung – Nicola Ronan, Cork, IE
18:15 – 18:30	WS20.5	Cystic Fibrosis related structural lung disease on high resolution computed tomography before and after ivacaftor therapy – Ianthe Sayers, Melbourne, AU

17:00 – 18:30 Workshop 21 - Cleaning the lungs

Moderators: Jennifer L. Agnew, Toronto, CA / Fred Lessire, De Haan, BE — Silver Hall

17:00 – 17:09	WS21.1	Evaluation of the use of IPV for the treatment of atelectasis in Cystic Fibrosis – Maggie McIlwaine, Vancouver, CA
17:09 – 17:18	WS21.2	Skeletal muscle strength measurements in adult CF patients compared to controls – Filip Pyl, Ghent, BE
17:18 – 17:27	WS21.3	Acute changes in the lung clearance index after physiotherapy in children with Cystic Fibrosis – Beryl Lin, Westmead, AU
17:27 – 17:36	WS21.4	Multiple breath nitrogen washout: The Exhalyzer D (Ecomedics) is more sensitive than the EasyOne Pro (NDD) in detecting ventilation inhomogeneities in children with CF and normal FEV_1 – William Poncin, Brussels, BE
17:36 – 17:45	WS21.5	The use of serum creatinine to estimate skeletal muscle mass in Cystic Fibrosis – Nathan Hilton, Liverpool, UK
17:45 – 17:54	WS21.6	Prognostic value of breathing reserve index at anaerobic threshold during cardiopulmonary exercise testing in children with Cystic Fibrosis – Rachel O'Connor, London, UK
17:54 – 18:03	WS21.7	The relationship of maximum inspiratory pressures with inspiratory muscle weakness and FEV_1 in patients with Cystic Fibrosis chronically infected with *Pseudomonas aeruginosa* – Katherine Lavery, Belfast, UK
18:03 – 18:12	WS21.8	Validity of the Oxygen Uptake Efficiency Slope (OUES) as a parameter of maximal and submaximal exercise testing in children with mild CF – Michiel Keyzer, Ghent, BE
18:12 – 18:21	WS21.9	Lung clearance index as a clinical trial outcome measure: Establishing the CTN LCI core facility – Clare Saunders, London, UK
18:21 – 18:30	WS21.10	Respiratory muscle endurance training with normocapnic hyperpnea in patients with Cystic Fibrosis. A randomized controlled study – Luigi Graziano, Rome, IT

17:00 – 18:30 Workshop 22 - Late breaking science

Moderators : Batsheva Kerem, Jerusalem, IL / Phillipe Reix, Lyon, FR — Hall 100

17:00 – 17:30		Modeling Cystic Fibrosis using intestinal organoids – Florijn Dekkers, Utrecht, NL
17:30 – 18:00		Highlights of the 12th ECFS Basic Science Conference – Frédéric Becq, Poitiers, FR
18:00 – 18:20		Plant derived Actin Inhibition Resistance Deoxyribonuclease I (AIR-DNase), novel treatment for Cystic Fibrosis – Yoseph Shaaltiel, Carmiel, IL
18:20 – 18:30		Wrap-up

17:00 – 18:30	**Special Symposium: Mental health screening programmes in Europe: Results and panel discussion of implementation practices**	
	Moderators : Trudy Havermans, Leuven, BE / Maya Kirszenbaum, Paris, FR	Hall 400
17:00 – 17:22	Early implementation of the international guidelines for mental health screening in the UK – Alistair Duff, Leeds, UK	
17:22 – 17:44	Mental health screening in the Netherlands – Murielle Verkleij, Amsterdam, NL	
17:44 – 18:06	Integrative mental healthcare in a CF clinic: The Innsbruck model – Helmut Ellemunter, Innsbruck, AT	
18:06 – 18:30	Panel Discussion: Implementation challenges and best practices – Panel: Alexandra Quittner, Miami, US / Janice Abbott, Preston, UK / Beth Smith, Buffalo, US / Lutz Goldbeck, Ulm, DE / Anna Georgiopoulos, Boston, US	

SATURDAY, JUNE 13

	Gold Hall	Copper Hall	Silver Hall
07:00			
07:30			
08:00			
08:30			
09:00			
09:30	SYMPOSIUM 25 09:00 – 10:30	SYMPOSIUM 26 09:00 – 10:30	SYMPOSIUM 27 09:00 – 10:30
10:00	Bad bugs new drugs	Managing exacerbations - Interactive debates 	Inflammation and lung remodeling, towards alternative therapeutic strategies
10:30			
11:00	COFFEE BREAK IN EXHIBITION		
11:30	CLOSING PLENARY 11:00 – 12:30		
12:00			
12:30			
13:00	CLOSING CEREMONY 12:30 – 13:00		
13:30			
14:00			
14:30			
15:00			
15:30			
16:00			
16:30			
17:00			
17:30			
18:00			
18:30			
19:00			
19:30			
20:00			
20:30			
21:00			

SATURDAY, JUNE 13

	Hall 100	Hall 400	Exhibition & Poster Area
07:00			
07:30			
08:00			
08:30			
09:00			
09:30	SYMPOSIUM 28 09:00 – 10:30	SYMPOSIUM 29 09:00 – 10:30	EXHIBITION & POSTERS
10:00	Gut inflammation and gastro-oesophageal reflux disease (GERD)	Registry: Which data to enter for optimizing surveillance?	
10:30			
11:00	COFFEE BREAK IN EXHIBITION		
11:30			
12:00			
12:30			
13:00			
13:30			
14:00			
14:30			
15:00			
15:30			
16:00			
16:30			
17:00			
17:30			
18:00			
18:30			
19:00			
19:30			
20:00			
20:30			
21:00			

SATURDAY, JUNE 13

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

09:00 – 10:30	Symposium 25 - Bad bugs new drugs	
	Moderators: Jean-Marc Rolain, Marseille, FR / Miguel Cámara, Nottingham, UK	Gold Hall
09:00 – 09:18	What can we learn from quorum-sensing inhibitors? – Miguel Cámara, Nottingham, UK	
09:18 – 09:36	*Pseudomonas* type III secretion inhibition – Carlos Milla, Palo Alto, US	
09:36 – 09:55	Artilysin – Rob Lavigne, Leuven, BE	
09:55 – 10:10	Phage therapy for *Pseudomonas* - PRO – Daniel De Vos, Brussels, BE	
10:10 – 10:25	Phage therapy for *Pseudomonas* - CON – Niels Høiby, Copenhagen, DK	
10:25 – 10:30	Discussion	

09:00 – 10:30	Symposium 26 - Managing exacerbations – Interactive debates	
	Moderators: Kris De Boeck, Leuven, BE / Stuart Elborn, Belfast, UK	Copper Hall
		
09:00 – 09:10	Use *in vitro* sensitivity data to choose IV antibiotics - PRO – Kirsten Schaffer, Dublin, IE	
09:10 – 09:20	Use *in vitro* sensitivity data to choose IV antibiotics - CON – Valerie Waters, Toronto, CA	
09:20 – 09:30	Discussion	
09:30 – 09:40	Duration of IV treatment - 14 days for all – Patrick Flume, Charleston, US	
09:40 – 09:50	Duration of IV treatment - Customize – Barry Plant, Cork, IE	
09:50 – 10:00	Discussion	
10:00 – 10:10	The efficacy of all inhaled antibiotics is equal - PRO – Tacjana Pressler, Copenhagen, DK	
10:10 – 10:20	The efficacy of all inhaled antibiotics is equal - CON – Michael Parkins, Calgary, CA	
10:20 – 10:30	Discussion	

09:00 – 10:30	Symposium 27 - Inflammation and lung remodeling, towards alternative therapeutic strategies	
	Moderators: Bob Scholte, Rotterdam, NL / Rabin Tirouvanziam, Atlanta, US	Silver Hall
09:00 – 09:22	Lessons from the AREST-CF study, early diagnosis CT scans and biomarkers lead the way – Stephen Stick, Perth, AU	
09:22 – 09:44	Inflammation and Fibrosis in CF mouse models – Teresinha Leal, Brussels, BE	
09:44 – 10:06	Modeling remodeling – Bob Scholte, Rotterdam, NL	
10:06 – 10:30	Neutrophil infiltration and inflammation in the CF lung – Rabin Tirouvanziam, Atlanta, US	

09:00 – 10:30	**Symposium 28 Gut inflammation and gastro-oesophageal reflux disease (GERD)**	
	Moderators: Siobhan Carr, London, UK / Anna Ermund, Gothenburg, SE	Hall 100
09:00 – 09:22	Abnormalities of the gut microbiota – Implications for dietary treatment – Shawn Somerset, Brisbane, AU	
09:22 – 09:44	The pathophysiology of GERD – Ans Pauwels, Leuven, BE	
09:44 – 10:06	The medical treatment of GERD – Yvan Vandenplas, Brussels, BE	
10:06 – 10:30	Lessons from reflux disease and lung transplantation – Paul Aurora, London, UK	

09:00 – 10:30	**Symposium 29 - Registry: Which data to enter for optimizing surveillance?**	
	Moderators: Isabelle de Monestrol, Stockholm, SE / Lutz Nährlich, Gießen, DE	Hall 400
09:00 – 09:22	Registries from the EMA's perspective – Laura Fregonese, London, UK	
09:22 – 09:44	Lung status in registries beyond FEV_1 – Sarath Ranganathan, Victoria, AU	
09:44 – 10:06	Comparing registries – The UK/US experience – Christopher Goss, Seattle, US	
10:06 – 10:30	Harmonization of CF registries worldwide – Geoff Sims, Sydney, AU	

10:30 – 11:00	COFFEE BREAK

11:00 – 12:30	**Closing Plenary**	
	Moderators: Kris De Boeck, Leuven, BE / Peter Vandamme, Ghent, BE	Gold Hall
11:00 – 11:30	Bacterial Infection in the CF Lungs. Diagnosis, prevention and treatment – Eshwar Mahenthiralingam, Cardiff, UK	
11:30 – 12:00	The changing challenges of CF – Stuart Elborn, Belfast, UK	
12:00 – 12:30	ECFS President's address – Kris De Boeck, Leuven, BE	

12:30 – 13:00	**Closing Ceremony**	
		Gold Hall

During the Closing Ceremony, Prof. Kris De Boeck, ECFS President, will present the following ECFS awards:

ECFS Young Investigators Awards
ECFS Best Poster/ePoster Awards in the following categories:

- Genetics/Screening/Diagnosis
- Immunology/Inflammation/Cell biology/New Therapies
- Upper and Lower Airways/Physiotherapy
- Microbiology
- Gastroenterology/Nutrition/Bone/Vitamin D/Liver Disease
- Complications of CF/Epidemiology/Registry
- Nursing/Psychosocial Issues/Quality Improvement

Awarded authors are respectfully requested to attend the Closing Ceremony to receive their prizes on stage.

POSTER AREA

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

POSTER AREA - LEVEL -2



244 - 301:
Nursing/Psychosocial/
Quality Improvement

302 - 313:
Epidemiology/Registry

215 - 243:
Gastroenterology/Nutrition

201 - 214:
Bone/Vitamin D/Liver Disease

171 - 200:
Complications of CF

151 - 170:
Physiotherapy

144 - 150:
Upper and Lower Airways

126 - 143:
New Therapies

41 - 125:
Microbiology

20 - 40:
Immunology/Inflammation/Cell Biology

14 - 19:
Screening/Diagnosis

1 - 13:
Genetics

Poster Help Desk

GUIDED POSTER TOURS - POSTER VIEWING

Poster authors are asked to be present next to their posters according to the following timetable:

THURSDAY, JUNE 11, 14:00 – 15:00

GUIDED POSTER TOUR

MICROBIOLOGY: EPIDEMIOLOGY AND SOURCES OF INFECTION
Leader: Benjamin T. Kopp, Columbus, US
Posters 70 to 77 - Meeting point and start of the tour at Poster 70

POSTER VIEWING

Immunology/Inflammation/Cell Biology:	Posters 20 to 40
Microbiology:	Posters 41 to 125
Upper and Lower Airways:	Posters 144 to 150
Bone/Vitamin D/Liver Disease:	Posters 201 to 214
Gastroenterology/Nutrition:	Posters 215 to 243

FRIDAY, JUNE 12, 14:00 – 15:00

GUIDED POSTER TOUR

EDUCATION
Leader: Trudy Havermans, Leuven, BE
Posters 244 to 252 - Meeting point and start of the tour at Poster 244

POSTER VIEWING

Genetics:	Posters 1 to 13
Screening/Diagnosis:	Posters 14 to 19
New Therapies:	Posters 126 to 143
Physiotherapy:	Posters 151 to 170
Complications of CF:	Posters 171 to 200
Nursing/Psychosocial/Quality Improvement:	Posters 244 to 301
Epidemiology/Registry:	Posters 302 to 313

POSTERS

LOCATION OF THE POSTERS

All posters will be displayed in the Poster Area within the Exhibition (Level -2).

THE POSTER AREA WILL BE OPEN AT THE FOLLOWING TIMES:

Wednesday, June 10	18:00 – 21:30
Thursday, June 11	08:00 – 18:00
Friday, June 12	08:00 – 18:00
Saturday, June 13	08:30 – 12:30

INFORMATION FOR POSTER PRESENTERS

SET-UP AND DISMANTLING
Posters may be set-up beginning Wednesday, June 10 at 14:00.
Poster presenters will have access to the Poster Area at 08:00 on June 11 and 12.
Posters should be removed on Saturday, June 13 between 12:30 and 14:00.
Any Posters not removed by 14:00 will be discarded.

ePOSTER SESSIONS

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

THURSDAY, JUNE 11, 14:00 – 15:00

ePS1	Genetics across the continents	ePoster Corner A
	Leaders: Celeste Barreto, Lisbon, PT / Milan Macek, Prague, CZ	
ePS01.1	Asian patients with CF: Does ethnicity influence our diagnostic criteria? – Barbara Bosch, Leuven, BE	
ePS01.2	First year evaluation of the Portuguese pilot neonatal screening for Cystic Fibrosis – Rodrigo Sousa, Lisbon, PT	
ePS01.3	Genotype-phenotype correlation in Russian Cystic Fibrosis patients with S466X-R1070Q complex allele – Nataliya Kashirskaya, Moscow, RU	
ePS01.4	Cystic Fibrosis neonatal screening in Castilla-León (Spain), a fifteen years experience – Maria-Jesus Alonso-Ramos, Valladolid, ES	
ePS01.5	Update of CFTR mutation spectrum in Cystic Fibrosis patients from Peru – Marie-Pierre Audrezet, Brest, FR	
ePS01.6	Application of next-generation sequencing for the analysis of CFTR in Serbian CF patients – Dragica Radojkovic, Belgrade, RS	
ePS01.7	Is confirmatory genetic testing of all CF screen positives in Ontario justified? – Nita Chauhan, London, CA	

ePS2	Challenges of fungal infections	ePoster Corner B
	Leaders: Malena Cohen-Cymberknoh, Jerusalem, IL / Laurence Delhaes, Lille, FR	
ePS02.1	Anti-*aspergillus fumigatus* antibodys in Cystic Fibrosis (CF) patients: A comparison of three methods – Anna Grancini, Milan, IT	
ePS02.2	Fungal colonization in a Cystic Fibrosis adult population – Gonçalo Freire, Lisbon, PT	
ePS02.3	*Pseudomonas aeruginosa* and *Aspergillus fumigatus* co-infection reduced the pro-inflammatory response in CF epithelial cells – Emma Reece, Dublin, IE - Young Investigator Award Winner	
ePS02.4	Fungus-reactive T-cells as sensitive and specific sensors to diagnose fungal infections in Cystic Fibrosis patients – Carsten Schwarz, Berlin, DE	
ePS02.5	A new risk factor predicts ABPA in patients with Cystic Fibrosis – Anja Thronicke, Berlin, DE	
ePS02.6	Rising prevalence of allergic bronchopulmonary aspergillosis (ABPA) in CF - An unforeseen result of climate change? – Kimberley Barber, Liverpool, UK	
ePS02.7	Significance of fungal isolation in CF paediatric patients – Ewa Romanowska, Warsaw, PL	
ePS02.8	Prevalence and clinical associations of fungal airway isolates in the UK adult Cystic Fibrosis population – Imogen Felton, London, UK	

ePS3	Adherence	ePoster Corner C
	Leaders: Gary Latchford, Leeds, UK / Jet van der Hulst, Groningen, NL	
ePS03.1	What is the relationship between patients' beliefs about medicine and treatment adherence in adults with Cystic Fibrosis? – Rebecca Keyte, Birmingham, UK - Young Investigator Award Winner	
ePS03.2	Are beliefs about inhaled medications related to actual adherence? – Louise Maclean, Leeds, UK	
ePS03.3	Longer term tolerance and likely adherence to TOBI Podhaler in CF adults – Catherine Brown, Birmingham, UK	
ePS03.4	Patient reported adherence to ivacaftor – Elyssa Williams, Melbourne, AU	
ePS03.5	Adherence monitoring in Cystic Fibrosis centres: Current practice and pharmacists' perspectives – Karen Mooney, Belfast, UK	
ePS03.6	Medication adherence and treatment practice in Hungary with Cystic Fibrosis patients – Reka Bodnar, Budapest, HU	

FRIDAY, JUNE 12, 14:00 – 15:00

ePS4	Lung function, imaging and intervention	ePoster Corner A
	Leaders: Alexander Horsley, Manchester, UK / Harm Tiddens, Rotterdam, NL	
ePS04.1	Longitudinal changes in lung clearance index in children with CF – François Vermeulen, Leuven, BE	
ePS04.2	Infant lung function: First report of a novel infant multiple breath washout apparatus – Anna Shawcross, Manchester, UK	
ePS04.3	Comparison of CF and non-CF LCI results using the Exhalyzer D and Innocor™ devices – Katie Bayfield, London, UK	
ePS04.4	Assessment of oxidative stress in Cystic Fibrosis: Comparison of airway and systemic malondialdehyde levels – Balazs Antus, Budapest, HU	
ePS04.5	MR diagnosis and follow-up in young CF patients with endobronchial invasive aspergillosis – Irene Borzani, Milan, IT	
ePS04.6	*A. fumigatus* chronic colonization and lung function decline in CF may have a two-way relationship – Maria Noni, Athens, GR	
ePS04.7	Tobramycin nebulization with I-neb® in children with Cystic Fibrosis (TONI study): Pharmacokinetics and safety – Annelies van Velzen, The Hague, NL	
ePS04.8	Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with Cystic Fibrosis (CF) diagnosed by neonatal screening – Alejandro Teper, Buenos Aires, AR	

ePS5	Highlights in nutrition	ePoster Corner B
	Leaders: Helen White, Leeds, UK / Dimitri Declercq, Ghent, BE	
ePS05.1	Nutritional formula pre-hydrolyzed by novel point of care lipase device (EFIC™) leads to increased fat absorption in young pigs with Exocrine Pancreatic Insufficiency (EPI) – Danica Grujic, Newton, US	
ePS05.2	Novel point of care immobilized lipase device (EFIC™) is compatible with a range of nutritional formulas and can simplify delivery of hydrolyzed fat during tube feeding – Greta Loring, Newton, US	
ePS05.3	Ivacaftor and its effects on body composition in adults with G551D related Cystic Fibrosis – Audrey Tierney, Melbourne, AU	
ePS05.4	A multidisciplinary approach can improve a low BMI in adults with Cystic Fibrosis – Sophie Whitehead, Southampton, UK	
ePS05.5	Cystic Fibrosis bone disease: Is the CFTR corrector C18 an option for therapy? – Frédéric Velard, Reims, FR	
ePS05.6	Cessation of Pancreatic Enzyme Replacement Therapy (PERT) after initiation of therapy with ivacaftor - A case series – Eric Cheah, Westmead, AU	
ePS05.7	Individual caloric intake in Cystic Fibrosis (CF) - How to calculate? – Sibylle Junge, Hannover, DE	
ePS05.9	Benefits of long-term supplementation with omega-3 polyunsaturated fatty acids in Cystic Fibrosis – Laurence Hanssens, Brussels, BE	

ePS6	Triggers of decline?	ePoster Corner C
	Leaders: Charles Haworth, Cambridge, UK / Mario Vaneechoutte, Ghent, BE	
ePS06.1	*Stenotrophomonas maltophilia* is increased in patients with Cystic Fibrosis-Related Diabetes and displays enhanced growth under physiologically-relevant levels of glucose – Joanne Fothergill, Liverpool, UK	
ePS06.2	Immune cell localization in different compartments of human end-stage CF lungs – Elise Lammertyn, Leuven, BE	
ePS06.3	Neutrophil elastase activity on the surface of sputum neutrophils is associated with severity of Cystic Fibrosis lung disease – Susanne Dittrich, Heidelberg, DE - Young Investigator Award Winner	
ePS06.4	Upper airway infection and inflammation in CF and healthy controls during exacerbation and stable phases – Julia Hentschel, Jena, DE	
ePS06.5	*Burkholderia cepacia* complex acquisition: A threat in all CF patients? – Julie Willekens, Brussels, BE	
ePS06.6	Full reversibility of lung function decline following clearance of *Mycobacterium abscessus* complex infection – Tavs Qvist, Copenhagen, DK	
ePS06.7	Factors associated with failure to eradicate first or newly acquired *Pseudomonas aeruginosa* in patients with CF – Malena Cohen-Cymberknoh, Jerusalem, IL	
ePS06.8	Cigarette smoke-induced changes in phenotype and virulence in *Pseudomonas aeruginosa* – Katie-Ann McGown, Belfast, UK	
ePS06.9	Lung disease progression and inflammatory parameters in children with Cystic Fibrosis chronically colonized with *Burkholderia cepacia* complex – Nataliya Kashirskaya, Moscow, RU	

NR	ABSTRACT TITLE	PRESENTER
GENETICS		
1	Why does Cystic Fibrosis (CF) show the prevalence and distribution observed in human populations? A literature review	A. Mowat
2	Genetic markers of low bone mineral density in patients with Cystic Fibrosis	T. Jakovska-Maretti
3	Connexin 37 and connexin 43 genotypes in correlation to cytokines in induced sputum and blood in Cystic Fibrosis (CF)	S. Schmitt-Grohé
4	The contribution of genes immune response modifiers in the development of Cystic Fibrosis and its phenotypes	G. Yankina
5	Is there an association between *Pseudomonas aeruginosa* chronic infection and CFTR genotype in adult Cystic Fibrosis (CF) patients?	S. Rached
6	How should we manage incidental identification of carrier status in children?	D. Vears
7	Frequency of five CFTR gene mutations in miscegenated Cystic Fibrosis population of the Brazilian Northeast	E. L. Souza
8	Molecular diagnosis of Cystic Fibrosis in the population of the Republic of Moldova	S. Sciuca
9	Analysis of Cystic Fibrosis gene mutations in children with Cystic Fibrosis in a regional center in Eastern Romania	L. M. Trandafir
10	Mild Cystic Fibrosis phenotype in adult patients with novel 3272-16T>A mutation	N. Kashirskaya
11	The risk of incorrect reporting or misinterpretation of genotype results	J. Wilson
12	Reverse hybridization enables fast and reliable detection of 25 common CF mutations	S. Weidler
13	Final stage of hemostasis and FGB gene polymorphism in patients with Cystic Fibrosis	Y. Gorinova
SCREENING/DIAGNOSIS		
14	Standardized protocol for ratiometric measurement of β-adrenergic/cholinergic sweating in human sweat glands	P. Melotti
15	Normal values and failure rate of sweat conductivity using Nanoduct Sweat Analysis System in healthy infants aged 4 days and 4 weeks	J. Barben
16	A qualitative study of parents' recommendations for improving the notification process and communication between health professionals and families for new diagnosis of Cystic Fibrosis	M. Razai
17	Infants diagnosed clinically after false negative Cystic Fibrosis newborn screening may present with Pseudo-Bartter's-syndrome	A. C. Gjerstad
18	Energy intake in infants with Cystic Fibrosis at diagnosis by newborn screening	N. West
19	Does newborn screening improve health status in CF children?	J. Panickar
IMMUNOLOGY/INFLAMMATION/CELL BIOLOGY		
20	More impact of inflammation on growth and respiratory function in girls	N. Lefevre
21	Long term azithromycin therapy in patients with Cystic Fibrosis	N. Emiralioğlu
22	Defining the Cystic Fibrosis arthropathy phenotype: A serological and imaging pilot study	G. Fitch
23	Seasonal variation in *Aspergillus* specific antibody levels - Does weather influence exposure?	K. Barber
24	Basophil Activation Test may facilitate ABPA diagnosis in CF patients	M. Noni
25	Interactions between Cystic Fibrosis (CF) and non-CF isolates of *Aspergillus fumigatus* and *Pseudomonas aeruginosa* in the development of a co-culture infection model for testing novel therapeutics	E. Devlin

26	sCD14 in macrophages from patients with Cystic Fibrosis: Origin and involvement in inflammatory functions	M. Lévêque
27	Chitinase and Cystic Fibrosis: A study of its expression and role in CF pathophysiology	G. Bouvet
28	ER stress and TLR activation inter-regulate through p65, p38, STAT3, and XBP1s to modulate inflammation in Cystic Fibrosis	A. Tang
29	Airway epithelial cell IP-10 production is regulated by miR-31 via the transcription factor IRF-1	L. Kerrigan
30	Oxidative stress diminishes the number of functional neutrophil granulocytes in lungs of Cystic Fibrosis (CF) patients, which is ameliorated by glutathione treatment	P. Schiøtz
31	Sphingosine 1-phosphate receptor 3 is highly upregulated on human neutrophils upon migration to the airways	S. Ingersoll
32	Mediation of pro/anti-inflammatory balance by vardenafil in mouse CF macrophages is dependent on CFTR expression	B. Dhooghe
33	Procalcitonin and C reactive protein levels in hospitalised patients receiving intravenous antibiotics	G. Fitch
34	Phagocyte collaboration for the control of *Pseudomonas aeruginosa*	S. Muntaka
35	Deficiency of the Planar Cell Polarity protein CELSR3 in CF bronchial epithelial cells increases susceptibility to epithelial-mesenchymal transition	S. Noel
36	Airway epithelial cell integrity protects from cytotoxicity of *P. aeruginosa* quorum-sensing signals	M. Chanson
37	The microbial metagenome of Cystic Fibrosis lower airways	B. Tümmler
38	Sphingoid long chain bases prevent lung infection by *Pseudomonas aeruginosa*	Y. Pewzner-Jung
39	Inhibition of CFTR slows forskolin-stimulated mucociliary clearance in ferret trachea	N. Joo
40	Is oxidative stress responsible for plasma membrane integrity alteration in macrophages from patients with Cystic Fibrosis?	S. Le Trionnaire

MICROBIOLOGY

41	Taxonomic signatures of CF airway microbiota distinguish between patients with lower and higher pulmonary function decline	A. Bevivino
42	Microbiologic bacterial agents in a young Cystic Fibrosis population	A. C. Freitas
43	Gram-negative emerging pathogens: Prevalence and strain typing results from a large UK adult CF centre	H. Green
44	Prevalence of emerging pathogens in a large paediatric CF centre	J. Panickar
45	Decision making by young adults with CF about risk of patient-patient and environmental acquisition of infection	A. Duff
46	Microbiological airway flora in children with Cystic Fibrosis in the first year of life (To treat or not to treat, that's the question!)	M. Hübsch
47	Diagnostic dilemmas for CF microbiology labs using MALDI-TOF	C. Williams
48	Altered gut microbiota in stable patients with Cystic Fibrosis (CF) compared to controls and its relationship with intravenous (IV) antibiotic usage and lung function	F. Fouhy
49	Propidium monoazide (PMA) sample pretreatment impacts the abundance of rare populations in high-throughput sequencing analysis of CF lung mycobiome and bacteriome	L. Nguyen
50	A prospective study on non-tuberculous mycobacteria (NTM) in patients with CF	C. Schwarz
51	Network infectivity analysis of NTM infection in children with Cystic Fibrosis (CF) in the North East of England	B. Silberberg
52	Clinical characteristics and diagnosis of NTM infection in children with Cystic Fibrosis (CF) in the North East of England	B. Silberberg

53	Non-tuberculous mycobacteria in Cystic Fibrosis: A single centre study of prevalence, sampling and microbiological outcomes	R. Dhillon
54	Limited transmission of non-tuberculous mycobacteria among Danish Cystic Fibrosis patients	M. Wang
55	Is whole genome sequencing necessary to exclude cross infection with *M. abscessus* ST26 in paediatric Cystic Fibrosis patients?	C. Williams
56	Colonization by *Rasamsonia argillacea* in Cystic Fibrosis patients: A two-year retrospective study	L. Cariani
57	Does Pandoraea cause clinical deterioration in healthy CF children?	J. Panickar
58	*Achromobacter xylosoxidans/ruhlandii* colonized CF patients have more hospitalisations and IV antibiotic days	F. De Baets
59	*Ralstonia mannitolilytica* - An emerging threat in Cystic Fibrosis and lung transplantation	A. Perry
60	*Serratia marcescens*: An emerging pathogen or innocent bystander?	B. Belkarty
61	Comparison of two chromogenic media for isolation of *Staphylococcus aureus* from respiratory samples from patients with Cystic Fibrosis	C. Preece
62	Molecular diagnosis of *Pseudomonas aeruginosa* infection in culture-negative samples from Cystic Fibrosis patients	M. Amiri
63	*Pseudomonas aeruginosa* pulmonary infection in CF patients in a Brazilian reference center: Antibody response monitoring	R. Mauch
64	Infection control (IC) knowledge, beliefs and behaviours (KBB) amongst those with epidemic *Pseudomonas aeruginosa* (ePA)	R. Somayaji
65	Clinical outcomes of chronic "Prairie Epidemic Strain" *Pseudomonas aeruginosa* infection in adults with Cystic Fibrosis	R. Somayaji
66	Incidence of *Burkholderia cepacia* complex infection in a Cystic Fibrosis Centre in Buenos Aires City, Argentina, from 2004 to 2014	L. Galanternik
67	CF patients with a declining FEV_1: At risk for acquisition of *Burkholderia cepacia* complex infection?	J. Willekens
68	Respiratory viral detection in children with Cystic Fibrosis (CF)	D. Tješić-Drinković
69	The Cystic Fibrosis Sputum Induction Trial (CF-SpIT). Induced sputum in young healthy non-productive children with Cystic Fibrosis	J. Forton
70	Dry powder inhalation devices are a safe alternative to nebulizers regarding contamination with CF specific pathogenic germs	P. Opitz
71	*Pseudomonas aeruginosa* in paranasal sinuses and in lower airways in Cystic Fibrosis patients	D. Dolce
72	Potential for airborne bacterial contamination in an outpatient respiratory clinic	D. Gilpin
73	Impact of community-acquired MRSA and hospital-acquired MRSA on pulmonary function of CF patients	S. Campana
74	*Burkholderia cepacia* complex infection in an adult Cystic Fibrosis centre over a ten year period	D. Keating
75	A single clone of *Achromobacter xylosoxidans* colonizes Belgian Cystic Fibrosis patients from different centres	P. Cools
76	Identification of *P. aeruginosa* infection in a paediatric CF population	E. Willis
77	Whole genome sequencing of multiple isolates of the *Pseudomonas aeruginosa* Liverpool Epidemic Strain reveals transmission and geographical clustering	M. Moore
78	Differences in infection, inflammation and structural abnormalities between the right and left lung	L. King
79	Development of the upper respiratory tract microbiome was investigated longitudinally in Cystic Fibrosis infants and controls 0-6 months of age	S.M.P.J. Prevaes
80	The microbiome in early Cystic Fibrosis lung disease: A longitudinal analysis	K. Frayman
81	The concordance between the microbiome of the upper and lower respiratory tract is investigated in infants with Cystic Fibrosis	S.M.P.J. Prevaes

82	Routine use of laryngeal aspiration reveals high prevalence of *Haemophilus influenzae* in respiratory secretions from young patients with Cystic Fibrosis	L. Vesterby
83	Contribution of early and repeated nasopharyngeal aspirate cultures in pediatric Cystic Fibrosis	E. Cakir
84	An optimized *In vitro* antibiotic susceptibility testing method for *Staphylococcus aureus* small colony variants	M. Precit
85	Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from the respiratory tract of Cystic Fibrosis patients	L. Galanternik
86	Molecular typing of rapidly growing mycobacteria (RGM) in patients with Cystic Fibrosis (CF)	A. Teri
87	Detection of enterotoxins (A-E) from *Staphylococcus aureus* isolated from CF sputum: Clinical significance of enterotoxigenic (ET^{+}) strains of *S. aureus* in paediatric and adult CF patients	H. Wen
88	Prevalence and characterization of unusual *Staphylococcus aureus* strains with a mucoid phenotype recovered from the airways of Cystic Fibrosis patients	B. Kahl
89	Molecular characterization of strains of methicillin-resistant *Staphylococcus aureus* (MRSA) in patients with Cystic Fibrosis (CF)	A. Teri
90	Phenotypic and genotypic characteristics of the epidemic clones of *Burkholderia cenocepacia* strains in patients with Cystic Fibrosis (CF) in Russian Federation	N. Kashirskaya
91	Retrospective chart review of cases of cepacia syndrome (CS) in adults with Cystic Fibrosis (CF)	M. Usacheva
92	Increasing virulence, acute phenotypic adaptations and evolving host-pathogen interactions during chronic *Burkholderia cepacia* complex infection of the Cystic Fibrosis lung	A. Brown
93	Production of virulence factors by *Prevotella* isolates belonging to the Cystic Fibrosis (CF) respiratory microbiota	L. Sherrard
94	Isolation and characterisation of bacteriophage infecting *Prevotella* spp. recovered from the Cystic Fibrosis (CF) airways	D. Mooney
95	Susceptibility of CF *Prevotella* isolates to neutrophil and complement mediated immune clearance	D. Mooney
96	Effect of *Prevotella* spp. capsular polysaccharide on resistance to antimicrobial peptides and host innate immune factors	M. Tunney
97	A review of inpatient antibiotic prescribing after 7 years - Scratching below the surface	E. Spencer-Clegg
98	Antibiotic prescription patterns for the treatment of Spanish Cystic Fibrosis patients: Results from a national multicentre survey study	J. D. D. Caballero
99	Active surveillance and containment of Carbapenemase Producing Enterobacteriaceae (CPE) in Cystic Fibrosis (CF) patients attending an Italian care centre	P. Morelli
100	Macrolide resistance is common among members of the CF airway microbiota	L. Sherrard
101	An audit of the clinical effectiveness of ceftazidime at varying doses in the treatment of respiratory exacerbations in Cystic Fibrosis	S. Hutchison
102	MRSA eradication in CF patients with lower respiratory tract infection	E. Vallières
103	Minimum inhibition concentration characteristic of antibiotics on *Pseudomonas aeruginosa* strains from patients with Cystic Fibrosis	M. Pronoza
104	Antimicrobial susceptibility of *Pseudomonas aeruginosa* (PA) and *Staphylococcus aureus* (SA) isolated from CF patients over 13 years	H. Dmeńska
105	The success of the early eradication therapy regimens for *P. aeruginosa* in Cystic Fibrosis	N. Emiralioğlu
106	Descriptive analysis of inhaled antibiotic combination therapy in a large Belgian referral center	C. Van De Kerkhove
107	Sputum flora among teenage Cystic Fibrosis patients using inhaled TOBI® therapy for 5 and more years from Sofia CF center	I. Galeva
108	Analysis of dry powder inhaler (DPI) antibiotics in an adult Cystic Fibrosis (CF) centre	A. Henry
109	Influence of nebulized antibiotics on ciliary activity *in vitro*	M. Boon

110	Aztreonam for inhalation solution (AZLI) for eradication of new onset *Pseudomonas aeruginosa* (PA) infection in children with Cystic Fibrosis (CF): Evaluation of treatment failures	H. Tiddens
111	An overview of a desensitization protocol to inhaled aztreonam	K. Gent
112	Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with Cystic Fibrosis (CF) who have chronic infection from *Pseudomonas aeruginosa*	T. Pressler
113	Inhalative meropenem-tobramycin-colistin combination improves lung function in chronic *P. aeruginosa* colonization	G. Herrmann
114	Investigating the activity of antibiotics at aerosolized concentrations against *Burkholderia cepacia* complex biofilms	S. Kennedy
115	Intravenous antibiotics for pulmonary exacerbations in people with Cystic Fibrosis - Cochrane review	M. Hurley
116	Pharmacokinetic variability of ciprofloxacin in Cystic Fibrosis - Is CYP3A4 involved?	A. Schultz
117	Safety profile of levofloxacin inhalation solution from 3 controlled Cystic Fibrosis clinical trials	P. Flume
118	Efficacy and safety of colistimethate sodium in a paediatric population: Results from the FREEDOM trial	A. Schuster
119	Cellular allergy tests for antibiotic drug hypersensitivity in Cystic Fibrosis	J. Röhmel
120	The prevalence of Ticarcillin hypersusceptible *Pseudomonas aeruginosa* isolates from Cystic Fibrosis patients compared to non-Cystic Fibrosis patients	I. Hettiarachchi
121	Extended HLA analysis in a cohort of patients hypersensitive to beta-lactam antibiotics	P. Whitaker
122	Successful *Burkholderia* spp. eradication with hypothiocyanite/Lactoferrin. *In vitro* study evidence over a worldwide collection of clinical strains	V. Juarez-Perez
123	Twenty years of clinical studies on Anti-*Pseudomonas* IgY to Cystic Fibrosis patients	H. Kollberg
124	Lack of antimicrobial activity of ivacaftor against clinical CF respiratory isolates	J. Payne
125	Viral load is high despite preserved interferon-β response in rhinovirus-infected CF cells	L. Lands

NEW THERAPIES

126	A phase 1 clinical study of CTX-4430 in Cystic Fibrosis patients	E. Springman
127	Pharmacokinetic and pharmacodynamic profile of CTX-4430 in two phase 1 studies	E. Springman
128	The metabolic consequences of CFTR modulation with ivacaftor in a single adult Cystic Fibrosis centre cohort	G. Ronan
129	A phase 1 drug-drug interaction study of CTX-4430 assessing CYP3A4 induction	S. Ahuja
130	Antimicrobial activity of liposomal β-glycan against *Pseudomonas aeruginosa* isolated from Cystic Fibrosis patients	A. Omri
131	The experience of nebulised aztreonam lysine at the All Wales Adult CF Centre (AWACFC)	A. Rees
132	Respirability assessment of amikacin from a novel dry powder inhaler versus nebulized solution	F. Borella
133	Cost-effectiveness of dry-powder mannitol for inhalation as an add-on to best supportive care (BSC) in the treatment of adult Cystic Fibrosis (CF) patients in Ireland	J. Van Stiphout
134	Rationale for evaluating (R)-roscovitine (Seliciclib) in patients with Cystic Fibrosis	L. Meijer
135	Transformational care at the All Wales Adult CF Centre (AWACFC) - The impact of ivacaftor (Kalydeco®) one year on	M. Lea-Davies
136	Long-term tiotropium bromide therapy was retrospectively analyzed in adults with Cystic Fibrosis	C. Brandt
137	Omalizumab therapy for allergic bronchopulmonary aspergillosis patients with Cystic Fibrosis	N. Emiralioğlu
138	Dysregulation of epithelial miR-148b contributes to goblet cell metaplasia, inflammation and alveolar damage in Cystic Fibrosis lung disease	R. Agrawal
139	OligoG fluorescent conjugation for localisation in a mucoid pseudomonal biofilm	M. Pritchard

140	Towards the clinical application of anti-pseudomonal bacteriophages: Activity is retained following nebulisation with a range of commercially available nebuliser systems	R. Pabary
141	An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis	G. Devereux
142	Development of an S/MAR based episomal vector for the CFTR gene delivery	D. De Rocco
143	Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction	S. Elborn

UPPER AND LOWER AIRWAYS

144	Effect of treatment with ivacaftor on exhaled nitric oxide	H. Grasemann
145	Lung ultrasound in CF children's exacerbation - One center experience	I. Ciuca
146	Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicentre, double-blind, controlled prospective trial	J. Mainz
147	Retained absorbable nasal packing after functional endoscopic sinus surgery (FESS) in paediatric Cystic Fibrosis patients with chronic rhinosinusitis	I. Aldag
148	Prevalence of chronic rhinosinusitis and upper airways colonisation in the Welsh adult Cystic Fibrosis population	R. Mills-Bennett
149	Etiological structure of lung infections in patients with Cystic Fibrosis	L. Balanetchi
150	Influence of the F508del mutation on pulmonary function of patients with Cystic Fibrosis	S. Sciuca

PHYSIOTHERAPY

151	Prevalence of musculoskeletal pain in the Welsh adult Cystic Fibrosis population	C. Bridges
152	Influencing factors of skeletal muscle weakness in adults with Cystic Fibrosis	F. Pyl
153	The 15m Shuttle Test is a valuable alternative to conventional shuttle tests in some CF patients	O. Van Hove
154	INSPIRE-CF: An interim review of participation of children with Cystic Fibrosis randomised to a weekly supervised exercise intervention	H. Douglas
155	Physical activity levels of children and adolescents with Cystic Fibrosis in Wales	R. Evans
156	Exercise performance in children with mild Cystic Fibrosis (CF): Are there arguments to enhance physical activity?	J. Cornette
157	Pulmonary and extrapulmonary determinants of physical activity in adults with Cystic Fibrosis	D. Hubert
158	Exercise in non-exercising adult Cystic Fibrosis patients - A year long lottery funded project, Ninewells Hospital, Dundee	A. Smith
159	Promoting physical exercise by stealth	F. Haynes
160	The prevalence of chronic rhinosinusitis in paediatric Cystic Fibrosis	N. Harnett
161	The effect of a short-stay revalidation program on lung function parameters and weight	H. Franckx
162	A review of non-medical prescribing in an adult CF centre	E. Forster
163	Phoniatric voice rehabilitation in Cystic Fibrosis	L. Graziano
164	Autogenic drainage and assisted autogenic drainage in children with Cystic Fibrosis: A systematic review	L. Corten
165	"Real world" introduction of tobramycin inhalation powder TIP™ in adults with Cystic Fibrosis	H. Langman
166	Improvements in inhalational treatment amongst children using the Philips I-neb insight online software	C. Yonge
167	Evaluation of the oscillatory Cough Assist E70 in adults with Cystic Fibrosis (CF)	L. Morrison
168	Combining inhalation by a breath-actuated nebulizer (BAN) and exhalation with oscillating positive expiratory pressure device (OPEP) offers potential for simultaneous therapy: A laboratory study	R. Sharpe

169	The use of Airvo™ high flow humidification with Cystic Fibrosis patients - Development of the service	N. Muggeridge
170	Safety of nebulised hypertonic saline via Pari eFlow with Pari positive expiratory pressure (PEP) device in circuit for paediatric Cystic Fibrosis patients	P. Wilson

COMPLICATIONS OF CF

171	Variation in random capillary blood glucose and HbA1c as predictors of Cystic Fibrosis Related Diabetes (CFRD)	H. White
172	Does the 60-minute OGTT value have clinical significance in CF adults?	M. Symes
173	Validation of near patient testing blood capillary glucose for the oral glucose tolerance test in Cystic Fibrosis	J. Burgess
174	Frequency of diabetic keto-acidosis in children with Cystic Fibrosis Related Diabetes	A. Kapur
175	Diabetes in patients with Cystic Fibrosis: An update from the DPV registry	N. Scheuing
176	Elevation of 90 minutes plasma glucose during oral glucose tolerance testing predicts development of Cystic Fibrosis Related Diabetes and lung function decline	A. Kotnik Pirs
177	Evolution of glycemia, insulinemia and glycosylated hemoglobin in a CF pediatric population	M.-H. Denis
178	Glucose tolerance in Cystic Fibrosis patients over a 3-year period (DIAMUCO study)	I. Durieu
179	12 years too late? Rethinking CFRD screening	M. McLean
180	Evaluation of leptin and ghrelin levels in the blood serum of patients diagnosed with Cystic Fibrosis	S. Wiecek
181	Loss of the incretin effect in Cystic Fibrosis Related Diabetes (CFRD)	G. Jones
182	Impact of ivacaftor on glycaemic health in patients carrying the G551D mutation	P. Barry
183	Intermittent exogenous insulin may prevent progression of dysglycemia in pre-diabetic adults	P. Dyce
184	Utility of an ultra-long acting insulin to treat Cystic Fibrosis Related Diabetes	P. Dyce
185	Use of the hemoglobin A1c test as a screening tool for Cystic Fibrosis Related Diabetes	M. Nicolo
186	Manifestation and progression of illness in young children with Cystic Fibrosis: A targeted literature review	A. O'Sullivan
187	Risk factors for pulmonary exacerbations (PEx) in pediatric Cystic Fibrosis (CF) patients	S. Lubovich
188	Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations	D. Sanders
189	Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response	C. Goss
190	Frequency and costs of pulmonary exacerbations and association with % predicted FEV_1 in patients with Cystic Fibrosis	M. Schechter
191	Lung function and health care resource utilization in patients with Cystic Fibrosis	M. Schechter
192	ABPAs in *Pseudomonas aeruginosa* colonized CF patients	F. De Baets
193	Isolated lung transplantation (LT) for Cystic Fibrosis patients with portal hypertension (PHT)	E. Cuquemelle
194	Sensorineural hearing loss in patients with Cystic Fibrosis: A cross-sectional study	K. Van Hoorenbeeck
195	The effect of aminoglycoside antibiotics therapy on audiovestibular function in Cystic Fibrosis patients at the All Wales Adult Cystic Fibrosis Centre (AWACFC)	D. Lau
196	Prevalence of cataracts in a population of Cystic Fibrosis patients homozygous for the F508del mutation	D. Waltz
197	Right ventricular function in Ukrainian children with Cystic Fibrosis	N. Rohovyk
198	Electrolyte depletion with metabolic alkalosis in infants with Cystic Fibrosis	S. Fustik
199	Metabolic alkalosis in patients with Cystic Fibrosis: Are we missing something?	G. Fitch
200	A novel entity of a CFTR-related respiratory disease	B. Tümmler

BONE/VITAMIN D/LIVER DISEASE

201	Tibial cortical bone is impaired in adults with CF	D. Gensburger
202	Bone mineral density and fractures at the All Wales Adult CF Centre (AWACFC)	D. Lau
203	Children's bone disease and its risk factors in our centre	I. Ciuca
205	Hand grip strength and DXA in adults with Cystic Fibrosis	L. Mead
206	Bone quality at the time of lung transplant in Cystic Fibrosis patients	G. Mailhot
207	Effect of high-dose cholecalciferol supplementation (HCDS) on serum vitamin D concentrations in adults with Cystic Fibrosis (CF)	E. Willcox
208	Long-term and seasonal impact of a vitamin D3 (cholecalciferol) supplementation protocol on vitamin D [25(OH)D] serum levels among Cystic Fibrosis adults in a Montreal clinic	M. Mailhot
209	Optimizing vitamin D levels through the winter months in children with Cystic Fibrosis	S. Ranganathan
210	Response to vitamin D supplementation protocol in CF pediatric patients	M.-H. Denis
211	Vitamin D insufficiency is associated with pulmonary exacerbations in children with Cystic Fibrosis	G. McPhail
212	Does our current diagnosis of Cystic Fibrosis related liver disease meet current diagnostic criteria?	S. Evans
213	Diagnosis of liver disease in children with Cystic Fibrosis: Are we getting it right?	V. Cheruvalli
214	Cystic Fibrosis and cirrhosis in Russia	E. Kondratyeva

GASTROENTEROLOGY/NUTRITION

215	Characterization of gastroesophageal reflux with combined multichannel intraluminal impedance-pH (MII-pH) in a group of children with CF	J. Brecelj
216	Gastrostomy button primary placement using an endoscopically guided gastropexy technique in Cystic Fibrosis: A single centre's early experience	P. Hutchings
218	Body composition estimation by bioelectrical impedance: Validation of an equation adapted to children with Cystic Fibrosis	A.-M. Charatsi
219	Nutritional intervention in paediatric Cystic Fibrosis patients leads to improvement of nutritional status - Preliminary results of a prospective study	S. Mexia
220	Nutritional outcomes of enteral nutrition in children with Cystic Fibrosis	K. Fisher
221	Influence of nutritional status of children with Cystic Fibrosis on disease outcome	N. Genkova
222	Prevalence of overweight & obesity in the Scottish paediatric CF population	J. Crocker
223	Prevalence of overweight and obesity in Scottish adults with Cystic Fibrosis	L. Robb
224	Nutritional status of patients with Cystic Fibrosis in Russia	E. Kondratyeva
225	Nutritional status of children with Cystic Fibrosis (CF) in Russia and neighboring territories	E. Roslavtseva
226	Ultrasound and adipometer body fat measurement of Cystic Fibrosis (CF) children and adolescents	P. Marostica
227	Differences in the nutritional status of adults with Cystic Fibrosis with and without the ΔF508 homozygous genotype	D. Hopkins
228	The association between nutritional status, serum creatinine and lung function in adults with Cystic Fibrosis	D. Hopkins
229	Pancreatic genotype-phenotype co-variations in Cystic Fibrosis	T. Engjom
230	History of meconium ileus is associated with low fat tissue mass in children and adolescents with Cystic Fibrosis	A. Kaditis
231	The effect of ivacaftor on exocrine pancreatic function in patients with Cystic Fibrosis and the G551D CFTR mutation who are naïve for ivacaftor	K. McKay

232	Changes in nutritional status prior to lung transplantation - Single centre experience over 10 years	J. Snowball
233	Resting energy expenditure in patients with Cystic Fibrosis decreases after lung transplantation	F. Hollander
234	Vegetable, fruit, dairy and discretionary food intake of Cystic Fibrosis (CF) patients and comparison with the general population: A cross-sectional study	A. Tierney
235	Serum zinc in pediatric patients with Cystic Fibrosis	V. Nedkova
236	Vitamin status in infants with Cystic Fibrosis during the first year of life	F. Ajmal
237	Meal and daily variation in enzyme to fat matching in CF patients across a 7 day period: A cross-sectional study	A. Tierney
238	How are pancreatic enzymes distributed over mealtimes and meal types?	D. Declercq
239	Intake of pancreatic enzymes: Consistent with the guidelines?	D. Declercq
240	A randomized, double-blind, multicentre, multinational crossover comparison of the pancreatic enzyme product (PEP) APT-1008 (ZENPEP®) to KREON® in the treatment of exocrine pancreatic insufficiency (EPI) associated with Cystic Fibrosis (CF) in patients ≥12 years of age	C. J. Taylor
241	Changes in fatty acid pattern of depot fat tissue in young pancreatic duct ligated pigs - Used as a model for humans with pancreatic exocrine insufficiency	A. Mößeler
242	Effects of experimentally induced pancreatic exocrine insufficiency on digestibility of electrolytes (praecaecal / total tract), urinary electrolyte content and acid-base status in young pigs - Used as a model for children	A. Mößeler
243	Effects of pancreatic exocrine insufficiency on growth, bone density and IGF 1 serum levels of young growing pigs - Used as a model for children	A. Mößeler

NURSING/PSYCHOSOCIAL/QUALITY IMPROVEMENT

244	Kim's word book helps the dialogue between parents and their 3 to 5 year-old child affected by Cystic Fibrosis	A. Pesle
245	Identifying needs in education for children aged 7-8 y and their parents	V. David
246	Parental understanding of mutation class-specific treatments for CF and implications for their child's CF	S. Parmar
247	CFRD education: What information do patients value and who do they ask?	D. L. Lamb
248	"muko.fit" - A comprehensive health-care approach for patients with CF with critical causes and/or psycho-social challenges. First results regarding the initial 12 months within the project	C. Moos-Thiele
249	Diabetes in Cystic Fibrosis - education (DICE) - The impact of a structured education programme for the management of Cystic Fibrosis Related Diabetes (CFRD) on quality of life	S. Collins
250	Young patients with Cystic Fibrosis (CF) - A new approach for nutritional care? - A dietician and Youth Ambassador project	G. Brekke
251	A personalized education program allows self-management in adult CF patients for intravenous antibiotic therapy at home	S. Therouanne
252	Recognition of pulmonary exacerbation (PEX) in adult patients with CF: An educational process to overcome barriers	V. David
253	Why do some patients regularly fail to attend a CF clinic?	D. Derry
254	The value of the routine annual review chest radiograph in adults with CF	C. Addy
255	Annual medication review by a clinical pharmacist in an adult Cystic Fibrosis care center	C. Challet
256	Understanding the psychological difficulties patients with Cystic Fibrosis share at annual review	K. James
257	Administering the PHQ8 and GAD7 in routine UK CF care: In situ utilisation in a paediatric and an adult centre	A. Duff
259	Improving inpatient Cystic Fibrosis Related Diabetes (CFRD) care: The patients' perspective	S. Pandya

260	Quality improvement program (QIP) for adolescents in Paris Robert Debré (RD) CF Centre	M. Gerardin
261	Audit and improvement of the Cystic Fibrosis liver service in a regional adult CF unit	A. Turnbull
262	Role of an adapted physical activities professional at a paediatric CF centre	D. Fuchs
263	The good, the bad and the future: Families' views on the Royal Brompton Hospital (RBH) paediatric Cystic Fibrosis (CF) homecare service	E. Dixon
264	How well established are links with allied medical and surgical specialties in CF care?	M. Symes
265	Drug allergy documentation in the All Wales Adult CF Centre (AWACFC)	M. Lea-Davies
266	Experience of *Mycobacterium abscessus* eradication therapy at Aberdeen Royal Infirmary	K. Griffiths
267	Peripherally-inserted central catheters use and care in Cystic Fibrosis: A survey on the practice of free-lance home care nurses in France	J. Chapron
268	Short-term pulmonary rehabilitation program in children and adolescents with chronic respiratory disease	P. Van de Wijdeven
269	Living with Cystic Fibrosis in a remote or rural area	M. Jessup
270	Home antibiotic treatment in Cystic Fibrosis: An effective, cost saving and preferred choice among patients with CF	E. Hatziagorou
271	The development of a paediatric telephone triage tool in a Cystic Fibrosis unit in the UK	J. Bloomer
272	A proposal for specific monitoring sheets for patients taking ivacaftor	M. Kerbrat
273	Influenza vaccination in CF adults: Coverage level and adverse reactions	L. Fila
274	Nurse prescribing for children with Cystic Fibrosis (CF). An initiative to improve service delivery	C. Sharpe
275	A quality improvement program (QIP) aimed at improving nutritional status of Cystic Fibrosis (CF) patients aged 2-12 years at CF Centre Roscoff: Update at the end of the 3 year period	J. Pengam
276	Parental preparation for first admission	K. James
277	Transformational care at the All Wales Adult CF Centre (AWACFC) - Is ivacaftor making us fat? The impact of ivacaftor (Kalydeco®) on body composition	A. Prosser
278	Depression, anxiety and adherence to inhalation therapy in adolescents and adults with Cystic Fibrosis	A. Fidika
279	Prevalence of pain in adults with CF with and without lung transplantation	K. Colpaert
280	Sleep in children with Cystic Fibrosis. A questionnaire-based case-control study	K. D'Hondt
281	Impact of physical activity on illness perception, self-esteem and HRQoL in children with CF	A. Vandenoetelaer
282	A preventative psychosocial care approach (PPCA) for promoting psychological wellbeing for people with CF (PWCF) and their caregivers	H. Oxley
283	Psycho-social aspects in children with Cystic Fibrosis from a regional centre in north-eastern Romania	D.-T.Anton-Paduraru
284	The Quality of Life (QoL) after lung transplantation (LT) between omnipotence, denial and reality principle	P. Catastini
285	The psychological impact of adverse drug reactions amongst adults with Cystic Fibrosis	N. Reid
286	Emotional distress, coping and quality of life in children with Cystic Fibrosis: A cross-cultural study	M. Touchèque
287	Perception of first infection with *Pseudomonas aeruginosa* by people with CF, their families and close friends	S. Palser
288	Resilience, intolerance of uncertainty, and CF patients' quality of life	H. Mitmansgruber
289	How do men and women with Cystic Fibrosis think their illness and associated experiences affect their body image, sexuality, relationships and their ideas about parenthood?	R. Anderson
290	Dietary forcing and conflicts during meals for children suffering from Cystic Fibrosis: The psychologist's point of view	P. Leger
291	The views of adolescents with CF on their transition and transfer to adult services	G. Bowmer

292	Cystic Fibrosis and transition to adult care in Northern Ireland	J. McNeilly
293	Understanding young people's anxiety about transitioning from paediatric to adult services - A service improvement project	R. Massey-Chase
294	Aspiring to independence: The personal experiences of young people with Cystic Fibrosis, asthma and healthy controls	D. Gladwell
295	Cognition in adult patients with Cystic Fibrosis (CF) with and without Cystic Fibrosis Related Diabetes (CFRD)	H. Chadwick
296	The French clinical trials network: The national platform for clinical research (NPCR)	A. Ronayette-Preira
297	Does socioeconomic status correlate with clinical outcomes in children with CF in Southwestern Ontario?	N. Chauhan
298	Comparison of adults with Cystic Fibrosis diagnosed in childhood vs adulthood	E. Baran
299	Cultural differences in illness perception and treatment adherence	M. Gur
300	Prevalence and characteristics of attention deficit hyperactivity disorder (ADHD) in patients with Cystic Fibrosis (CF)	M. Cohen-Cymberknoh
301	Contraceptive practices and gynecological survey in women with Cystic Fibrosis	C. Rousset Jablonski

EPIDEMIOLOGY/REGISTRY

302	MucoDoméos: An electronic medical record (SMR) dedicated to the CF patients	E. Bonomo
303	Smoking cessation help should be available at CF reference centres - A Belgian national survey of smoking in patients with Cystic Fibrosis	V. Godding
304	Children with typical CF have better spirometric data than children with non CF bronchiectasis (BE) - A Belgian multicentric study	V. Godding
305	CF registry in Northern Greece over a 7 year period	E. Hatziagorou
306	National Registry of patients with Cystic Fibrosis in the Republic of Moldova in 2009-2014	S. Sciuca
307	Cystic Fibrosis Patient Registry of Moscow and Moscow Region (CFPRMMO) in 2010-2012	E. Amelina
308	National Cystic Fibrosis Patients Registry of Russia (RCFPR) in 2012	E. Amelina
309	Poor prognosis factors in CF children	N. Lefevre
310	Prevalence of CF and spectrum of CFTR mutations in the Portuguese population	A. Grangeia
311	Treatment and demographic factors affecting time to next pulmonary exacerbation in Cystic Fibrosis	D. VanDevanter
312	Outcomes and factors associated with poor outcome of children with Cystic Fibrosis admitted to the intensive care unit	J. Bucher
313	An international study of survival of children with Cystic Fibrosis after the first episode of invasive mechanical ventilation	A. Prayle

MEETINGS & COURSES OVERVIEW

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

TUESDAY, JUNE 9

08:15 – 16:45	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	Room 211+212
08:30 – 17:30	ECFS Board Meeting*	Room 202
08:30 – 17:00	Quality Management / Quality Improvement Training Course**	Room 204

WEDNESDAY, JUNE 10

08:00 – 16:30	International Nurse Specialist Group/CF Meeting**	Room 201 A/B
08:15 – 12:30	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	Room 211+212
08:30 – 15:30	ECFS CTN Training and Development*	Room 202
09:00 – 18:15	CF Course**	Room 204
09:00 – 12:30	CFE/ECFS Joint Symposium: Access to new therapies: How can patient organizations, researchers, health professionals, authorities and industry contribute?	Hall 400
09:00 – 13:45	ECFS Exercise Working Group*	Room 311
09:00 – 16:30	European Cystic Fibrosis Nutrition Group Meeting	Room 213+215
09:30 – 15:00	ECFS Neonatal Screening Working Group Meeting	Arc Room
09:30 – 16:00	European Psychosocial Special Interest Group (EPSIG) Meeting**	Room 206
12:30 – 14:00	International Physiotherapy Group for Cystic Fibrosis (IPG/CF) Annual General Meeting*	Room 211+212
13:00 – 16:00	Journal of Cystic Fibrosis Editorial Board Meeting*	Room 203
13:15 – 17:00	ECFS CTN Steering Group Meeting*	Room 202
14:00 – 16:00	ECFS Patient Registry Executive Committee Meeting*	Room 311
14:30 – 17:00	Physiotherapy Case Presentations	Room 211+212
15:15 – 17:00	ACTIVATE-CF Meeting*	Arc Room
16:00 – 18:00	CF Pharmacists Meeting	Room 214-216
16:00 – 17:00	ECFS Patient Registry Harmonisation Group Meeting*	Room 311
17:00 – 18:00	ECFS Annual General Meeting*	Hall 400

THURSDAY, JUNE 11

12:30 – 14:30	ECFS CTN Standardisation Committee Meeting	Hall 400
12:30 – 13:30	ECFS Patient Registry Data Quality Project Group Meeting	Hall 100
13:00 – 14:00	UK Newborn Screening Special Interest Group*	Silver Hall
13:30 – 14:30	ECFS Patient Registry - Meeting for Interested Parties	Hall 100
14:00 – 16:00	UK Cystic Fibrosis Trust Meeting*	Room 202
18:30 – 20:30	ECFS CTN Blood Inflammatory Markers Standardisation Group	Gold Hall
18:30 – 19:30	ECFS Patient Registry Software Training Reports & Encounters*	Arc Room
19:00 – 20:00	European CF Registry Forum*	Copper Hall

FRIDAY, JUNE 12

12:30 – 14:30	ECFS Diagnostic Network Working Group Meeting	Hall 100
12:30 – 14:30	ECFS Patient Registry Steering Group Meeting	Silver Hall

SATURDAY, JUNE 13

12:00 – 17:00	CF Europe/CF Belgium Family Conference: “Research, hope for today and tomorrow!”	Silver Hall
13:30 – 18:00	ECFS Scientific Committee Meeting - Basel 2016*	Room 213+215

* closed meeting ** extra registration required

TUESDAY, JUNE 9

08:15 – 16:45	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	**extra registration required
	Moderator: Helen Parrott, London, UK	Room 211+212
08:15 – 08:30	Registration	
08:30 – 08:45	Welcome and housekeeping – Helen Parrott, London, UK	
08:45 – 09:45	Musculoskeletal dysfunctions in Cystic Fibrosis - Common presentations and the impact of bone disease – Anna Middleton, Sydney, AU	
09:45 – 11:15	Assessment/screening approaches - When and why?	
	Experience using the Manchester screening tool – Julia Taylor, Manchester, UK	
	Developing an annual review musculoskeletal assessment – Brenda Button, Melbourne, AU	
11:15 – 11:45	COFFEE BREAK	
11:45 – 12:30	Musculoskeletal dysfunctions and the impact on airway clearance and exercise ability – Anna Middleton, Sydney, AU	
12:30 – 13:30	LUNCH BREAK	
13:30 – 14:45	Pro/con debate: CF musculoskeletal dysfunction should be treated by the CF specialist physiotherapist – Jane Ashbrook, Manchester, UK / Brenda Button, Melbourne, AU	
14:45 – 15:15	COFFEE BREAK	
15:15 – 16:15	Treatment strategies for the thoracic spine plus a case study – Jane Ashbrook, Manchester, UK	
16:15 – 16:45	Panel Q&A	

08:30 – 17:00	Quality Management / Quality Improvement Training Course**	** extra registration required
		Room 204
08:30 – 09:30	Goals of the day, self-introduction of the participants – Martin Stern, Tübingen, DE	
09:30 – 09:50	The philosophy of quality improvement in CF – Dominique Pougheon-Bertrand, Paris, FR	
09:50 – 10:20	Quality improvement in CF: The US experience – Bruce Marshall, Bethesda, US	
10:20 – 10:50	COFFEE BREAK	
10:50 – 11:05	WORKSHOP I: Data quality and benchmarking Moderator: Martin Stern, Tübingen, DE	
10:50 – 11:05	Insuring good data quality as a basis – Vincent Gulmans, Baarn, NL	
11:05 – 11:20	Definitions, standards and references – Lutz Nährlich, Giessen, DE	
11:20 – 11:35	Benchmarking: The German example – Martin Stern, Tübingen, DE	
11:35 – 12:00	Round table discussion and summary	
12:00 – 13:00	WORKSHOP II: Centre care and peer review Moderator: Helmut Ellemunter, Innsbruck, AT	
12:00 – 12:20	Centre care, CF team: The Innsbruck example – Helmut Ellemunter, Innsbruck, AT	

12:20 – 12:40	Peer review, centre accreditation: The UK example – Elaine Gunn, London, UK
12:40 – 13:00	Round table discussion and summary
13:00 – 13:45	LUNCH BREAK
13:45 – 15:40	WORKSHOP III: LLC and international learning Moderator: Gilles Rault, Roscoff, FR
	Registry data, best practice, LLC: The French example – Gilles Rault, Roscoff, FR
	International learning – Laura Viviani, Milan, IT
	Round table discussion and summary
	The ECFS Patient Registry – Edward McKone, Dublin, IE
	The new software system, ECFS tracker – Jacqui van Rens, Leuven, BE
	Patient-friendly public reporting, quality of life, patient satisfaction – Birgit Dembski, Bonn, DE
15:40 – 16:00	COFFEE BREAK
16:00 – 17:00	WORKSHOP IV: Start QI now Moderators: Martin Stern, Tübingen, DE / Gilles Rault, Roscoff, FR

WEDNESDAY, JUNE 10

08:00 – 16:30	International Nurse Specialist Group/CF Meeting** **extra registration required Moderators: Vibsen Bregnballe, Aarhus, DK / Annick Lacroix, Brussels, BE / Ellen Julie Hunstad, Oslo, NO / Cindy Ruelens, Leuven, BE / Kristine Colpaert, Leuven, BE / Chris Van De Kerkhove, Brussels, BE Room 201 A/B
08:00 – 08:30	Registration
08:30 – 08:35	Welcome – Ellen Julie Hunstad, Oslo, NO
08:35 – 08:50	Welcome to Belgium – Françoise Delacollette, Liège, BE
08:50 – 09:20	Rehabilitation in Cystic Fibrosis care: Medical issues – Patricia Van de Wijdeven, Pulderbos, BE
08:20 – 09:50	Rehabilitation in Cystic Fibrosis care: Social issues – Thijs Verbruggen, De Haan, BE
09:50 – 10:30	Nurse issues from rehabilitation centers: Case presentation adult and child/adolescent – Leen Govaerts, Pulderbos, BE / Catharine Verleye, De Haan, BE
10:30 – 11:00	COFFEE BREAK
11:00 – 11:45	New guidelines & practical implications for care: Standards of care & infection control – Petra Schelstraete, Ghent, BE
11:45 – 12:30	New guidelines & practical implications for care: Nurse experience – Hilde Stevens, Antwerp, BE / Ann Raman, Ghent, BE
12:30 – 13:30	LUNCH BREAK
13:30 – 14:00	Challenges facing different cultures: Patient experience - video – Ann Raman, Ghent, BE / Kristine Colpaert, Leuven, BE
14:00 – 14:30	Challenges facing different cultures: Lecture – Anne Malfroot, Brussels, BE

14:30 – 15:00	Challenges facing different cultures: Nurse experience – Hilde Felix, Brussels, BE / Chris Van De Kerkhove, Brussels, BE
15:00 – 15:15	COFFEE BREAK
15:15 – 16:00	Abstract presentations
16:00 – 16:30	Annual General Meeting

08:15-12:30	Physiotherapy Short Course: Beyond the lungs - Musculoskeletal dysfunction in CF**	**extra registration required
	Moderator: Helen Parrott, London, UK	Room 211+212
08:15 – 08:30	Welcome and introduction – Helen Parrott, London, UK	
08:30 – 09:30	Yoga - The evidence base, practicalities and adaptations for treatment of thoracic kyphosis – Pamela Scarborough, London, UK	
09:30 – 10:30	Is prevention the key? – Anna Middleton, Sydney, AU	
10:30 – 11:00	COFFEE BREAK	
11:00 – 12:00	Pilates and the pelvic floor – Muireann Lohan, Limerick, IE	
12:00 – 12:30	Panel Q&A and close	

09:00 – 18:15	CF Course**	** extra registration required
		Room 204
09:00 – 09:45	Pathophysiology of CF and spectrum of CF – Nico Derichs, Berlin, DE	
09:45 – 10:20	CFTR related disease – Cristina Bombieri, Verona, IT	
10:20 – 11:05	New therapies – Silke van Koningsbruggen-Rietschel, Cologne, DE	
11:05 – 11:35	COFFEE BREAK	
11:35 – 12:20	CF microbiology and choice of antibiotics – Pavel Drevinek, Prague, CZ	
12:20 – 13:05	Inhaled therapies: From nebulizers to dry powder inhalers – Hettie M. Janssens, Rotterdam, NL	
13:05 – 14:00	LUNCH BREAK	
14:00 – 15:30	Group Paediatric:	
14:00 – 14:45	Diagnosis and newborn screening – Jürg Barben, St. Gallen, CH	
14:45 – 15:30	Early CF lung disease: Prevention/monitoring/treatment – Elpis Hatziagorou, Thessaloniki, GR	
14:00 – 15:30	Group Adult:	
14:00 – 14:45	Diagnosis in the adult – Jaqueline Rendall, Belfast, UK	
14:45 – 15:30	Advanced CF lung disease – Charles Haworth, Cambridge, UK	
15:30 – 16:00	COFFEE BREAK	
16:00 – 16:45	The CF multidisciplinary team: From baby to transition to adult care – Marijke Proesmans, Leuven, BE	
16:45 – 17:30	Gastro-intestinal issues in CF: Pancreatic insufficiency and beyond – Michel Abély, Reims, FR	
17:30 – 18:15	CFR DM: Pathophysiology and treatment – Nicola Bridges, London, UK	

MEETINGS & COURSES PROGRAMME

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

09:00-12:30	CFE/ECFS Joint Symposium: Access to new therapies: How can patient organizations, researchers, health professionals, authorities and industry contribute?
	Moderator: Karleen De Rijcke, Brussels, BE — Hall 400
09:00 – 09:15	Intro by CF Europe: Access to CF therapies in Europe – Karleen De Rijcke, Brussels, BE
09:15 – 10:30	Accelerating access to new therapies: The patient, academic and industry point of view
	The patient point of view – Ulrike Pypops, Brussels, BE
	Academic point of view – Isabelle Fajac, Paris, FR
	Vertex Pharmaceuticals – Simon Bedson, London, UK
	PTC Therapeutics – Manuela Maronati, Zug, CH
10:30 – 11:00	COFFEE BREAK
11:00 – 11:30	The regulatory point of view
	Orphan drug regulation and authorisation procedures in Europe – Laura Fregonese, London, UK
	European cooperation to enhance access to new therapies – Flaminia Macchia, Brussels, BE
11:30 – 12:00	Collaboration can accelerate the access to new treatments for CF patients
	Models of collaboration: ECFS Clinical Trial Network – Tim Lee, Leeds, UK
	Models of collaboration: CFF drug pipeline: Collaboration with pharmaceutical companies to enhance the development of CFTR- correctors and potentiators – Preston Campbell, Bethesda, US
	Changing the reimbursement decision for 100 Cystic Fibrosis patients in Ireland: How CF Ireland successfully reversed the decision on the reimbursement of a Cystic Fibrosis medicine – Philip Watt, Dublin, IE
12:00 – 12:30	Panel discussion (academic, patient organisations, industry, authorities): How can all stakeholders collaborate to ensure that CF patients in all European countries have equal access to CF treatments?

09:00-13:45	ECFS Exercise Working Group* — * closed meeting
	Moderator: Helge Hebestreit, Würzburg, DE — Room 311
09:00 – 09:15	Introduction – Helge Hebestreit, Würzburg, DE
09:15 – 09:45	Update on the statement on exercise testing in CF – Helge Hebestreit, Würzburg, DE
09:45 – 10:15	Update on the position stand on the assessment of physical activity – Judy Bradley, Belfast, UK
10:15 – 10:45	COFFEE BREAK
10:45 – 11:15	Update on the clinical practice guideline on activity/exercise counselling – Anne Swisher, Morgantown, US / Helge Hebestreit, Würzburg, DE
11:15 – 11:45	Update on ACTIVATE-CF – Helge Hebestreit, Würzburg, DE
11:45 – 12:15	LUNCH BREAK
12:15 – 13:45	Discussion: The future of the Exercise Working Group

09:00-16:30	European Cystic Fibrosis Nutrition Group Meeting	
	Moderators: Chris Smith, Brighton, UK / Dimitri Declercq, Ghent, BE	Room 213+215
09:00 – 09:30	Registration	
09:30 – 10:00	Annual General Meeting	
10:00 – 10:20	Abstract 238	How are pancreatic enzymes distributed over mealtimes and meal types? Intake of pancreatic enzymes: Consistent with the guidelines? – Dimitri Declercq, Ghent, BE
10:20 – 10:40	Abstract 205	Hand grip strength and DXA in adults with Cystic Fibrosis – Lucy Mead, Cambridge, UK
10:40 – 11:00	Abstract 233	Resting energy expenditure in patients with CF decreases after lung transplantation – Francis Hollander, Utrecht, NL
11:00 – 11:15	COFFEE BREAK	
11:15 – 11:35	Abstract 208	Longterm and seasonal impact of a vitamin D3 supplementation protocol on vitamin D serum levels among CF adults in a Montreal clinic – Marjolaine Mailhot, Montreal, CA
11:35 – 11:55	Abstract 211	Vitamin D insufficiency is associated with pulmonary exacerbations in children with Cystic Fibrosis – Gary McPhail, Cincinnati, US
11:55 – 12:15	Abstract 178	Glucose tolerance in CF patients over a 3 year period DIAMUCO study – Isabelle Durieu, Lyon, FR
12:15 – 13:30	LUNCH BREAK	
13:30 – 13:50	Abstract 220	Nutritional outcomes of enteral nutrition in children with CF – Katherine Fisher, Birmingham, UK
13:50 – 14:10	Abstract 218	Body composition estimation by bioelectrical impedance: Validation of an equation adapted to children with CF – Anna-Maria Charatsi, Paris, FR
14:10 – 14:30	Abstract 222	Prevalence of overweight and obesity in Scottish paediatrics CF population – Julie Crocker, Glasgow, UK
14:30 – 14:50	Abstract 223	Prevalence of overweight and obesity in Scottish adult CF population – Lianne Robb, Edinburgh, UK
14:50 – 15:00	Case presentations – Obesity in CF	
15:00 – 15:15	COFFEE BREAK	
15:15 – 16:00	Group discussion and sharing practice in prevention and treatment of obesity in CF	
16:00 – 16:30	Discussion, award and close	

Actavis + ALLERGAN

This meeting is supported by Actavis + Allergan

09:30-15:00	ECFS Neonatal Screening Working Group Meeting	
	Moderators: Marijke Proesmans, Leuven, BE / Kevin Southern, Liverpool, UK	Arc Room
09:30 – 10:00	TEA AND COFFEE	
10:00 – 10:15	Welcome and update from Belgium – Marijke Proesmans, Leuven, BE	
10:15 – 10:30	Progress in Europe, a report from the ECFS Newborn Screening Working Group – Kevin Southern, Liverpool, UK	
10:30 – 10:55	Newborn Screening for CF in South America, progress and implications for programme structure – Silvia Gartner, Barcelona, ES	

10:55 – 11:20	Early experience from the Turkish Newborn Screening Programme – Refika Ersu, Istanbul, TR / Bülent Karadağ, Istanbul, TR
11:20 – 11:45	Moving towards a national newborn screening programme for CF in Germany – Olaf Sommerburg, Heidelberg, DE
11:45 – 12:10	CFSPID from the perspective of an adult CF physician – Nicholas Simmonds, London, UK
12:10 – 12:45	LUNCH BREAK
12:45 – 13:30	The Evolving Clinical and Laboratory Standards Institute (CLSI) Guidelines on NBS of CF – Olaf Sommerburg, Heidelberg, DE
13:30 – 14:00	The impact of carrier identification on families – Danya Vears, Parkville, AU
14:00 – 14:35	Advances in molecular genetics; Treasure chest or Pandora's box – Milan Macek, Prague, CZ
14:35 – 15:00	Discussion

This meeting is supported by Perkin Elmer and Dynabio.

PerkinElmer For the Better

dynabio

09:30-16:00	European Psychosocial Special Interest Group (EPSIG) Meeting**	extra registration required
		Room 206
09:30 – 09:35	Welcome	
09:35 – 11:05	Topic 1: From diagnosis to first admission	
	Parental preparation for first admission – Kirsty James, Bristol, UK	
	Evening for parents: More than just peer support – Jet van der Hulst, Groningen, NL	
	Coaching after diagnosis of CF in the heel prick – Yol Kuijer, Bilthoven, NL	
11:05 – 11:20	COFFEE BREAK	
11:20 – 12:35	Topic 2: Creative points of view and interventions	
	An introduction to working with creative methods – Shari Jansegers, Brussels, BE	
	Dietary forcing and conflicts during meals for children suffering from Cystic Fibrosis: The psychologist's point of view – Pilar Leger, Nantes, FR	
12:35 – 13:35	LUNCH BREAK	
13:35 – 15:00	Recognition of pulmonary exacerbation (PEX) in adult patients with CF: An educational process to overcome barriers – Valérie David, Nantes, FR	
	Signs of Well-being – Alexandra Saey, Antwerp, BE	
	Extending a rehabilitation program at home through a mobile app – Thijs Verbruggen, De Haan, BE	
15:00 – 15:15	COFFEE BREAK	

15:15 – 16:00	Topic 3: Families and teams facing lung transplant
	Paediatric lung transplant: Linking with CF- teams – Andrea Ralph, London, UK
	Case presentation: Young adults and lung transplant – Pavla Hodková, Prague, CZ
16:00	Closing remarks

14:30 – 17:00	Physiotherapy Case Presentations	
	Moderator: Ruth Dentice, Sydney, AU	Room 211+212
14:30 – 14:55	Wolff-Parkinson-White: A risky wave to surf! – Helen Douglas, London, UK	
14:55 – 15:20	Intrapulmonary percussive ventilation associated to conventional chest physiotherapy in Cystic Fibrosis as a bridge to transplantation: A case report – Luigi Graziano, Rome, IT	
15:20 – 15:45	Right upper lobe atelectasis in a 40-day old infant with Cystic Fibrosis: Effectiveness of treatment with PEP-MASK – Beatrice Ferrari, Florence, IT	
15:45 – 16:10	The psychological impact of long term illness and functional deterioration for an adolescent CF boy with *Mycobacterium abscessus* infection – Tom Meredith, Southampton, UK	
16:10 – 16:35	Adequate physiotherapy for a patient with massive abdominal anamnesis and chronic complications? – Louise Lannefors, Copenhagen, DK	
16:35 – 17:00	The *Mycobacterium abscessus* eradication challenge – Melanie Lees, Westmead, AU	

THURSDAY, JUNE 11

12:30 – 14:30	ECFS CTN Standardisation Committee Meeting	
	Moderators: Isabelle Sermet, Paris, FR / Kate Hayes, Belfast, UK	Hall 400
12:30 – 12:40	Welcome, update and future orientations – Isabelle Sermet, Paris, FR	
	Microbiology update:	
12:40 – 12:50	PA identification manuscript – Giovanni Taccetti, Florence, IT	
12:50 – 13:00	PA identification SOP – Miles Denton, Leeds, UK	
13:00 – 13:10	MALDI-TOF survey – Kate Hayes, Belfast, UK	
	CFTR biomarkers update:	
13:10 – 13:20	NPD: Certified centres/CTN TDN SOPs – Inez Bronsveld, Utrecht, NL	
13:20 – 13:30	ICM: Update on certification – Nico Derichs, Berlin, DE	
13:30 – 13:40	Respiratory function update: LCI: Update on certification – Jane Davies, London, UK	
13:40 – 13:50	Inflammatory markers update – Stephanie Bui, Bordeaux, FR	
13:50 – 14:00	Anthropometrics update: Manuscript – Anne Munck, Paris, FR	
14:00 – 14:10	Lung imaging update – Mariette Kemner, Rotterdam, NL	
14:10 – 14:30	Summary – Isabelle Sermet, Paris, FR	

13:30 – 14:30	ECFS Patient Registry - Meeting for Interested Parties	
	Moderator: Edward McKone, Dublin, IE	Hall 100
	The meeting is open for anyone with an interest in the ECFS Patient Registry. It is an informative meeting open to potential contributors, persons with an interest in obtaining data for research and other interested parties.	
13:30 – 13:40	Introduction ECFS Patient Registry – Edward McKone, Dublin, IE	
13:40 – 13:50	The annual report and centre report: Useful tools – Anna Zolin, Milan, IT	
13:50 – 14:00	Introduction ECFSTracker, the data-collection software – Jacqui van Rens, Leuven, BE	
14:00 – 14:10	How to set-up a (national) patient registry – Vincent Gulmans, Baarn, NL	
14:10 – 14:20	A patient's view – Ulrike Pypops, Brussels, BE	
14:20 – 14:30	Questions & Answers	

18:30 – 20:30	ECFS CTN Blood Inflammatory Markers Standardisation Group	
	Moderators: Isabelle Sermet, Paris, FR / Kate Hayes, Belfast, UK	Gold Hall
18:30 – 18:45	Welcome, introduction – Isabelle Sermet, Paris, FR	
18:45 – 20:15	SOP and manuscript open discussion – Stephanie Bui, Bordeaux, FR	
20:15 – 20:30	Summary – Isabelle Sermet, Paris, FR	

FRIDAY, JUNE 12

12:30 – 14:30	ECFS Diagnostic Network Working Group Meeting	
	Moderator: Nico Derichs, Berlin, DE	Hall 100
12:30 – 12:35	The ECFS DNWG: Overview and next steps – Nico Derichs, Berlin, DE	
12:35 – 13:00	Real life practice of sweat test performance in Europe and development of an ECFS sweat test guideline – Natalia Cirilli, Ancona, IT	
13:00 – 13:30	How to document diagnostic patients in the ECFS Patient Registry: CF, CFTR-related disorder, CFSPID – Lutz Nährlich, Gießen, DE	
13:30 – 13:45	Challenge the experts: Unresolved CF diagnostic cases from Belgium & participants – Elke De Wachter, Brussels, BE	
13:45 – 14:00	Short presentation of Best diagnostic posters ECFC 2015 – Jürg Barben, St. Gallen, CH	
	Progress report of ongoing DNWG projects:	
14:00 – 14:15	ECFS NPD SOP multicenter validation: Diagnostic recommendations & reference data – Isabelle Sermet, Paris, FR / Michael Wilschanski, Jerusalem, IL	
14:15 – 14:25	CFTR3: Personalised characterization of rare CFTR mutations – Sheila Scheinert, Berlin, DE	
14:25 – 14:30	ECFS DNWG: Collaboration with South America – Nico Derichs, Berlin, DE	

This meeting is supported by Bayer and PTC.

SATURDAY, JUNE 13

12:00 – 17:00	**CF Europe/CF Belgium Family Conference: "Research, hope for today and tomorrow!"** Moderator: Karleen De Rijcke, Brussels, BE — Silver Hall
	Conference language is English, simultaneous translation is provided in French and Dutch. The conference targets families and patients from Belgium and Europe but everyone interested in a research update in lay language is welcome to attend.
12:00 – 13:30	REGISTRATION AND LUNCH
13:30 – 13:40	Welcome CF Belgium and CF Europe – Karleen De Rijcke, Brussels, BE
13:40 – 14:00	Research, hope for today and tomorrow, introduction ECFS President – Kris De Boeck, Leuven, BE
14:00 – 14:40	Molecular basis of personalized therapies for CF: Can we treat all patients? – Margarida Amaral, Lisbon, PT
14:40 – 15:15	Adding tomorrows, update on the American CF research pipeline – Preston Campbell, Bethesda, US
15:15 – 15:40	How to talk to politicians about affordable CF therapy: New drugs, new hope – Anil Mehta, Dundee, UK
15:40 – 16:00	COFFEE BREAK
16:00 – 16:30	Update on nutrition and gastrointestinal issues (European CF Nutrition Group) – Dimitri Declercq, Ghent, BE / Chris Smith, Brighton, UK
16:30 – 16:50	Q&A panel
16:50 – 17:00	Closing remarks

This meeting is supported by CF Europe and Muco Vereniging.


SQUARE
BRUSSELS MEETING

EXHIBITION & SATELLITE SYMPOSIA

SPONSOR ACKNOWLEDGEMENT

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

THE ECFS WOULD LIKE TO THANK THE FOLLOWING SPONSORS

PLATINUM

Actavis + ALLERGAN

GILEAD

NOVARTIS PHARMACEUTICALS

VERTEX THE SCIENCE of POSSIBILITY

GOLD

Mylan® Seeing is believing

SILVER

PARI

THE ECFS WISHES TO THANK ROCHE FOR THE UNRESTRICTED EDUCATIONAL GRANT.

Roche

COME VISIT US AT THE ECFS TOMORROW LOUNGE!

New ways of **connecting**
Implementing **new innovations**
Bridging the **generations of knowledge**
Leading experts **advising a new generation** of specialists
A common platform for a **multi-disciplinary community**
Active participation in an international society that is **setting European standards**

The ECFS Tomorrow initiative is specially geared towards assembling those who are interested in building their future career in the Cystic Fibrosis community and the ECFS of tomorrow.

We see the ECFS Tomorrow as a means to improve one of the fundamental objectives of the society – **To support and engage young scientists working in the field of Cystic Fibrosis**. It is essential to provide professionals who are new to the community with opportunities to connect in a meaningful way with current leaders and experts. In turn, the new generation of specialists bring up-to-date approaches and practices to the wealth of experience that already exists within the society's ranks.

Located in the Exhibition Area of the conference venue, the ECFS Tomorrow Lounge will feature two mini workshops aimed at career development.

WEDNESDAY, JUNE 10

20:00 – 21:00 Meet & Greet

THURSDAY, JUNE 11

12:45 – 13:45 How to establish a research group
Dominik Hartl, Tübingen, DE

20:00 ECFS Tomorrow Get-Together
(Registration at the ECFS Tomorrow Lounge directly)

FRIDAY, JUNE 12

12:45 – 13:45 Writing successful grants
Alexandra Quittner, Miami, US

SATURDAY, JUNE 13

10:30 – 11:00 Farewell Coffee

The ECFS Tomorrow Lounge is supported by:

Actavis + ALLERGAN GILEAD Mylan Seeing is believing VERTEX

SATELLITE SYMPOSIA

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

THURSDAY, JUNE 11

12:30 – 14:00 The effect of CFTR modulation on the disease progression of Cystic Fibrosis in the era of precision medicine

Moderator: Stuart Elborn, Belfast, UK — Copper Hall

12:30 – 12:40	Welcome and introduction: The rationale for applying the principles of precision medicine in the new era of therapeutic CFTR modulation – Stuart Elborn, Belfast, UK
12:40 – 12:55	Characterizing and predicting disease progression in patients with Cystic Fibrosis – Jane Davies, London, UK
12:55 – 13:05	Case presentation with interactive panel
13:05 – 13:20	Review of the data for the effects of therapeutic CFTR modulation on disease progression – Scott Bell, Brisbane, AU
13:20 – 13:30	Case presentation with interactive panel discussion
13:30 – 13:45	Evaluating the impact of CFTR modulation therapeutics on the patient with Cystic Fibrosis – Nico Derichs, Berlin, DE
13:45 – 14:00	Panel discussion and conclusion

19:00 – 20:30 Anti-pseudomonal treatments – Enhancing the potency of regimen

Moderators: Rainald Fischer, Munich, DE / Carsten Schwarz, Berlin, DE — Silver Hall

19:00 – 19:20	Pharmacokinetic, efficacy and safety profiles of Vantobra® and TOBI® in CF patients – Dorota Sands, Warsaw, PL
19:20 – 19:40	Pharmacokinetics of Vantobra® and TOBI® in healthy volunteers – Dominik Kappeler, Gauting, DE
19:40 – 20:00	Inhalation of antibiotics: Dry powder versus nebuliser – Carsten Schwarz, Berlin, DE
20:00 – 20:20	High-dose antibiotic therapy in CF – Rainald Fischer, Munich, DE
20:20 – 20:30	Discussion

FRIDAY, JUNE 12

12:30 – 14:00 Personalising care to meet lifelong challenges in Cystic Fibrosis

Moderators: Nicholas Simmonds, London, UK / Harry Heijerman, The Hague, NL / Silke van Koningsbruggen-Rietschel, Cologne, DE — Gold Hall

NOVARTIS PHARMACEUTICALS

12:30 – 12:35	Welcome and introduction – Stuart Elborn, Belfast, UK
12:35 – 13:00	Addressing multiple pathogens with inhaled and systemic antibiotics – Nicholas Simmonds, London, UK
	Discussion panel
13:00 – 13:25	How can we reduce treatment burden without compromising outcomes? – Harry Heijerman, The Hague, NL
	Discussion panel
13:25 – 13:50	Making treatment decisions in CF: What are the priorities? – Silke van Koningsbruggen-Rietschel, Cologne, DE
	Discussion panel
13:50 – 14:00	Conclusion – Stuart Elborn, Belfast, UK

12:30 – 14:00 Focus on *Pseudomonas aeruginosa* in Cystic Fibrosis: Past, present and future

Moderator: Kris De Boeck, Leuven, BE — Copper Hall

GILEAD

12:30 – 12:34	Welcome and introduction – Kris De Boeck, Leuven, BE
12:34 – 13:01	Past: The history of treatment with inhaled antibiotics – Patrick Flume, Charleston, US
13:01 – 13:28	Present: The current treatment landscape for chronic PA infections – Barry Plant, Cork, IE
13:28 – 13:55	Future: Potential approaches to treat PA infections – Miguel Cámara, Nottingham, UK
13:55 – 14:00	Meeting close – Kris De Boeck, Leuven, BE

GILEAD
Advancing Therapeutics.
Improving Lives.

The Gilead-sponsored symposium,
'Focus on *Pseudomonas* in Cystic Fibrosis: Past, Present and Future',
will be taking place in the **Copper Hall** on **Friday 12 June** from **12:30 to 14:00**

Visit stand number 17 to pick up your abstract CD-ROM.

Take our survey on pulmonary exacerbations in Cystic Fibrosis.

For every survey completed, Gilead will make a contribution of **€10** to **Cystic Fibrosis Europe (CFE)**

We look forward to welcoming you to our stand.

Gilead Sciences is proud to be Platinum Sponsor of the 38th European Cystic Fibrosis Conference

199/IHQ/15-02//1033a • March 2015

EXHIBITION FLOOR PLAN

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

LEVEL -2

BOOTH NO.	COMPANY
14	Actavis + Allergan
09	ALAXIA
24	CF CARE Programme
23	ECO Medics AG
03	ELITechGroup Inc.
04	Eumedica Pharmaceuticals
17 & 27	Gilead Sciences Europe
08	Illumina, Inc.
21	Laboratoire de la Mer
18	Mylan Inc.
02	ndd Medizintechnik AG
16	Novartis Pharma AG
06	OxyCare
28	PARI
20	Profile Pharma
26	PTC Therapeutics GmbH
07	Trudell Medical International
22	Vectura GmbH
25	Vertex Pharmaceuticals
05	Vitalograph

CF Community Area	European Cystic Fibrosis Society
	ECFS Clinical Trials Network
	ECFS Patient Registry
	Belgium Cystic Fibrosis Association
	Cystic Fibrosis Europe
	Cystic Fibrosis Worldwide
	Elsevier



BOOTH 14

Actavis + Allergan
1 Grand Canal Square
Docklands Dublin 2
Dublin
Ireland
Website: www.actavis.com

Actavis plc is a pharmaceutical company focused on developing, manufacturing and commercialising affordable generic and innovative branded pharmaceutical products for patients suffering from diseases in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities.

BOOTH 09

ALAXIA
Bâtiment Adenine
60 avenue Rockefeller
69008 Lyon
France
Website: www.alaxia-pharma.eu

Alaxia is a private company incorporated in 2008 with strong skills and multiple patents owned.
Our aim is the development of medicinal products for respiratory diseases.
Come to see us to discuss future clinical steps.

BOOTH 24

CF CARE Programme
Vertex Pharmaceuticals (Switzerland) Sàrl
Business Park Terre-Bonne - Building A3
Rte de Crassier 23
CH-1262 Eysins
Switzerland

CF CARE (Cystic Fibrosis Collaborative Adherence Resources & Education) is an educational programme lead by an international panel of CF experts. The programme aims to identify barriers to treatment adherence and provide educational content and tools to address adherence challenges. CF CARE is sponsored by Vertex Pharmaceuticals.

BOOTH 23

ECO Medics AG
Bubikonerstrase 45
8635 Duernten
Switzerland
Website: www.ecomedics.com

ECO Medics AG – Switzerland offers devices for Nitrogen Washout FRC / LCI and slope analysis for single / multiple breath washout tests and FeNO tests for exhaled, alveolar and nasal measurements. The application ranges from neonates, children to adults for routine clinical use.

BOOTH 03

ELITechGroup Inc.
Wescor, Inc
370 W 1700 S
84321 Logan, Utah
United States
Website: www.elitechgroup.com

ELITechGroup (formerly Wescor) is the recognised leader in sweat testing systems for Cystic Fibrosis. The company's sweat testing systems have been used in over 4 million tests worldwide. The chloridometers and conductivity analysers give quick and accurate quantitative results with small sample size. ELITechGroup transforms elite technology into diagnostic solutions tailored to the needs of all professionals.
ELITechGroup BV represents the company in Belgium, the Netherlands and Luxembourg.

BOOTH 04

Eumedica Pharmaceuticals
Chemin de Nauwelette 1
7170 Manage
Belgium
Website: www.eumedica.com

Eumedica Pharmaceuticals, a different partnership to the hospital environment, seeks to ensure the development & continuity of vital treatment in serious indications. We currently operate in six major therapeutic areas: infectiology, haematology, anaesthesiology, obstetrics, gastro-enterology and psychiatry. Eumedica also provides solutions for the logistical needs of pharmaceutical companies and with our expertise and rapidly growing distribution network; we guarantee the best possible services.
For more information, please go to www.eumedica.com

BOOTH 17/27

Gilead Sciences Europe
2 Roundwood Avenue
Stockley Park
UB11 1AF Uxbridge
South East
United Kingdom
Website: www.gilead.com

Gilead was founded in 1987 in Foster City, California. In just over 25 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, a growing pipeline of investigational drugs and approximately 7,200 employees in offices across five continents. Millions of people around the world are living healthier, more fulfilling lives because of innovative therapies developed by Gilead. Gilead is proud to support the 38th European Cystic Fibrosis Conference.

BOOTH 08

Illumina, Inc.
5200 Illumina Way
92122 San Diego
United States
Website: www.illumina.com

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the universal adoption of genomics solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com.

BOOTH 21

Laboratoire de la Mer
ZAC de la Madeleine
Avenue du Général Patton
35400 Saint Malo
France
Website: www.respimer.com

Created 25 years ago, Laboratoire de la Mer is a French pharmaceutical laboratory specialising in ENT & paediatrics. We develop and market healthcare products based on research into the sea and seaweed, in order to improve quality of life for consumers. For every one of the healthcare products that we develop we pay particular attention to proving efficacy and optimising tolerability. To this end, our products are verified by clinical studies and are also developed in association with hospitals.

BOOTH 18

Mylan Inc.
1000 Mylan Boulevard
PA 15317 Canonsburg
United States
Website: www.mylan.com

We began as a pharmaceutical distributor 50 years ago, providing products to customers in smaller communities. Today we are one of the world's leading generics and specialty pharmaceutical companies, with sales in approximately 140 countries and territories. At Mylan, we are committed to setting new standards in healthcare. Working together to provide 7 billion people access to high-quality medicines, we
• Innovate to satisfy unmet needs
• Make reliability and service excellence a habit
• Do what's right, not what's easy
• Impact the future through passionate global leadership

BOOTH 02

ndd Medizintechnik AG
Technoparkstrasse 1
8005 Zurich
Switzerland
Website: www.ndd.ch

ndd Medical Technologies provides equipment for lung function testing. The ndd product line has been designed to offer robust, easy to use portable instruments to measure Spirometry, DLCO, Lung Clearance Index (LCI), Scond, and Sacin. With the Nitrogen Washout method, ndd provides easy to perform and highly accurate tests to measure LCI in patients with Cystic Fibrosis and Alpha-1-Antitrypsin Deficiency.
All products are calibration free, ready-to-use without warm-up time and do not require maintenance.

BOOTH 16

Novartis Pharma AG
Forum 1
Novartis Campus
4056 Basel
Switzerland
Website: www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit
www.novartis.com

BOOTH 06

OxyCare
Holzweide 6
28307 Bremen
Germany
Website: www.oxycare.eu

Oxycare GmbH, Oxygen • Respiratory Technology
The German based company OxyCare GmbH is an internationally active company marketing medical products relating to oxygen supply, POC's for mobility, secretolysis, ventilation technology, sleep apnea and wound healing. OxyCare was founded in 1999. Started with 5 employees, it counts today a team of about 160 employees. Since 2013 there is also an associate branch company in Vienna, Austria. A special feature are its own inventions as the vibration vest for secretolysis or the O2-Wound-System. OxyCare is certified according to DIN EN ISO 13485 and 9001. For more information, please visit
www.oxycare.eu

EXHIBITORS PROFILES

BOOTH 28

PARI
Moosstrasse 3
82319 Starnberg
Germany
Website: www.pari.de

PARI develops and manufactures products for respiratory diseases. We focus on optimising the combination of drug and device to advance aerosol therapies in Cystic Fibrosis and other respiratory indications. Well known worldwide as "The GOLD Standard" in nebuliser therapy, we combine tradition with innovation. To discover more, visit us at our booth!

BOOTH 20

Profile Pharma
Bicentennial Building
Southern Gate
PO19 8EZ Chichester
United Kingdom
Website: www.profilepharma.com

Profile Pharma Ltd is a specialist pharmaceutical company recognised for its expertise in treating patients with complex respiratory conditions, rare diseases and severe infections. We are committed to providing innovative solutions to improve quality of life for the patients we treat.

BOOTH 26

PTC Therapeutics GmbH
Baarerstrasse 14
6300 Zug
Switzerland
Website: www.ptcbio.com

PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing and commercialising novel oral treatments for patients with serious and life-limiting disorders. By targeting the processes that modulate RNA biology and affect protein production, we bring an innovative approach to drug discovery. We are focused particularly on the development and commercialisation of treatments for rare and neglected disorders.

BOOTH 07

Trudell Medical International
Biocity Nottingham
Pennyfoot Street
NG11GF Nottingham
United Kingdom
Website: www.trudellmed.com

Trudell Medical International manufactures a range of products to help with management and medication delivery in respiratory conditions. The company offers a novel Oscillating Positive Expiratory Pressure (OPEP) device which helps to clear excess mucus and can help improve gas perfusion in COPD, Cystic Fibrosis and similar conditions. TMI's OPEP device is simple to use, robust and easy to clean. TMI also makes a breath actuated nebuliser (BAN) which delivers medication only when the patient is inhaling, maximising medication delivery to the lung.

BOOTH 22

Vectura GmbH
Wohraer Str. 37
35285 Gemünden
Germany
Website: www.vectura.com

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases.
This growing market includes asthma and COPD. Vectura has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and license agreements with several pharmaceutical companies.

BOOTH 25

Vertex Pharmaceuticals
Business Park Terre-Bonne - Building A3
Rte de Crassier 23
CH-1262 Eysins
Switzerland
Website: www.vrtx.com

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines, so people with serious diseases can lead better lives. In addition to our clinical development programmes focused on Cystic Fibrosis, Vertex has more than a dozen ongoing research programmes aimed at other serious and life-threatening diseases.

BOOTH 05

Vitalograph Ltd
Maids Moreton
MK18 1SW Buckingham
United Kingdom
Website: www.vitalograph.co.uk

Vitalograph is a world leading manufacturer of high quality cardio-respiratory devices. Our extensive range includes high performance spirometers and monitoring devices for COPD, asthma and Cystic Fibrosis. Many of our products have won design awards, our Clinical Trials Services Division delivers standardised equipment, with customised software, and centralised data capture services for cardio-respiratory clinical trials.

The Effect of CFTR Modulation on the Disease Progression of Cystic Fibrosis in the Era of Precision Medicine

SATELLITE SYMPOSIUM

Thursday, June 11, 2015 • 12:30-14:00
Square—Brussels Meeting Center
Copper Hall, Level 0

AGENDA

12:30–12:40	**Welcome and Introduction,The Rationale for Applying the Principles of Precision Medicine in the New Era of Therapeutic CFTR Modulation**	J. Stuart Elborn, MD
12:40–12:55	**Characterizing and Predicting Disease Progression in Patients with Cystic Fibrosis**	Jane Davies, MD
12:55–13:05	**Case Presentation with Interactive Panel Discussion**	
13:05–13:20	**Review of the Data for the Effects of Therapeutic CFTR Modulation on Disease Progression**	Scott Bell, MD
13:20–13:30	**Case Presentation with Interactive Panel Discussion**	
13:30–13:45	**Evaluating the Impact of CFTR Modulation Therapeutics on Patients with Cystic Fibrosis**	Nico Derichs, MD
13:45–14:00	**Panel Discussion and Conclusion**	

CHAIR

J. Stuart Elborn, MD
Professor of Respiratory Medicine
Dean, Medicine, Dentistry and Biomedical Science
Queen's University of Belfast
Belfast, Northern Ireland, United Kingdom

PLEASE VISIT
http://cysticfibrosis.elsevierresource.com

FACULTY

Jane Davies, MD
Professor of Paediatric Respirology and Experimental Medicine
Imperial College London
Honorary Consultant in Paediatric Respiratory Medicine
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom

Scott Bell, MD
Director, Adult Cystic Fibrosis Centre
The Prince Charles Hospital
Group Leader, Lung Bacteria Group
QIMR Berghofer Medical Research Institute
Queensland, Australia

Nico Derichs, MD
Director, CFTR Biomarker Center and Translational CF Research Group
Senior CF Physician, Paediatric and Adult CF Center
Paediatric Pulmonology and Immunology
Charité Universitätsmedizin Berlin
Berlin, Germany

EXHIBITION & SATELLITE SYMPOSIA

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME

This activity is supported by an educational grant from Vertex Pharmaceuticals Incorporated

EXHIBITION & SATELLITE SYMPOSIA

Abbreviated Prescribing Information June 2014
Product name: Creon® Micro, Creon® 10000, Creon® 25000, Creon® 40000
Active ingredient: Pancreatin.
Therapeutic indications: Treatment of pancreatic exocrine insufficiency in pediatric and adult patients.
Dosing recommendations: Take during or immediately after meals. In Cystic Fibrosis: Weight-based dosing of 1000 lipase units/kg/ meal < age 4 and 500 lipase units/kg/meal for > age 4. Most patients should remain ≤ 10000 lipase units/kg body weight/day or 4000 lipase units/gram fat intake. Other conditions associated with PEI: individualized per patient according to degree of maldigestion and fat content of meal. Required dose for a meal ranges from 25000 to 80000 Ph. Eur. lipase units/meal and 1/2 the individual dose for snacks.
Contraindications: Hypersensitivity to the active substance or to any of the excipients.
Special warnings and precautions for use: Unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed, especially in patients taking in excess of 10000 units of lipase/kg body-weight/day. Side effects: Most commonly observed: gastrointestinal disorders, primarily mild or moderate in severity. Allergic reactions have been reported.

For further prescribing information, please consult the local prescribing information.

GLCRE150001

Mylan
Seeing is believing

EUROPEAN CYSTIC FIBROSIS SOCIETY (ECFS)

Kastanieparken 7
7470 Karup
Denmark
Tel.: +45 8667 6260
Fax: +45 8667 6290
Info@ECFS.eu
Website: www.ECFS.eu

The ECFS is a society of European and international experts in all fields of CF research and CF care. With cross-border partnerships - the ECFS is:

- Continuing to create a network of European and international CF specialists including Allied Health Professionals to promote and stimulate the exchange of information about CF
- Holding annual conferences where specialists can meet and discuss all issues linked with CF.
- Promoting young researchers.
- Organising regular consensus meetings to develop standardised European documentation for CF care.
- Supporting a Clinical Trials Network and a European Patient Registry.
- Promoting the establishment of specialist Working Groups.
- Publishing a Journal of CF (JCF) with six issues a year with supplements.

ECFS CLINICAL TRIALS NETWORK

Veerle Bulteel
Executive Coordinator
Tel.: +32 16 34 03 37
Fax: +32 16 34 38 17
ECFS -CTN@uzleuven.be
Website: www.ecfs.eu/ctn

The ECFS Clinical Trials Network (CTN) is active since 2008 and provides access to 30 large and experienced CF centres, located in 11 different countries throughout Europe. The aim of the CTN is to intensify clinical research in the area of Cystic Fibrosis and to bring new medicines to the patients as quickly as possible. CTN activities include protocol review, follow-up of patient recruitment, standardisation of procedures and training. More information is available at the CTN booth.

ECFS CYSTIC FIBROSIS PATIENT REGISTRY

Jacqui van Rens
Executive Coordinator
Tel.: +32 484 443 435
ecfs-pr@uzleuven.be
Website: www.ecfs.eu/projects/ecfs-patient-registry/intro

The ECFS Patient Registry collects demographic and clinical data from consenting CF patients in Europe. The outcomes of data-analyses and comparisons are used to better understand CF, encourage new standards of dealing with the disease, provide data for research and facilitate public health-planning.
To apply for data from the Patient Registry please contact ecfs-pr@uzleuven.be
See more about the Patient Registry on www.ecfs.eu/projects/ecfs-patient-registry/intro

BELGIUM CYSTIC FIBROSIS ASSOCIATION

Karleen De Rijcke
Av. J. Borlélaan 12
1160 Brussels
Belgium
Tel.: +32 2 66 33 904
karleen@muco.be
Website: www.muco.be

The Belgian CF association (Association Muco - Mucovereniging) strives for a better and longer life of all CF patients and families in Belgium. Nearly 1/20 Belgians carry a gene causing the disease. Each week a child is born with CF. More than 1300 CF patients -about all patients known in Belgium- and their families are member of our CF association; more than 60% are older than 18. We offer information, psychological, financial, legal and social support for patients and families; organise awareness programmes; finance clinical care and research projects and lobby with authorities to gain better access to quality care and social services.

CYSTIC FIBROSIS EUROPE

Hilde De Keyser
Tel.: +32 2 61 32 716
Hilde.dekeyser@cf-europe.eu
Website: www.cf-europe.org

Cystic Fibrosis Europe (CFE) is the federation of national CF Associations in Europe. CFE represents 40 000 persons with CF and their families in 40 European countries.
The mission of the organisation is to ensure a better and longer life for all people with Cystic Fibrosis in Europe. Our main activities are stimulating equal access to optimal care, promoting patient centered research, empowering national CF patient associations and education and solidarity projects with less privileged care regions.
CFE works in close collaboration with all stakeholders in the international CF and rare disease community and is an active partner in several European projects

CYSTIC FIBROSIS WORLDWIDE

Terry Stewart CEO and President
PO Box 1089
Baulkham Hils
NSW 2153
Australia
terence56@hotmail.com
Website: www.cfww.org

Cystic Fibrosis Worldwide (CFW) is an international member organisation working to improve quality of life and life expectancy for people living with Cystic Fibrosis (CF). Our primary function is to spread information about the disease among scientists, medical professionals, caregiver, patients and families and act as a platform for the exchange of information between our 67 member countries. Visit our booth and learn about our many exciting projects such as the Worldwide CF Day and the CFW Educational Program.

ELSEVIER

32 Jamestown Road
Camden
NW17BY London
South East
United Kingdom
Website: www.elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Journal of Cystic Fibrosis, and over 33,000 book titles, including a number of iconic reference works. Stop by the Elsevier stand in the ECFS Community Area where complimentary journals will also be available.


SQUARE
BRUSSELS MEETING

GENERAL INFORMATION & INDICES

CONFERENCE FLOOR PLAN

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

OVERVIEW



LEGEND

Session Room | Meeting Room | Exhibition Area | Poster Area

CONFERENCE FLOOR PLAN

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

LEVEL -2

EXHIBITION & POSTER AREA



LEVEL -1

ENTRANCE, REGISTRATION AND CLOAKROOM
COPPER HALL



LEGEND

Session Room | Meeting Room | Exhibition Area | Poster Area

CONFERENCE FLOOR PLAN

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

LEVEL 0

GOLD HALL, SILVER HALL, COPPER HALL, SPEAKER PREVIEW ROOM



LEGEND

Session Room | Meeting Room | Exhibition Area | Poster Area

CONFERENCE FLOOR PLAN

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

LEVEL 1

HALL 100



LEVEL 2

MEETING ROOMS



LEVEL 3

ARC ROOM, ePOSTER CORNER C & MEETING ROOMS



LEVEL 4

HALL 400



LEGEND

Session Room | Meeting Room | Exhibition Area | Poster Area

GENERAL INFORMATION A – Z

ABSTRACT BOOK AND ABSTRACT CD-ROM

All accepted abstracts are published in the abstract book and on the abstract CD-ROM. The abstract book and a voucher for the CD-ROM can be found in your conference bag.
The abstract CD-ROM is generously sponsored by the company Gilead Sciences Europe Ltd.

ACCOMMODATION

Please visit the hotel counter in the registration area if you wish to reserve a hotel room or if you have any problems with your hotel reservation.

BANKING FACILITIES

Banks are open Monday to Friday from 09:00 to 16:00. The closest cash machine is located at the corner between Cantersteen straat and rue des Sols/Stuiverstraat. The closest bank to the conference venue is BNP-Paribas-Fortis Ravenstein (rue Montagne du parc/Warandebergstraat, 3 – 1000 Brussels).

BASEL INFORMATION

The 39th European Cystic Fibrosis Conference will take place in Basel from 8 to 11 June 2016.
Basel brochures are available onsite, in front of the Exhibition & Poster Area.

BRUSSELS INFORMATION POINT

The Brussels information point is located at the Entrance foyer (level -1) of the conference venue. Taxis can be booked at the Brussels information point. The Brussels booth will be open during the following hours:

Wednesday, June 10	08:00 – 20:00
Thursday, June 11	07:00 – 19:30
Friday, June 12	07:00 – 19:00
Saturday, June 13	08:30 – 13:30

CATERING AREA

A Catering Area is at your disposal within the Exhibition Area. It is open on Thursday and Friday from 12:00 to 15:00. There you can purchase sandwiches and desserts as well as beverages. Payments can be made in cash or with a credit card.

CERTIFICATE OF ATTENDANCE

A certificate of attendance for registered delegates can only be acquired in the designated areas in the conference venue. They cannot be issued after the conference.

CLIMATE

Belgium has a temperate maritime climate with cool summers influenced by the North Sea and Atlantic Ocean. Lightweight clothing is recommended, but it is appropriate to always carry rainwear for summer.

CME CREDITS

Accreditation for CME Credits points has been applied for and was pending an answer at the time of going to print with the final programme. To apply, please complete the CME credits attendance form to be found on the ECFS website www.ecfs.eu/brussels2015 and email it back scanned to ecfs2015-abstracts@kit-group.org prior to Friday, July 3.

CLOSING CEREMONY

The Closing Ceremony will take place on Saturday, June 13 from 12:30 to 13:00.

CLOAKROOM

The cloakroom is located close to the registration counters, on Level -1 of the conference venue.
The charge is € 2 per checked item.

The cloakroom will be open during the following hours:

Wednesday, June 10	08:00 – 21:30
Thursday, June 11	07:00 – 21:00
Friday, June 12	07:00 – 19:00
Saturday, June 13	08:30 – 13:30

CONFERENCE BAG

The Conference bag, containing the Conference Material, can be obtained at the conference material counter next to the registration area. The conference bag is generously sponsored by the company Mylan Inc.

CONFERENCE COURTESIES AND CODE OF CONDUCT

In consideration of all conference participants, mobile phones should be turned off in all session rooms. Conference Participants are expected to refrain from the following:

1) Inflicting personal threat or harm to any conference participant, exhibitor or staff
2) Inflicting damage to any property
3) Preventing speakers from giving their speeches

CROSS INFECTION POLICY

The ECFS discourages individuals with CF to attend the conference as a bug free environment cannot be guaranteed. If individuals with CF decide to attend the conference despite this recommendation, we kindly ask them to report to the registration counter. ECFS advises they show consideration to others by sticking the little rose provided at the registration counter on their name badge.
There might be occasions when a member of the Faculty is a person with CF. In such cases, the ECFS takes at heart the safety of the individual and will inform the individual of the cross infection policy and post a sign on the room door of the session where the Faculty member with CF is.

CURRENCY

The currency of Belgium is the Euro (EUR).

DISABILITIES

The conference venue is accessible to conference participants with disabilities.

EUROPEAN CYSTIC FIBROSIS SOCIETY

The conference organiser, the European Cystic Fibrosis Society (ECFS), will be present during the conference with a booth located in the CF Community Area in the Exhibition area, where you may obtain information about the Society and become an ECFS Member.

ECFS 2015 SMARTPHONE APPLICATION

The ECFS 2015 Conference App is designed to enhance the experience of the participants before, during and after the conference, by placing the following features and information at their fingertips:

- Interactive conference programme
- Consult the abstracts and ePosters through the Library Button
- Maps and floor plans
- Exhibitors listings

The ECFS 2015 App is generously sponsored by the company Vertex Pharmaceuticals Incorporated.

ECFS ANNUAL GENERAL MEETING

All ECFS Members are invited and encouraged to attend the ECFS Annual General Meeting on Wednesday, June 10 from 17:00 to 18:00 in Hall 400.

ECFS PRE-CONFERENCE PROGRAMME

Each year several special interest CF groups hold their meetings in conjunction with the conference. You can find them in the Meetings section of the final programme.

ECFS TOMORROW LOUNGE

The ECFS Tomorrow initiative is specially geared towards assembling those who are interested in building their future career in the Cystic Fibrosis community and the ECFS of tomorrow.
Located within the Exhibition area on level -2 of the conference venue, the ECFS Tomorrow Lounge will feature:

- An exciting series of mini-workshops aimed at career development
- A relaxed space for conversation and networking

ELECTRICITY

Belgium uses the Europlug (Type C & F) for electricity, with two round prongs.

ePOSTERS AREA

An ePoster is an electronic version of the traditional paper poster which is displayed on computers.
You will be able to consult the ePosters by using one of the computers in the ePosters area located within the Exhibition Area.
A specific ePoster can be viewed any time during the conference and will also be available on the ECFS Website after the conference for ECFS Members only.

The ePosters are indexed by topic and you will have the possibility to post messages to the authors of the ePosters.
Please note that abstracts selected for oral presentation will only be available as ePosters.

ePOSTER CD-ROM

All accepted abstracts are published as ePosters on the ePoster CD-ROM. A voucher for the CD-ROM can be found your conference bag.
The ePoster CD-ROM is generously sponsored by the company Vertex Pharmaceuticals.

ePOSTER CORNERS

The ePoster Corners A and B are located within the Exhibition and Poster Area.
The ePoster Corner C is located on level 3 of the conference venue.

EXHIBITION

Conference Participants are invited to visit the Exhibition located on level -2. The Exhibition will feature commercial exhibitors and will be open during the following hours:

Wednesday, June 10	18:00 – 21:30
Thursday, June 11	09:00 – 18:00
Friday, June 12	09:00 – 18:00
Saturday, June 13	09:00 – 12:30

FILMING AND TAKING PICTURES

Out of respect for speakers' copyright, it is forbidden to take pictures and/or to film during any session.

GREENING POLICY

ECFS is taking its environmental responsibilities seriously and is committed to ensuring that it minimises the effect which the ECFS Conference has on the environment and has taken proactive steps. See page 95 for more details.

INTERNET ACCESS AND INTERNET CAFÉ

Wireless LAN will be available for registered participants free of charge at the conference venue. There will be an Internet Café available to participants in the Exhibition area.
Internet access and Internet Café are generously sponsored by the company Actavis + Allergan.

Login: ecfs2015
Wi-Fi Password: Allergan

INSURANCE AND LIABILITY

The Conference Organiser, the European Cystic Fibrosis Society and the ECFS Conference Secretariat do not accept any liability for personal injury, loss of or damage to belongings of Conference Participants, either during or as a result of the conference. Please check the validity of your own insurance.

LANGUAGE

The official conference language is English.

LETTER OF INVITATION

Individuals requiring an official letter of invitation can request one during the online registration process or from the ECFS Registration Department (ecfs2015@kit-group.org). To receive a letter of invitation, attendees must first register to the conference and submit payment in full. Letters of invitation will not be sent after the standard registration deadline.
The letter of invitation does not financially obligate the conference organisers in any way. All expenses incurred in relation to the conference are the sole responsibility of the attendee.

LOST & FOUND

Lost items can be collected at the cloakroom during the conference. Any objects found during the conference and not claimed will remain at the conference venue.

GENERAL INFORMATION A – Z

NAME BADGE

A badge is required for admittance to all official conference sessions and events, as well as the Exhibition and poster Area. Each participant is asked to present the badge in order to gain access to the Conference. The badge must be clearly displayed. Lost name badges can be replaced at the registration counter for a respective fee.

OFFICIAL AIRLINE

The Star Alliance™ member airlines are appointed as the official airline network for the conference.

OPENING PLENARY AND WELCOME RECEPTION

The Opening Plenary on Wednesday, June 10 will take place from 18:30 to 20:00. It will be followed by a Welcome Reception from 20:00 to 21:30 in the Exhibition Area. Both events are free of charge to all registered participants.

PARKING AT THE CONGRESS CENTRE

There are 660 parking spaces right underneath SQUARE – MEETING CENTRE. You can get in via Place de la Justice-Gerechtsplein, and Stuiversstraat-rue des Sols, and then walk straight into the building.

POCKET PROGRAMME

A Pocket Programme will be available at the Conference Material Counter with your Badge Holder.

POSTER EXHIBITION

The Poster Exhibition is located within the Exhibition on the level -2 of the conference venue.

The Poster Area is open at the following hours:

Wednesday, June 10	18:00 – 21:30
Thursday, June 11	08:00 – 18:00
Friday, June 12	08:00 – 18:00
Saturday, June 13	08:30 – 12:30

POSTER SESSIONS

Poster Presenters are asked to be available at their poster according to the timetable which can be found page 43.
Guided Poster Tours take place on both Thursday, June 11 and Friday, June 12 from 14:00 to 15:00.

PROGRAMME CHANGES

The Organiser cannot assume liability for any changes in the Conference Programme due to external or unforeseen circumstances.

PUBLIC TRANSPORTATION

There are numerous metro links, bus and tram stops close by. SQUARE - MEETING CENTRE is located close to the Bruxelles Central/Brussel Centraal train station (2 minutes walk).
Order Tickets online, View metro map
www.stib-mivb.be
www.belgianrail.be

RECYCLING

Please help us recycle your Badge Holder by using the Recycling Box at the exit of the Conference Venue.

REGISTRATION TO THE CONFERENCE

All Conference Participants are required to personally check in at the appropriate Registration Counter.

The Registration Counters are open during the following times:

Tuesday, June 9	07:45 – 17:00
Wednesday, June 10	08:00 – 20:00
Thursday, June 11	07:00 – 19:30
Friday, June 12	07:00 – 19:00
Saturday, June 13	08:30 – 13:30

Registration Fees Onsite (per person)

Medical/Scientific/Other

ECFS Member	€ 605
Non Member	€ 725
Registration and Membership Package	€ 725

Allied Health Professional

ECFS Member	€ 380
Non Member	€ 500
Registration and Membership Package	€ 500

Students

Doctoral and PhD Students	€ 150
Registration and Membership Package	€ 270

Meet the Experts

All (except Students)	€ 45
Students	€ 20

Educational Pre-Conference Courses

Quality Management Course NEW (Limited Seating)	€ 180
Physiotherapy Short Course	€ 270
CF Course NEW (Limited Seating)	€ 180

Pre-conference Meetings

European Psychosocial Interest Group Meeting	€ 25
International Nurse Specialist Group/CF Meeting	€ 25

ECFS Conference Party – Friday, June 12

All (except Students)	€ 35
Students	€ 25

ENTITLEMENTS

The Registration Fees include:

- Admission to the Scientific Programme
- Admission to the Exhibition and Poster Area
- Opening Plenary and Closing Ceremony
- Conference Bag containing Programme and Abstract Book*

*Conference material cannot be guaranteed for late registrants.

SMOKING POLICY

It is forbidden to smoke in any part of the conference venue.

SOCIAL MEDIA

Visit us on

Find us on

SPEAKER PREVIEW ROOM

All speakers must report to the Speaker Preview Room at least two hours prior to their presentation in order to hand over and check their presentation. The Speaker Preview Room is located on Level L of the conference venue and will be open at the following hours:

Wednesday, June 10	10:00 – 19:00
Thursday, June 11	06:45 – 18:00
Friday, June 12	06:45 – 18:00
Saturday, June 13	08:00 – 11:00

SUPPORT

We thank visit.brussels for their kind support.

SURVEY

A survey about the conference will be available online after the conference. This survey will help us better understand your needs and wishes. By completing the survey, you will be entered into a draw to win one of three FREE Conference Registrations to the 39th ECFS Conference in Basel.

TAXIS

Taxis can be booked at the Brussels information point located in the Entrance Foyer.
Taxi Verts: +32 (0)2 349 49 49
Taxi Bleus: +32 (0)2 268 00 00

TRANSPORT FROM BRUSSELS AIRPORTS

The railway station within Brussels Airport is served by four hourly trains to Brussels from approximately 5.30 am till midnight. A one way ticket costs € 8.50. All trains stop at the three major stations in Brussels: Bruxelles-Nord/Brussel-Noord, Bruxelles-Central/Brussel-Centraal and Bruxelles-Midi/Brussel-Zuid, where connections with most domestic services are available.
Brussels South Charleroi Airport is situated 50 minutes from Brussels city centre and linked to the city by a bus network (terminal at Bruxelles-Midi/Brussel-Zuid train station).

TRAVEL GRANTS

Young European Investigators under the age of 35 registered for a PhD or Post-Graduate Degree or graduated within 12 Months are eligible to be considered for an ECFS Travel Grant. This year, the ECFS has awarded 21 Travel Grants. The Travel Grant Award consists of a monetary grant of € 300, a free registration to the conference and a 2015 ECFS Membership subscription.

YOUNG INVESTIGATOR AWARDS

The ECFS Young Investigators Awards recognise outstanding and promising work by investigators under the age of 35 who have submitted an abstract to the ECFS Conference. Three Young Investigators are recipients this year. They will be presented at the Closing Ceremony on June 13. The grants consist of a monetary grant of € 750, a free registration to the conference and a 2015 ECFS Membership subscription.

SOCIAL PROGRAMME

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

WELCOME RECEPTION

WEDNESDAY, JUNE 10 | 20:00 – 21:30

The Welcome Reception will follow the Opening Plenary and will take place in the Exhibition Area (Level -2).

CONFERENCE PARTY

FRIDAY, JUNE 12 | 21:00 – 02:00

Launched in 2012 in the Guinness Storehouse in Dublin, the ECFS Conference Party has become a popular event to meet friends and colleagues in an informal atmosphere on the last evening of the Conference.
Located in the heart of Brussels, the building of La Tentation, which was originally a fabric store, was renovated and opened in 1997. Centro Galego de Bruxelas, the cultural centre which operates La Tentation, was originally created in order to develop and promote the Galician culture. Today La Tentation has emerged as an intergenerational area which welcomes all communities, generations and social classes offering exchanges and meetings.
Enjoy this evening with one of Belgium's most popular cover bands, "The Planes"! These five musicians from Brussels will make sure that this year's Conference party will once again be an event not to be missed!

Entrance fee: € 35 Regular | € 25 Students
Location: La Tentation
28 Rue de Laeken/Lakensestraat 28
1000 Brussels

La Tentation is located only 1.3km from Square Brussels Meeting Centre, and therefore only a 15-minute walk through Brussels' charming city centre. To walk from Square to La Tentation, go down the Mont des Arts and cross Rue de la Chapelle. Go onto Rue Infante Isabelle which turns into Boulevard de l'Impératrice. Turn left onto Rue d'Arenberg, which turns into Rue de l'Evêque. When you have reached Place Sainte-Catherine, turn right onto Rue de Laeken. The building of La Tentation will be on your left. Please note that some finger food and snacks will be offered but this is not to be considered a dinner replacement.

There will be no return bus shuttle service provided.

GREENING THE ECFS CONFERENCE

ECFS takes its environmental responsibilities seriously and is committed to ensuring that it minimises the effect the ECFS Conference has on the environment. This involves a number of measures, including:

- Eco-friendly and reusable Conference Bags made in partnership with the Township project. Township Patterns has been supporting women entrepreneurship in township communities in Cape Town since 1997.
  The Conference bags are made of 100% natural cotton and jute. Township Patterns collaterals are printed on Forest Stewardship Council (FSC) certified paper.

- Since 2012, the paper used in all ECFS Publications is recycled paper which is either certified by Der Blaue Engel or FSC or EU Ecolabel.

  More information about the certifications: www.blauer-engel.de/en, www.fsc.org, www.eu-ecolabel.eu
  The Final Programme is printed thanks to a LED printing press. All production of LED-print objects needs 80% less energy and LED-colours are 100% deinkable.

  LED UV eco•printed WITH LED•UV

- Fewer paper posters: ECFS encourages the development of electronic posters instead of paper posters by removing poster walls

- Paperless processes thanks to web-based platforms: an online registration system; an online conference programme; a web-based purchase ordering tool for exhibitors and sponsors; and the development of an ECFS 2015 Smartphone Application to disseminate information.
  If you consult the Conference Programme with your smartphone App, we kindly ask you not to take a printed Final Programme at the Conference Material Counter.
  The Second Announcement was only available online this year.

- ECFS encourages the participants to recycle their badge holder by using the recycling box at the exit of the conference venue.

- The majority of hotels are situated within walking distance of the conference venue.

- SQUARE – MEETING CENTRE received its first star (*) from the Brussels environmental department for its participation in a specific and demanding ecological program named “Entreprise écodynamique” (Ecodynamic Company).
  Measures taken by the conference venue:
  - Control systems that help save energy on electricity, heating & A/C have been installed
  - Automatic systems are in place to save water consumption
  - Recycling facilities are provided within the conference venue for paper and plastic.

INDEX

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

A

B

C

INDEX

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

M

N

O

P

INDEX

38th EUROPEAN CYSTIC FIBROSIS CONFERENCE

DOWNLOAD THE ECFS 2015

CONFERENCE APP

USE YOUR SMARTPHONE OR TABLET TO EASILY NAVIGATE ECFS 2015!

- Interactive Conference Programme
- Abstracts and ePosters available via the library
- Maps and Floor Plans

Search for "ECFS 2015" in Apple App Store, Google Play Store or Windows App Store

Visit us on Facebook

Join us on linked In

App generously sponsored by:

VERTEX
THE SCIENCE of POSSIBILITY

8 – 11 JUNE 2016
BASEL, SWITZERLAND

39th EUROPEAN CYSTIC FIBROSIS CONFERENCE

ABSTRACT SUBMISSION DEADLINE:

15 JANUARY 2016

WWW.ECFS.EU/BASEL2016

FREE MEMBERSHIP FOR YOUNG INVESTIGATORS
under 35 years during the Conference

BECOME AN ECFS MEMBER TODAY!

Membership is open to anyone with a qualified professional interest in CF research or CF clinical care.

Become a member of the ECFS and join a prestigious network of professionals involved in Cystic Fibrosis care or research.

To join the ECFS and learn more about the ECFS membership options and benefits, simply visit us at our booth in the CF Community Area or apply online: www.ecfs.eu/membership